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Abstract	
 
Repeated or chronic stress experience can precipitate serious psychiatric disorders like 
depression or anxiety. In many psychiatric disorders, both the hypothalamic-pituitary-adrenal (HPA) axis 
and brain serotonergic systems are dysregulated. My dissertation addresses the role that glucocorticoids 
(GCs) play in the control of brain serotonergic function. The overarching hypothesis is that chronically 
elevated GCs in otherwise healthy individuals, acting through corticotropin-releasing factor (CRF)-
dependent mechanisms, are sufficient to worsen emotionality and alter serotonergic functionality. To test 
this hypothesis, I developed a non-invasive rodent model by treating adult, male rats chronically with 
corticosterone (CORT), the rodent equivalent to human cortisol, via the drinking water. 
 
Using behavioral tests and in situ hybridization histochemistry, I first found that chronic CORT 
exposure, without the experience of external stressors per se, is sufficient to cause an anxiety- and 
depressive-like behavioral state, and to alter diurnal tph2, slc6a4 and htr1a mRNA expression in a dose-
dependent manner that indicates overall elevated serotonergic function in anxiety-related subdivisions of 
the midbrain dorsal raphe nucleus (DR). Tph2 encodes tryptophan hydroxylase (Tph2), the rate-limiting 
enzyme for neuronal 5-hydroxytryptamine (5-HT) synthesis, slc6a4 the serotonin transporter, and htr1a 
the auto-inhibitory 5-HT1A receptor. High pressure liquid chromatography (HPLC) with electrochemical 
detection then revealed that chronic CORT intake also increases acoustic startle stress (AS)-induced Tph 
activity selectively within the median raphe nucleus (MnR), dorsal hippocampus, and in the dorsal (DRD) 
and caudal DR (DRC), indicating respective effects on sleep/wake-, memory-, and anxiety-related 
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serotonergic signaling. Lastly, pharmacological blockade of CRF receptor type 1 (CRFR1) within and 
around the DR immediately before AS resulted in a remarkable increase of AS-induced Tph activity, most 
likely due to inhibition of CRFR1-mediated stimulation of gamma-amino butyric acid (GABA)-ergic 
afferents, while CRF receptor type 2 (CRFR2) blockade prevented AS-induced increases in Tph activity 
within the anxiety-related DRD and DRC. 
 
These results elucidate how chronic GC exposure may impair serotonergic function, and identify 
signaling mechanisms that may serve as medication targets for high-risk individuals, e.g. Cushing’s 
syndrome patients, people with a family history of mood or affective disorders, or servicemen that are 
sent into a predictably stressful environment.  
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CHAPTER	I	
	
Introduction	–	Stress,	glucocorticoids,	and	brain	
serotonergic	systems	
 
1. Summary 
Both the hypothalamic-pituitary-adrenal (HPA) axis and brain serotonin (5-hydroxytryptamine, 5-
HT) systems are commonly dysregulated in a variety of psychiatric disorders, but it is unclear if there is a 
causal link between dysregulation of these systems. This chapter briefly summarizes relevant clinical and 
experimental literature on the fact that stress exposure often precipitates the development of psychiatric 
disorders, and describes how glucocorticoids (GCs), the effector hormones of the HPA axis, are thought 
to interact with serotonergic neurons or signaling, leading to changes in emotional behavior. At the end of 
the chapter, I introduce the overarching hypothesis that circulating GCs are important factors controlling 
brain serotonergic function and emotional behavior, and describe the rationale behind the model and 
experimental approach used to test this hypothesis. 
 
Recent evidence suggests a direct dependency of the diurnal variation in tph2 expression on the 
circadian GC rhythm. Tph2 is the gene encoding the rate-limiting enzyme for brain 5-HT synthesis, 
neuronal tryptophan hydroxylase (Tph2). Because the exact neuronal mechanisms underlying these 
observations and the cause and effect relationships among HPA axis activity and brain serotonergic 
function have yet to be addressed, I developed a non-invasive, adrenal-intact rat model of chronic GC 
elevation to investigate how and where chronic administration of corticosterone (CORT) - the rodent 
equivalent of human cortisol - affects brain serotonergic activity and emotional behavior. I hypothesized 
that chronically elevated GCs, without the perception of an external stressor per se, cause an anxiety- 
and depression-like behavioral phenotype, and act within anxiety-related neuronal networks to alter the 
expression of tph2, slc6a4 (encoding the 5-HT transporter, SERT) and htr1a (encoding the autoinhibitory 
5-HT receptor 5-HT1A) in a way that increases overall serotonergic activity within the midbrain 
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serotonergic dorsal raphe nucleus (DR) and in target regions of the DR, and that the effects of chronic 
GC exposure are ultimately mediated through changes in local corticotropin-releasing factor (CRF) 
receptor type 1 (CRFR1) or type 2 (CRFR2) signaling within the DR.  
 
My overall hypothesis stands contrary to the commonly assumed “5-HT deficiency” theory of 
affective disorders, which is largely based on backwards arguments delineated from the pharmacological 
actions and therapeutic efficacy of selective serotonin reuptake inhibitors (SSRIs). Nevertheless, in these 
studies I attempt to systematically address some very fundamental questions of how one physiological 
component of chronic or repeated stress exposure, namely elevated circulating GC levels, affects brain 
serotonergic function. 
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2. Stress-induced precipitation of psychiatric disorders and HPA axis imbalance  
It is well established that traumatic or chronic stressful experiences can precipitate or worsen 
stress-related psychiatric disorders such as depression (Kessler, 1997; Kendler et al., 2004; Kendler et 
al., 2005; Reagan et al., 2008) or anxiety disorders (Shelton, 2004; Graeff, 2007). In fact, the onset of 
psychiatric disorders might depend largely on interactions between the body’s response to stressful life 
events and an individual’s 5-HT-related genetic predisposition (Caspi et al., 2003; Kendler et al., 2005). At 
the same time, dysregulation of HPA axis functionality is a common feature in many of these disorders. 
Typical findings in melancholic MDD, for instance, are elevated 24 h rhythms of plasma cortisol 
concentrations, impaired negative feedback of the HPA axis at the level of the pituitary and the 
hypothalamic paraventricular nucleus (PVN) (clinically assessable as non-suppression of 
adrenocorticotropin (ACTH) and cortisol release after the combined administration of dexamethasone 
(DEX) and CRF), a flattened diurnal rhythm of plasma cortisol, an elevated stress response to an acute, 
psychosocial stressor (e.g. the Trier Social Stress Test), an abnormal ratio of mineralocorticoid (MR) to 
glucocorticoid receptor (GR) expression  in the hippocampus and other limbic regions, and altered 
ultradian pulsatility of plasma cortisol (Heuser et al., 1994; Deuschle et al., 1997; Holsboer, 2000; Weber 
et al., 2000b; Juruena et al., 2004; de Kloet et al., 2005; Gillespie and Nemeroff, 2005; Pariante, 2009). 
 
Examples of corticosteroid dementia or steroid psychosis (Sirois, 2003; Sacks and Shulman, 
2005), and the fact that patients with Cushing’s syndrome, a disease characterized by chronic elevation 
of endogenous cortisol, display an increased prevalence of depression (Kelly et al., 1980; Sonino et al., 
1998; Pereira et al., 2010) provide support for a causal link between chronically elevated GCs and the 
development of psychiatric disorders.  
 
One common temporary pattern, furthermore, appears to be that the presence of stress-related 
anxiety disorders early in life is often predictive of depressive episodes later in life (Waterhouse et al., 
1986), potentially indicating stress-induced dysregulation of anxiety circuits prior to the manifestation of 
imbalance in brain regions representative of depression. The opposite, meaning suffering from 
depression first, followed by anxiety-spectrum disorders later in life, is rarely the case.  
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3. Brain serotonin (5-HT) synthesis, actions, and metabolism  
The monoamine 5-HT is derived from the amino acid tryptophan, and because tryptophan itself 
cannot cross the blood-brain barrier it is taken up into the brain via a non-selective large amino acid 
transporter, LAT1 (Duelli et al., 2000; Killian and Chikhale, 2001), operating at the surface of the brain 
capillary endothelial cells. Only about 1% of the circulating tryptophan enters the brain, and on its way in it 
has to compete with all other large neutral amino acids (Baumann, 1979; Filippini et al., 1996; Allegri, 
2003). Tryptophan is one of the eight essential amino acids that the human body cannot synthesize on its 
own, but must be absorbed from our food (Sidransky, 1985, 2002; Sarubin-Fragakis and American 
Dietetic Association., 2003; Davis, 2006).  
 
Once in the extracellular fluid of the brain, tryptophan is transported into 5-HT neurons via a high-
affinity neuronal tryptophan transporter. In the cytosol of the serotonergic neuron, tryptophan is 
hydroxylated at the 5-position by the rate-limiting enzyme of serotonin biosynthesis namely the neuronal 
isoform of tryptophan hydroxylase (TPH), called TPH2 (Walther and Bader, 2003; Walther et al., 2003; 
Zhang et al., 2004). In peripheral tissue, including the pineal gland, this step is performed by TPH1, the 
peripheral isoform of the enzyme. In both cases, the product is 5-hydroxytryptophan (5-HTP), which is 
then instantly converted into the neurotransmitter 5-HT via decarboxylation by a common enzyme, 
aromatic amino acid decarboxylase (AADC). Catalysis of the enzymatic conversion of 5-HTP to 5-HT by 
AADC is much faster than the conversion of tryptophan to 5-HTP by TPH, and therefore not rate-limiting. 
For an overview of tryptophan metabolism within the brain see Cooper et al. (2003). 
 
In the brain, 5-HT is utilized in many ways, not all of which are fully understood yet. It is known 
that it plays an important role in the control of basic homeostasis including body temperature and sleep 
(Sallanon et al., 1982; Goodrich et al., 1989; Rausch et al., 2003), emotions such as anger, aggression or 
mood in general (Van Praag, 1994; Schwartz et al., 1999; Abrams et al., 2005; Giegling et al., 2006; 
Lowry et al., 2008c; Lowry and Hale, 2010), and that it contributes to the control of nutritional and 
reproductive functions like appetite, sexuality and arousal (Feist and Galster, 1974; Curzon, 1990; Menani 
et al., 2000; Popova and Amstislavskaya, 2002). Its postsynaptic effects can be inhibitory or excitatory, 
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depending on the receptor type that 5-HT interacts with. The expression and distribution of 5-HT receptor 
types varies throughout brain regions and types of neurons. To date, more than 15 genes encoding 
functional 5-HT receptors have been identified in the mammalian brain. With the exception of 5-HT3 
receptors - which are ionotropic receptors - all others are metabotropic G-protein-coupled receptors 
(GPCRs) (Peroutka, 1992; Millan et al., 2008). Post-genomic modifications, such as alternative splicing or 
mRNA editing further broaden the range of 5-HT receptor types. There are at least seven categories, and 
multiple subcategories, of 5-HT receptors. 5-HT1 and 5-HT2 were the first neuronal 5-HT receptors to be 
identified, with 5-HT1 being mainly inhibitory, whereas 5-HT2 rather exerts excitatory effects (Murphy et 
al., 1998; Barnes and Sharp, 1999). 5-HT1A receptors are autoreceptors that play a very important role in 
the immediate feedback / auto-regulation of 5-HT neurons. However, they are also found in postsynaptic 
membranes (Hjorth et al., 1996; Dos Santos et al., 2008), and can thus not be considered serotonergic 
markers (as opposed to, for example TPH2, or the serotonin transporter, SERT). 5-HT is considered a 
modulatory neurotransmitter partially because, in contrast to classic neurotransmitter receptors, 5-HT 
receptors are rather localized in the surround of synapses (pre- or post-synaptically), but rarely within the 
synaptic cleft (Nichols and Nichols, 2008). The exact functions and intracellular signaling pathways of 5-
HT-GPCR-interacting proteins are not yet fully understood, but may include fine-tuning of signaling, 
trafficking to or from the membrane, and desensitization.  
 
 Reuptake of 5-HT into the presynaptic neuron occurs largely by means of the serotonin 
transporter (SERT, SLC6A4), a high-affinity, but low-capacity monoamine transporter. Recycling 5-HT 
from the synaptic cleft or extracellular space back into neurons (and/or glial cells) also serves as a major 
termination mechanism for the actions of 5-HT. Together with tph2 mRNA, slc6a4 mRNA (encoding 
SERT) is almost exclusively expressed in cell bodies of the DR and the median raphe nucleus (MnR), but 
both proteins are also transported to distant 5-HT nerve terminals where SERT serves as a bi-directional, 
plasma membrane carrier, depending on the extracellular/intracellular concentration gradient of 5-HT, and 
where TPH2 catalyzes the conversion of tryptophan to 5-HTP. Selective 5-HT-reuptake inhibitors (SSRIs) 
such as fluoxetine (Prozac®) are a major group of antidepressants (Apparsundaram et al., 2008; Narboux-
Neme et al., 2008). Other modes of recycling 5-HT into neurons or glial cells are likely to include low-
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affinity, high capacity organic cation transporters (OCTs), predominantly OCT3 (Gasser et al., 2009), the 
plasma membrane transporter (PMAT,(Duan and Wang, 2010)), and most likely also the norepinephrine 
transporter (NET) (Daws et al., 2005).  
 
Cytosolic breakdown of 5-HT to 5-hydroxyindoleacetic acid (5-HIAA) happens mostly via 
deamination by monoamine oxidase (MAO), type A. MAOs are a target for another powerful, but less 
widely used, class of antidepressants, the MAO inhibitors (Youdim and Weinstock, 2004). In the pineal 
gland, 5-HT is metabolized to melatonin by 5-hydroxyindole-O-methyltransferase. For the development of 
antidepressant treatments (such as tryptophan supplementation), it is important to recognize, however, 
that only about 1% of the body’s tryptophan gets metabolized along the 5-HT pathway. The other 99% is 
metabolized differently, along the kynurenine pathway, and also into protein synthesis pathways. The 
strength of the kynurenine pathway in one individual compared to another might be an important factor 
influencing the availability of the serotonin precursor tryptophan (Schmitz et al., 1974; Ruddick et al., 
2006). 
 
4. The dorsal raphe nucleus – topographical and functional organization 
The serotonergic neurons of the midbrain raphe nuclei constitute the key source for 5-HT in the 
brain. Amongst these midbrain raphe nuclei, the dorsal raphe nucleus (DR) is the most prominent 
serotonergic structure (Kohler and Steinbusch, 1982; Imai et al., 1986). In humans, the DR is located in 
the pons, in rodents it is located in the midbrain. The DR is topographically and hodologically organized 
into functional subdivisions and subpopulations of serotonergic neurons (Lowry et al., 2008a; Hale and 
Lowry, 2011a). For example, collateral efferent projections from 5-HT neurons of the dorsal (DRD) and 
caudal DR (DRC) branch out towards anxiety-related and stress-sensitive limbic and cortical structures, 
such as the medial prefrontal cortex (mPFC), the basolateral amygdala (BL) (Abrams et al., 2005), the 
bed nucleus of the stria terminalis (BNST), the central amygdaloid nucleus (Ce), the (dorsal and ventral) 
hippocampus, and periventricular hypothalamic regions (Lowry et al., 2005; Hale and Lowry, 2011a), 
while the rostral DR tends to innervate areas involved in voluntary somatic motor output, such as the 
caudate putamen and the substantia nigra (Imai et al., 1986).  
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5. Dysfunction of serotonergic systems in psychiatric disorders 
Dysfunction of 5-HT neurotransmission is the leading hypothesis regarding the pathophysiology 
of anxiety- and mood disorders (Lesch et al., 1995; Lesch et al., 1996; Naughton et al., 2000; Arango et 
al., 2002; Mann, 2003) and other neuropsychiatric disorders such as schizophrenia (Veenstra-
VanderWeele et al., 2000), autism (Veenstra-VanderWeele and Cook, 2004) aggression, suicidal 
behavior (Arango et al., 2003), and attention deficit disorder (Gainetdinov et al., 1999; Quist and 
Kennedy, 2001). About one of five Americans suffers from an episode of major depressive disorder 
(MDD) during their lifetime (Kessler et al., 1994; Varghese and Brown, 2001; Bloom, 2004), and the 
prevalence for depression is twice as high in women compared to men (Earls, 1987; Nolen-Hoeksema, 
1987). Various theories, such as the “monoamine theory of depression” (global paucity of serotonin, 
within the entire brain), or the “receptor-theory of depression” (postsynaptic, rather than presynaptic 
changes being responsible for the development of depression and, vice versa, its cure), have been 
proposed, but exact mechanisms are still poorly understood.  
 
While multiple genetic polymorphisms affecting the 5-HT system have now been associated with 
anxiety and depression (Anguelova et al., 2003a; Sun et al., 2004; You et al., 2005; Haghighi et al., 
2008), suicide (Anguelova et al., 2003b; Arango et al., 2003), bipolar disorder (De Luca et al., 2005a; 
Shink et al., 2005; Harvey et al., 2007), and other affective disorders (Giegling et al., 2006), some 
patients may not carry any of these genetic polymorphisms, and some people that do, never go on to 
develop one of the listed psychiatric disorders. Thus, it is most likely that a gene by environment 
interaction underlies the majority of psychiatric diseases, and how an individual responds to repeated or 
chronic stress may be one of the key contributors to the etiology of the disease. 
 
Common psychiatric medications, such as antidepressants, target the brain 5-HT system 
indirectly by inhibiting either SERT (Kennedy, 2007; Nierenberg et al., 2008; Heydendael and Jacobson, 
2010), MAOs (Feldstein et al., 1965; Schmauss et al., 1988; Baker et al., 1992), or by interacting with 5-
HT receptors (Cryan and Leonard, 2000; Berrocoso and Mico, 2008; Navines et al., 2008). However, 
most antidepressants take several weeks to show the desired treatment effect and to make the patient 
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feel better (Frazer and Benmansour, 2002). One interpretation of this is that complex postsynaptic 
changes, such as receptor expression levels in the target cells, and complex presynaptic changes, are 
required before the drug is effective (Lee et al., 2010b). However, over the past decade, more and more 
attention has been drawn to TPH2 (Walther et al., 2003; Zhang et al., 2004), which has been found to be 
widely associated with neuropsychiatric disorders, be it through mutations in the TPH2 gene, or through 
the dysregulation of TPH2 mRNA and TPH protein expression (Zill et al., 2004; Zhang et al., 2005; Bach-
Mizrachi et al., 2006; Harvey et al., 2007; Maron et al., 2007). TPH2 provides a potential direct 
pharmacological target to up- or downregulate brain 5-HT synthesis.  
 
6. Neuronal tryptophan-hydroxylase (TPH2) – discovery and disorders 
In 2003, TPH2 was discovered to be the brain-specific version of TPH (Walther and Bader, 2003; 
Zhang et al., 2004). Previous studies either did not discriminate between TPH1 and TPH2 or solely 
measured TPH1, the enzyme that mainly controls 5-HT synthesis in peripheral tissues and in the pineal 
gland, but shows a very weak expression level in the DR (Malek et al., 2005). TPH2 activity requires not 
only the substrate tryptophan, but also the co-factor Fe2+, and co-substrates oxygen (O2) and 
tetrahydrobiopterin (BH4) for the hydroxylation reaction. Interestingly, TPH2 is only about 25-50% 
saturated with its substrate tryptophan under basal conditions (Hofto et al., 2008; Windahl et al., 2008). 
Tryptophan supplementation can thus hardly exhaust the enzyme’s capacity. The activity of the enzyme 
can be increased by phosphorylation through protein kinase A, by Ca2+-phospholipids and also by partial 
proteolysis (Winge et al., 2008).  
 
A number of studies have linked defective TPH2 gene expression or polymorphisms of the TPH2 
gene to emotional instability, or anxiety and affective disorders (Gutknecht et al., 2007; Chen and Miller, 
2012), especially to MDD (Sun et al., 2004; Zill et al., 2004). For instance, Zhang et al. (2005) identified a 
single nucleotide polymorphism (SNP) in the TPH2 coding region in about 13% of a group of patients 
suffering from mild anxiety to severe unipolar depression. When TPH2 with the same SNP (replacement 
of the highly conserved Arg441) is expressed in cell culture, the same mutation causes an 80% reduction 
of 5-HT synthesis. Polymorphisms of the TPH2 gene, however, have also been found in members of a 
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French Canadian family with bipolar disorder (Harvey et al., 2007), and among women with panic 
disorder (Maron et al., 2007), and various polymorphisms have been associated with suicidality, 
schizophrenia, and alcohol-dependence (De Luca et al., 2005a; De Luca et al., 2005b; Lopez de Lara et 
al., 2007; Haghighi et al., 2008). 
 
While many studies report less 5-HT or less of its metabolite, 5-HIAA, in the brainstem of suicide 
victims (Mann et al., 1989) and in the cerebrospinal fluid of depressed suicide attempters (Placidi et al., 
2001), more carefully conducted studies have found an increased 5-HT turnover (elevated 5-HIAA 
concentrations) in the cerebrospinal fluid of females with comorbid depression and anxiety disorder 
(Sullivan et al., 2006), and in patients suffering from un-medicated MDD or panic disorder, as represented 
by elevated 5-HIAA concentrations in the jugular vein, an imbalance that was reversible with successful 
antidepressant treatment with SSRIs (Esler et al., 2007; Barton et al., 2008). Also, TPH2 mRNA 
expression and the number and density of TPH-positive neurons in the DR of depressed suicide victims 
was found to be about 33% higher than in age-matched controls (Underwood et al., 1999; Boldrini et al., 
2005; Bach-Mizrachi et al., 2006; Bonkale et al., 2006; Bach-Mizrachi et al., 2008). All of the described 
findings suggest a link between chronically altered serotonergic function and psychiatric disorders (De 
Luca et al., 2005b; Shink et al., 2005). 
 
7. Stress – and glucocorticoid (GC) interactions with brain serotonergic systems  
In both animals and humans, important links have been established among stressful early-life 
experiences, altered 5-HT function, and later-life vulnerability to the onset of anxiety- or depressive-like 
states (Chaouloff, 2000). In rodents, for example, maternal separation, which induces a chronic anxiety-
like state in adulthood (Huot et al., 2001; Daniels et al., 2004), increases CRF binding in the dorsal raphe 
nucleus (Ladd et al., 1996; Ladd et al., 2000), suggesting that adverse early life experience alters the 
dynamic between stress and serotonergic function. Consistent with this hypothesis, maternal separation 
alters basal and stress-induced expression of tph2 and slc6a4 mRNA (encoding SERT) later in life 
(Gardner et al., 2005; Gardner et al., 2009a; Gardner et al., 2009c).  
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During adulthood, acute and chronic stress increase serotonergic neuronal function. For example, 
acute (Evans et al., 2009) and repeated sound stress, as well as repeated immobilization stress elevate 
the enzymatic activity of Tph (Singh et al., 1990a), and increase tph2 mRNA and Tph protein expression 
(Chamas et al., 1999; Chamas et al., 2004). In addition, 5-HT release increases significantly in response 
to foot shock, cold environment, repeated immobilization, or tail pinches (Pei et al., 1990; Clement et al., 
1993; Inoue et al., 1994). Interestingly, inescapable stress increases 5-HT-neuronal activation (Grahn et 
al., 1999; Greenwood et al., 2003), and leads to increased 5-HT release within the DR (Maswood et al., 
1998) and within target areas of the DR (Bland et al., 2003; Amat et al., 2005), as demonstrated by a 
series of microdialysis studies in rats. These studies suggest that elevated 5-HT activity in the DR is 
necessary and sufficient for behavioral sensitization of anxiety and fear measured 24 h following stress 
exposure in a model of learned helplessness, manifesting in a failure of coping strategies in the face of 
stressful events (Maier and Watkins, 2005). 
 
The latter experiments indicate that (the perception of) controllability, mediated by the medial 
prefrontal cortex (mPFC), is an important factor determining stress-induced activation of serotonergic 
systems, while there is no effect of controllability on the HPA axis stress response. Yet, repeated or 
chronic exposure to elevated circulating GCs, without the perception of behavioral/executive control, may 
cause a similar increase or imbalance in 5-HT release or serotonergic signaling within the DR, and thus 
lead to the manifestation of an anxiety- or depressive-like behavioral phenotype. 
 
Various experimental or genetic rodent models have also utilized chronic exposure to elevated 
GCs (Fernandes et al., 1997; Ardayfio and Kim, 2006; Brummelte and Galea, 2010; Sterner and 
Kalynchuk, 2010; Touma et al., 2010) or chronic stress paradigms such as chronic mild stress (Willner, 
1990; Willner, 2005) or repeated social defeat (Keeney and Hogg, 1999; Becker et al., 2007) to induce 
behavioral phenotypes and pathophysiological symptoms resembling those observed in patients with 
stress-related psychiatric disorders. Amongst those, a host of studies revealed that stress, either during 
early life or during adulthood, or direct exposure to elevated circulating levels of GCs can alter 
serotonergic function (Dinan, 1996; Lanfumey et al., 2008).  
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  Most importantly, however, recent studies suggest that GCs themselves control tph2 gene 
transcription in both rats and mice, but in opposite directions between the two species. In both 
ovariectomized female and intact male mice, repeated administration of DEX induces a decrease in tph2 
expression at the mRNA and the protein level in the DR, an effect that is abolished by co-administration 
of mifepristone, a GR antagonist (Clark et al., 2005; Clark et al., 2008). Also in mouse, adrenalectomy 
(“GC deprivation”) results in an elevation of tph2 mRNA levels in midbrain serotonergic systems, and this 
effect is reversed by GC replacement (Heydendael and Jacobson, 2009).  
 
  In contrast, in rats GCs tend to enhance 5-HT neurotransmission (Barr and Forster, 2011), while 
adrenalectomy leads to a decrease of Tph protein expression and 5-HT synthesis in the brain (Singh et 
al., 1990a; Azmitia et al., 1993). In adrenal-intact rats, tph2 mRNA expression (Malek et al., 2005) and 
Tph protein (Malek et al., 2004) are elevated before and during the first hours of the active phase (dark 
phase in rodents) of the diurnal light cycle, and the peak in tph2 mRNA expression correlates closely with 
the diurnal peak of CORT. Mechanistically, adrenalectomy (Singh et al., 1990a; Malek et al., 2007) 
abolishes the diurnal pattern of tph2 mRNA expression, while CORT restores the normal 24 h pattern of 
tph2 mRNA expression only when replaced orally in the drinking water during the 12 h dark phase. The 
latter delivery pattern of CORT is likely to mimic the natural, pulsatile release of CORT (Jasper and 
Engeland, 1991; Droste et al., 2008) because CORT is released about once per hour in rodents, and 
unpublished observations confirm 30-60 min intervals between drinking bouts in rats. In contrast, a 
constant level of CORT delivery throughout the diurnal cycle using subcutaneous pellets fails to restore 
the cyclic 24 h pattern of tph2 mRNA expression (Malek et al., 2007). Together, these studies suggest 
that GCs may directly contribute to the control of tph2 gene transcription, and that a rhythmic pattern of 
CORT secretion (including normal trough- and peak levels) is required for the normal diurnal variation in 
tph2 mRNA expression.  
 
The GC-dependency of tph2 mRNA expression comes as somewhat of a surprise because to date no 
GC-response element (GRE) has been identified in the promoter region of the gene. Thus, post-
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transcriptional mechanisms for GC-mediated regulation of TPH2 mRNA and protein expression are likely, 
such as an interaction with the 3‘-UTR of TPH2 mRNA, as found in rhesus monkeys with self-injurious 
behavior by Chen et al. (2010). 3’-UTR interactions have the potential to modulate mRNA stability, 
translocation and translation (Chen and Miller, 2012). Interestingly, GC-mediated regulation of mRNA 
stability is not necessarily dependent on activation of GR itself (Tillis et al., 2012). 
 
Precisely because of the reported dependency of tph2 expression on GC-diurnal rhythmicity, and 
in order to use an animal model as intact as possible, I decided to deliver GCs to adrenal-intact rats via 
the drinking water, instead of using subcutaneous pellets or adrenalectomized rodents. I hypothesized 
that chronically elevated GCs, without the perception of an external stressor per se, are sufficient to 
cause an anxiety- and depression-like behavioral phenotype, and act within anxiety-related neuronal 
networks to alter the gene expression of tph2, slc6a4 and htr1a (encoding the autoinhibitory 5-HT1A 
receptor) in a way that is likely to increase overall serotonergic activity within midbrain serotonergic 
systems and in specific target regions of the DR, and that the effects of chronic GC exposure are 
ultimately mediated through changes in local CRFR1 or CRFR2 signaling within the DR or its immediate 
surround. 
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CHAPTER	II	
	
Chronic	non‐invasive	corticosterone	administration	
abolishes	the	diurnal	pattern	of	tph2	expression	
 
1. Summary 
In a preliminary study, we characterized the effects of a drinking water-based CORT paradigm on 
serotonergic neuronal activation after only one day of treatment, and here use the same non-invasive 
mode of delivery as a rat model for chronic hypercortisolism to record the paradigm’s effects on 
physiology, behavior, and the expression of tph2, the gene encoding Tph2, the rate-limiting enzyme for 
brain 5-HT synthesis. Patients with Cushing’s disease, major depression, or other psychiatric disorders 
are often characterized by hypercortisolism.  
 
We delivered CORT (40 μg/ml, 100 μg/ml or 400 μg/ml) or vehicle (0.45% 2-hydroxypropyl-β-
cyclodextrin in tap water) to adrenal-intact adult, male rats via the drinking water for three weeks. On days 
15, 16, 17 and 18, respectively, the rats’ emotionality was assessed in the open-field (OF), social 
interaction (SI), elevated plus-maze (EPM), and forced swim tests (FST). On day 21, half of the rats in 
each group were killed 2 h into the dark phase of a 12/12 h reversed light/dark cycle; the other half were 
killed 2 h into the light phase. We then measured indices of HPA axis activity, plasma glucose and 
interleukin-6 (IL-6) availability, and neuronal tph2 expression at each time point. 
 
Chronic CORT intake was sufficient to cause increased anxiety- and depressive-like behavior in a 
dose-dependent manner. It also disrupted the diurnal pattern of plasma ACTH, plasma CORT, and 
plasma glucose concentrations, caused adrenal atrophy, and prevented regular weight gain. No diurnal or 
treatment-dependent changes were found for plasma levels of IL-6. Remarkably, all doses of 
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corticosterone treatment abolished the diurnal variation of tph2 mRNA expression in the DR by elevating 
the gene’s expression during the animals’ inactive (light) phase.  
 
Our data demonstrate that chronic elevation of GCs can create a vulnerability to a depression-like 
syndrome that is associated with increased tph2 expression, similar to that observed in depressed 
patients. 
 
(This study has been published: Donner NC, Montoya CD, Lukkes JL, Lowry CA (2012). Chronic non-
invasive corticosterone administration abolishes the diurnal pattern of tph2 expression. 
Psychoneuroendocrinology, 37, 645-661.) 
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2. Background 
Dysregulation of hypothalamic-pituitary-adrenal (HPA) axis functionality (Daban et al., 2005; 
Graeff, 2007; Pariante and Lightman, 2008; Walker et al., 2008) and brain serotonergic systems (Mann et 
al., 1989; Owens and Nemeroff, 1994; Naughton et al., 2000; Arango et al., 2002; Zill et al., 2004; De 
Luca et al., 2005a; You et al., 2005) is a common feature of many stress-related psychiatric disorders, 
including major depressive disorder (MDD), bipolar disorder, and anxiety disorders. Meanwhile, various 
animal models of depression have been validated, in part, because of their impairments in emotionality 
together with HPA axis- and serotonergic dysfunctions (Neumann et al., 2011). It is unclear, however, if 
HPA axis abnormalities such as hypercortisolemia are a cause or an effect of the observed serotonergic 
irregularities and behavioral symptoms (Lowry, 2002; Porter et al., 2007; Lanfumey et al., 2008; 
Heydendael and Jacobson, 2009). The fact that patients with Cushing’s syndrome, a disease 
characterized by chronic elevation of endogenous cortisol, have an increased prevalence of depression 
suggests that hypercortisolism itself may increase the vulnerability to development of psychiatric disease 
(Kelly et al., 1980; Sonino et al., 1998; Michaud et al., 2009; Pereira et al., 2010). 
 
Several lines of evidence report dysregulated HPA axis activity in MDD, a disease that affects 
about 20% of the US population and is the leading cause for disability between the ages of 15 and 44 
(Kessler et al., 2005). Depressed patients often display hypercortisolism under basal conditions (Plotsky 
et al., 1998b; Barden, 2004; Gillespie and Nemeroff, 2005), a flattened diurnal variation of circulating 
cortisol (Weber et al., 2000b; Putnam et al., 2008; Van den Bergh and Van Calster, 2009), and an 
abnormal ultradian pulsatility profile of cortisol (Deuschle et al., 1997; Wichers et al., 2008a). A classic 
diagnostic characteristic of melancholic depression is impaired negative feedback inhibition of the HPA 
axis in form of non-suppression of  adrenocorticotropin (ACTH) and cortisol release after the combined 
dexamethasone /corticotropin-releasing factor suppression test (Holsboer et al., 1982; Heuser et al., 
1994). As a possible compensatory response to the hypercortisolism, the ratio of glucocorticoid to 
mineralocorticoid receptor expression appears to be lower in depressed patients (Juruena et al., 2004). 
Meanwhile, promising treatment effects on both HPA axis activity and mood are observed in a new class 
CHAPTER II 
16 
 
of antidepressants that are designed to reduce the amount of circulating glucocorticoids (O'Dwyer et al., 
1995; Laakmann et al., 2004; Carvalho and Pariante, 2008).  
 
With respect to the serotonergic system, tph2, the gene encoding the rate-limiting enzyme for 
brain serotonin (5-hydroxytryptamine; 5-HT) synthesis (Walther and Bader, 2003; Walther et al., 2003; 
Patel et al., 2004; Zhang et al., 2004), may be a reliable biomarker for MDD: tph2 mRNA and protein 
expression has consistently been found to be elevated in depressed suicide victims, both in the brainstem 
dorsal raphe nucleus (DR) (Underwood et al., 1999; Boldrini et al., 2005; Bach-Mizrachi et al., 2006; 
Bonkale et al., 2006; Bach-Mizrachi et al., 2008; Underwood et al., 2010), the main source of 5-HT in the 
brain, and in DR projection regions (Perroud et al., 2010). Increased tph2 expression also concurs with 
the recent finding that depressed patients have increased brain 5-HT turnover that returns to basal levels 
following successful antidepressant treatment (Barton et al., 2008).    
 
Importantly, tph2 expression appears to depend largely on the circadian nature of circulating 
glucocorticoids. In adrenal-intact rats, tph2 mRNA expression (Malek et al., 2005) and protein (Malek et 
al., 2004) are elevated before and during the first hours of the active phase (dark phase in rodents), which 
correlates with peak plasma concentrations of corticosterone, the rat equivalent of human cortisol. 
Adrenalectomy abolishes the daily pattern of tph2 expression (Singh et al., 1990a; Malek et al., 2007), 
while corticosterone restores the diurnal tph2 mRNA rhythm when replaced via the drinking water for 12 h 
during the active phase. In contrast, a constant, clamped substitution of corticosterone through 
subcutaneous pellets fails to restore the diurnal pattern of tph2 expression (Malek et al., 2007).  
 
Based on these findings, we hypothesized that chronic elevation of glucocorticoids is sufficient to 
upregulate tph2 gene expression and cause a depressive-like phenotype. To test this hypothesis, we 
delivered three different doses of corticosterone for three weeks to adrenal-intact, male rats via the 
drinking water, and assessed their emotionality, endocrine function, and tph2 mRNA expression in the 
brainstem DR.  
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3. Materials and Methods 
3.1. Animals  
Sixty-four adrenal-intact, adult male Sprague Dawley rats (Harlan, Indianapolis, IN, USA; 200-225 
g) were kept with ad libitum access to vehicle or CORT solution, and standard rat chow (Teklad 22/5 
Rodent diet(W) 8640, Harlan) on a reversed 12:12 h light/dark cycle (lights on at 1900 h). Twenty-two 
age-matched conspecifics were used as partner rats in the social interaction (SI) test.  
 
3.2. Treatment 
Rats were pair-housed according to treatment group, and treated for 21 days with CORT (11β, 
21-dihydroxy-4-pregnene-3, 20-dione, Cat. No. C2505, Sigma-Aldrich, St. Louis, MO, USA) or vehicle 
(tap water containing 0.45% 2-hydroxypropyl-β-cyclodextrin, Cat. No. 332607, Sigma-Aldrich; n = 16). All 
CORT-containing drinking bottles were wrapped in aluminum foil to prevent light-induced degradation of 
the hormone, and clean bottles with freshly-prepared vehicle or corticosterone solutions were supplied 
every four days. Similar to doses used in previously reported rodent models (Conrad et al., 2007; Malek 
et al., 2007; Gourley et al., 2008b; David et al., 2009; Gourley and Taylor, 2009; Lee et al., 2010a), rats in 
the experimental groups were either treated with 40 μg/ml CORT (Cort-40, approximately 7 mg/kg (David 
et al., 2009), n = 16), 100 μg/ml CORT (Cort-100, approximately 30 mg/kg (Gourley et al., 2008b), n = 
16), or 400 μg/ml CORT (Cort-400, approximately 70-120 mg/kg (Conrad et al., 2007), n = 16). We chose 
this non-invasive drinking-water-mediated paradigm to retain the overall integrity of the diurnal CORT 
rhythmicity present in normal animals (Windle et al., 1998; Droste et al., 2008; Karatsoreos et al., 2010). 
 
3.3. Behavioral testing 
The behavioral tests were intentionally arranged in the order of the least stressful (OF) to the 
most stressful (FST) event to prevent effects of one test on the next day’s behavior. Detailed testing 
procedures are described below. All behavioral tests occurred between 0900 and 1600 h during the rats’ 
active phase within the dark cycle, and were recorded using low light conditions (red light, range: 3.5 - 
27.5 lux, see detailed descriptions below for lux measurements in each behavioral apparatus), and a low 
light-sensitive web cam (Microsoft® LifeCam VX-6000, Microsoft, Seattle, WA, USA) that was mounted 
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above the respective behavioral apparatus. Each behavioral apparatus was cleaned evenly with a damp 
cloth and a small amount of Windex® before individual animals were tested. Again, each experiment was 
run in randomized blocks on each of two consecutive days such that four rats of each treatment group 
were studied at each time point on each day. All behaviors were scored while blinded to the treatment 
groups. 
 
3.4. Open-field (OF) test 
The rats’ explorative and anxiety-related behaviors were tested in the OF test, as described 
previously (Hale et al., 2008a), on day 15. Our OF consisted of a 90 cm x 90 cm polyvinyl chloride (PVC) 
box with 40 cm-high walls and an open top, and the total duration was reduced to 10 instead of 15 min. 
The light intensity varied from 16.7 lux in the center of the OF to an average of 10.9 ± 1.1 lux in the 
corners of the OF. As an optical aid for scoring, the OF was divided into 6 x 6 equal-sized squares with 
tape. To analyze the rats’ exploration of the OF quantitatively, an outer zone was defined as the sum of 
all squares adjacent to the walls, an inner zone as the sum of all squares adjacent to the outer squares, 
and a center zone as the sum of the four inner-most squares using the spatial analysis software 
‘EthoVision XT’ (version 6.0; Noldus Information Technologies, Wageningen, The Netherlands). In the 
beginning of the test, each rat was placed into the same corner of the outer zone facing towards the 
center. The time spent in each zone, as well as the time spent immobile, the total distance moved, the 
number of rears at the walls, and the latency to enter the inner and center zones were the parameters we 
chose to score and report. Increased time spent in the inner or center zone is associated with increased 
anxiety states (Walsh and Cummins, 1976). As in our previous studies (Spiga et al., 2006), the open-field 
test also served as a familiarization of the test rat with the same environment that was used the following 
day for the social interaction test. 
 
3.5. Social Interaction (SI) 
The rats’ social behavior was assessed in the SI test (File, 1980; Spiga et al., 2006) for 10 min on 
day 16. During the SI test, each test rat was exposed to an age-matched unfamiliar male conspecific, the 
so-called partner rat, in the same PVC box and lighting conditions used the day before for the OF test. 
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The test rat was placed in one corner, and the partner rat was placed in the opposing corner of the OF. 
During the test the following behaviors were classified as active social interaction only when initiated by 
the test rat: sniffing, following, grooming, wrestling with, and crawling over or under the partner. The 
number of rears at the walls of the OF were analyzed as a general explorative parameter. Social 
interaction time and the number of rears (of the test rat) were evaluated using ‘The Observer’ software 
(version 5.0, Noldus Information Technologies). No aggressive behavior was observed. An increase in 
the percent time spent interacting is indicative of an anxiolytic treatment effect, a decrease signifies an 
anxiogenic effect (File, 1980). 
 
3.6. Elevated plus-maze (EPM) 
On day 17, all rats were tested once more for their explorative versus anxiety-related behavior 
(Pellow et al., 1985), this time in a slightly more contrasting behavioral paradigm, namely the EPM . Each 
rat was exposed to the EPM for 5 min. The EPM consisted of an elevated plus-shaped PVC platform with 
two closed arms (10 cm x 50 cm arm area with 40 cm-tall walls on both sides and at the end; average 
light intensity: 3.5 ± 0.2 lux) and two open arms (no walls; average light intensity: 26.0 ± 0.8 lux), 
connected in the center by a neutral, wall-free zone (10 cm x 10 cm; light intensity: 17.5 lux). All materials 
for the EPM were provided by Alpha Plastic & Design (Fort Collins, CO, USA). The contrast between the 
protected closed arms and the exposed open arms challenges the animal with a conflict situation 
between its exploratory drive and its innate fear of open and exposed areas (Pellow et al., 1985). Each rat 
was placed in the neutral zone with its head facing into the same closed arm. The following parameters 
for anxiety-related behavior were scored using ‘The Observer’ software (version 5.0; Noldus Information 
Technologies): the amount of time spent in the neutral center area, the time spent in the open versus the 
closed arms of the EPM, the number of entries (partial entry, meaning past shoulders) and full entries 
(past hind legs) into the closed and open arms, the latency to first enter an open arm, the number of rears 
at the walls of the closed arms, and the time spent grooming.  
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3.7. Forced swim test (FST) 
To assess the rats’ active versus passive stress coping behavior, all rats were exposed to the 
FST for 5 min on day 18 of treatment, after being trained for the novel task the day before, 3 hours after 
testing in the EPM, in a non-recorded pretest session for 15 min. In many behavioral and pharmacological 
labs, the FST is routinely used to analyze despair-like behavior (reactive versus proactive stress coping 
behavior) and effects of antidepressants in rodents (Porsolt et al., 2001). Two rats at a time were tested in 
the FST in separate round PVC buckets (30.5 cm diameter) that were filled with 25 °C tap water at 35 cm 
depth. From a camera above, the rats’ behavior was recorded, and later analyzed with ‘The Observer’ 
software (version 5.0, Noldus Information Technologies). The time spent climbing (proactive coping 
behavior involving high-pace front leg paddling that breaks the water surface, strong hind leg strokes), the 
time spent swimming (proactive coping behavior involving slow-pace front and hind leg movements, no 
breaking of the water surface), the time spent immobile (reactive, despair-like behavior involving minimal 
hind leg movements required only to stay afloat and keep the nose above water, and stiff body posture) 
and the number of dives (interpreted as proactive, explorative escape-seeking behavior) were scored 
(Cryan et al., 2005b).  
 
3.8. Measuring body weight (BW) & food and water intake 
The rats’ body weight was measured on day 0 (treatment start), and on days 7, 14 and 21. The 
total amount of food and drinking water consumed per cage each week was calculated based on the 
weight of the remaining food or drinking bottles, before the drinking bottle weight was converted into 
volume (density of 1g/1 ml). 
 
3.9. Experimental procedure  
To investigate diurnal variations in hormone concentrations and gene expression, half of the rats 
in each treatment group were killed between 0830 h and 0930 h (approximately 2 h into the active, dark 
phase), the other half between 2030 and 2130 h (approximately 2 h into the inactive, light phase) via 
rapid decapitation on day 21 of treatment. CORT drinking bottles were replaced with vehicle 90 min 
before sacrifice to reduce individual variability in plasma hormone concentrations. Brains were removed 
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immediately, fresh-frozen on dry ice, and stored at –80 °C until sectioning. Trunk blood was collected into 
sterile Falcon tubes containing 200 µl of 2% ethylene-diamine-tetraacetic acid (EDTA; Cat. No. EDS, 
Sigma-Aldrich) and 5% heparin (Cat. No. H6279, Sigma-Aldrich) in 0.05 M phosphate buffered saline. 
Blood samples were kept on ice until subsequent centrifugation in a microfuge (Beckman Coulter, 
Fullerton, CA, USA) for 15 min (10,000 rpm, 4 ºC). On ice, plasma samples from each rat were aliquoted 
and stored at ‒80 ºC. The pituitary and adrenal glands were dissected from surrounding tissue, their wet 
weight measured, and post-fixed in 0.1 M sodium phosphate buffer with 4% paraformaldehyde fixative 
(paraformaldehyde Cat. No. 158127, Sigma-Aldrich).  
 
3.10. Plasma hormone, glucose and cytokine assays 
Plasma ACTH concentrations were determined using an enzyme-linked immunoassay kit (Cat. 
No. EK-001-21, Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA). The immunoassay has reportedly 
a sensitivity of 70 pg/ml, a 5-10% intra-assay coefficient of variation, and an inter-assay coefficient of 
variation of less than 15%. The assay was conducted in duplicates, and plasma samples were used in 
original, undiluted form without prior extraction. 
 
CORT concentrations within the plasma samples were analyzed with an enzyme-linked 
immunoassay kit from Assay Designs (Cat. No. 900-097, Ann Arbor, MI, USA). According to the 
manufacturer, this assay has a sensitivity of 0.027 ng/ml, an intra-assay coefficient of variation of 6–8%, 
and an inter-assay coefficient of variation of 8-13%. Prior to being analyzed in duplicates in the assay, all 
CORT plasma samples were diluted 1:40 in assay buffer containing 2.5% steroid displacement reagent 
(provided by the kit).  
 
Plasma glucose concentrations were analyzed using an enzymatic assay kit from Cayman 
Chemical Company (Cat. No. 10009582, Ann Arbor, MI, USA). This assay has a range of 0-250 mg/dl, an 
intra-assay coefficient of variation of 5-8%, and an inter-assay coefficient of variation of 2-11%. 
Duplicates of glucose assay plasma samples were used in original, undiluted form.  
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Plasma concentrations of the pro-inflammatory cytokine interleukin 6 (IL-6) were determined in 
original, undiluted duplicate samples with an enzyme-linked immunoassay from Invitrogen (Cat. No. 
KRD0061C, Carlsbad, CO, USA). This IL-6 assay has a range of 5.0 – 1500 pg/ml, an intra-assay 
coefficient of variation of 3-6%, and an inter-assay coefficient of variation of 5-9%. 
 
3.11. In situ hybridization histochemistry (ISHH) and analysis of tph2 mRNA expression 
Brains were cryosectioned at 12 µm in series of six between bregma –7.568 mm and –8.648 mm 
(Paxinos and Watson, 1998), thaw-mounted onto VistaVision HistoBond® microscope slides (VWR 
Scientific, West Chester, PA, USA), and used in an in situ hybridization histochemistry (ISHH) assay with 
a cRNA probe complementary to bases 761 to 1343 of rat tph2 mRNA, similar to a previously described 
protocol (Donner and Handa, 2009). Briefly, brain slices were post-fixed, washed in 2x standard saline 
citrate (SSC) buffer, and hybridized with 1 x 106 cpm of [35-S]-UTP-labeled cRNA (per slide) in a 
humidified chamber at 55 °C. The next day, hybridization buffer was washed off with 2x SSC, and tissue 
was treated with RNase A to degrade non-hybridized cRNA. Slides were then desalted twice in 0.1x SSC 
buffer, dehydrated in an ascending alcohol series, air-dried, and apposed to a Kodak BioMax 
autoradiography film (PerkinElmer, Waltham, MA, USA) for 7 days. Digital autoradiography images were 
captured and analyzed with ImageJ (NIH, Bethesda, MD, USA) to measure background-corrected “optical 
density x area” using matrices in the shape of each subdivision of the brainstem DR. Based on Gardner 
et al. (2009c), Abrams et al. (2004), and Paxinos & Watson (1998), a total of 16 rostro-caudal levels 
containing 5 functional subdivisions of the DR (dorsal raphe nucleus, caudal part, DRC; dorsal raphe 
nucleus, dorsal part, DRD; dorsal raphe nucleus, interfascicular part, DRI; dorsal raphe nucleus, ventral 
part, DRV; dorsal raphe nucleus, ventrolateral part/ventrolateral periaqueductal gray region, 
DRVL/VLPAG) were analyzed. 
 
3.12. Morphological analysis of adrenal glands 
Post-fixed adrenal glands were cryosectioned at 30 µm, mounted on VistaVision HistoBond® 
microscope slides (VWR), and stained with 0.5% cresyl violet acetate (Paxinos and Watson, 1998) (Cat. 
No. 1791, Sigma-Aldrich). Based on digital photomicrographs, the width of the three adrenocortical layers 
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(Vinson, 2003), zona glomerulosa, zona fasciculata and zona reticularis (at 100x total magnification), and 
the diameter of the adrenal medulla (at 40x total magnification) were measured using ImageJ (Ichimura et 
al.). At 100x total magnification, an investigator blinded to the treatment groups also counted the number 
of cells within an area of 50 µm x 50 µm in each of the three adrenocortical subdivisions, using a 
microscope eyepiece with an integrated 10 x 10 mm reticule (Type 020-518.500, Leica Microsystems, 
Wetzlar, Germany).  
 
3.13. Statistical analysis  
All data were analyzed using SPSS (version 17, SPSS Inc., Chicago, IL, USA). Due to outlier 
identification via the Grubbs’ test (Grubbs, 1969), we excluded 6.2% of the data points for ‘immobility’, 
7.8% of the data points for the ‘latency until first inner entry’, and 3.1% each of the data points for ‘latency 
until first center zone entry’, and ‘time in center zone’ from the OF data set. Similarly, we eliminated 4.7% 
from the plasma CORT data set and 1.6% of the values from the plasma glucose data set. Body weight 
gain, food and water consumption were compared using a multifactor analysis of variance approach with 
treatment as the between-subjects factor and time (week 1, 2 and 3) as the within-subject factor. 
Behavioral parameters and pituitary and adrenal data were analyzed using a one-way ANOVA with the 
between-subjects factor treatment. Tph2 expression in the entire DR, and plasma hormone, glucose and 
IL-6 concentrations were analyzed using two-way ANOVA with treatment and killing time point as 
between-subjects factors. Tph2 expression within the different subdivisions of the DR was compared 
using an ANOVA for repeated measurements (within-subject factor subdivision) with treatment and killing 
time point as between-subjects factors. Where appropriate, a Fisher’s Protected least significant 
difference (LSD) post hoc analysis was performed. Significance was accepted at p < 0.05, and values are 
shown as the mean ± the standard error of the mean (SEM). Graphs for our figures and correlations were 
either designed in Excel 2007 (Microsoft), SigmaPlot (version 11.0, Systat Software Inc., Evanston, IL, 
USA), or SPSS (version 17, SPSS Inc., Chicago, IL, USA). 
 
Please refer to Appendix A) for methodological details and supplemental data.  
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4. Results 
4.1. Body weight (BW) gain 
Over the course of the three-week treatment, vehicle control rats gained an average of 85.8 g in 
body weight (BW), while Cort-40 and Cort-100 rats gained significantly less weight (Fig. 1A). Cort-400 
animals continuously lost weight during the three week period (treatment, F(3, 60) = 416.87, p < 0.001; 
time, F(2, 61) = 425.04, p < 0.001; interaction, F(6, 52) = 19.51, p < 0.001). CORT treatment also resulted 
in altered physical appearance such as a visible reduction in abdominal diameter (Fig. 1B).  
 
4.2. Body weight (BW)-corrected food & water intake  
When corrected for body weight, CORT treatment increased both food consumption (treatment, 
F(3, 28) = 2.41, p = 0.09; time, F(2, 29) = 988.12, p < 0.001; interaction, F(6, 20) = 2.97, p < 0.05) and 
water intake (treatment, F(3, 28) = 20.35, p < 0.001; time, F(2, 29) = 1723.11, p < 0.001; interaction, F(6, 
20) = 7.76, p < 0.001) dose-dependently during the three weeks of treatment. In other words, when body 
weight was taken into account, Cort-400 rats consumed more food than vehicle controls after two weeks 
of treatment, and significantly more food than all other treatment groups after three weeks of treatment 
(Fig. 1C). At the same time, Cort-100 and Cort-400 groups drank more water after two and three weeks 
than all other (on average heavier) treatment groups (Fig. 1D). 
 
4.3. Absolute food & water intake  
After two and three weeks of treatment, absolute food intake (Fig. A1, panel A, in Appendix A)), 
i.e., not corrected for body weight, was reduced in both the Cort-100 and the Cort-400 group, compared 
to vehicle controls and Cort-40 rats (treatment, F(3, 28) = 3.33, p < 0.05; time, F(2, 29) = 1214.57, p < 
0.001, interaction, F(6, 20) = 5.44, p < 0.001). Similarly, in absolute terms the Cort-400 group drank less 
water than all other treatment groups (treatment, F(3, 28) = 17.24, p < 0.001; time, F(2, 29) = 2547.48, p 
< 0.001; interaction, F(6, 20) = 3.63, p < 0.01; Fig. A1, panel B, in Appendix A)). 
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Figure 1. Body weight gain (A), physical appearance (B), food intake (C) and water consumption (D) of 
adrenal-intact male rats during treatment with either vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or 
40, 100 or 400 µg/ml corticosterone (CORT) via the drinking water for 21 days. All data represent 
cumulative values, meaning the difference compared to day 0 of the experiment. The arrows in (B) 
indicate the abdominal diameter, based on photographs of representative rats from each treatment group. 
All data are displayed as means + SEM. *p < 0.05, **p < 0.01 versus (a) vehicle, (b) Cort-40, and (c) Cort-
100, after post hoc analysis with Fisher’s Protected LSD test (vehicle, n = 16; Cort-40, n = 16; Cort-100, n 
= 16, Cort-400, n = 16).  
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4.4. Open-field (OF) 
Cort-400 rats spent significantly less time in the center zone of the OF (Fig. 2A) than vehicle 
controls (F(3, 41) = 3.46, p < 0.05), and also remained immobile longer than the Cort-40 and Cort-100 
groups (F(3, 56) = 3.27, p < 0.05). Cort-400 rats also took more time before entering the inner (F(3, 55) = 
3.16, p < 0.05) and center zones of the open-field for the first time (F(3, 41) = 3.07, p < 0.05). The 
observed treatment differences are indicative of a dose-dependent anxiogenic effect of CORT.  
 
4.5. Elevated plus-maze (EPM) 
The EPM revealed a strong anxiogenic effect of chronic CORT treatment, as reflected in an 
incremental dose-response within most behavioral parameters (Fig. 2B). Compared to the vehicle group, 
Cort-100 and Cort-400 rats, but not Cort-40 animals, spent more time in the protected, closed arms (F(3, 
60) = 4.35, p < 0.01), and less time in the unprotected, open arms (F(3, 60) = 5.97, p < 0.01). All doses 
reduced the number of full open arm entries (F(3, 60) = 6.32, p < 0.01) and increased rears at the walls of 
the closed arms (F(3, 60) = 9.39, p < 0.001) relative to the vehicle group. Rats of the Cort-400 group also 
entered the open arms of the EPM less often than the vehicle and Cort-40 groups (F(3, 60) = 2.97, p < 
0.05). No treatment-dependent differences were detected for the time spent in the neutral central area, 
grooming, or the number of entries into the closed arms (a measure of locomotor activity).  
 
4.6. Social interaction (SI)  
Cort-400 rats interacted less with the conspecific male than vehicle controls (F(3, 60) = 3.10, p < 
0.05; Fig. 3), indicating increased anxiety-like behavior. No differences in SI were observed between the 
Cort-40, Cort-100 and the vehicle group, and no treatment effects on rearing behavior were observed. 
 
4.7. Forced Swim Test (FST) 
Compared to vehicle controls and the Cort-40 group, Cort-100 and Cort-400 animals displayed 
less climbing behavior (F(3, 60) = 4.24, p < 0.01), and more immobility (F(3, 60) = 3.97, p < 0.05; Fig. 4) 
in the FST. CORT treatment also tended to increase the number of dives, although this comparison only 
approached significance (F(3, 60) = 2.62, p = 0.059; Fig. 4). Scores for swimming behavior were similar 
amongst all treatment groups. 
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Figure 2. Anxiety-related behavioral parameters that were assessed in the open-field on day 15, and on 
the elevated plus-maze on day 17 of treatment. Adult, male rats were either treated with vehicle (0.45% 
hydroxypropyl-beta-cyclodextrin) or 40, 100 or 400 µg/ml corticosterone (CORT) via the drinking water for 
a total of 21 days. Both tests were performed during the rats’ active phase. Panel (A) displays the amount 
of time the rats spent in the outer, inner and center zones of the open-field, as well as the total duration of 
immobility during the test. Panel (A) also shows the latency to first enter the inner and center zones, and 
the total distance moved. Panel (B) depicts the percent time the rats spent either in the closed arms, the 
open arms, or in the neutral middle-square of the elevated plus-maze. The percent time spent grooming, 
the number of closed, open, and full open arm entries, and the number of rears at the walls are also 
indicated in panel (B). Data are displayed as means + SEM. *p < 0.05, **p < 0.01 versus (a) vehicle, (b) 
Cort-40, and (c) Cort-100, after post hoc analysis with Fisher’s Protected LSD test (vehicle, n = 16; Cort-
40, n = 16; Cort-100, n = 16, Cort-400, n = 16).  
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Figure 3. Social interaction scores on day 16 of treatment. Rats were either treated with vehicle (0.45% 
hydroxypropyl-beta-cyclodextrin) or 40, 100 or 400 µg/ml corticosterone (CORT) in the drinking water for 
a total of 21 days. Shown is the percentage of time each group spent actively engaging in social 
interaction with the partner rat, and the number of rears at the walls of the open-field. Data are displayed 
as means + SEM. *p < 0.05 versus vehicle, after post hoc analysis with Fisher’s Protected LSD test 
(vehicle, n = 16; Cort-40, n = 16; Cort-100, n = 16, Cort-400, n = 16). 
 
 
 
Figure 4. The rats’ stress coping behavior as assessed in the forced swim test on day 18 of treatment. 
Adult, male rats were either treated with vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or 40, 100 or 
400 µg/ml corticosterone (CORT) via the drinking water. Shown is the percentage of time the rats spent 
either actively climbing or swimming, or immobile (passive coping behavior). The number of dives 
(proactive escape seeking behavior) for each treatment group is displayed on the right side. Data are 
displayed as means + SEM. *p < 0.05, **p < 0.01 versus (a) vehicle or (b) Cort-40, after post hoc analysis 
with Fisher’s Protected LSD test (vehicle, n = 16; Cort-40, n = 16; Cort-100, n = 16, Cort-400, n = 16).
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4.8. Plasma ACTH, CORT, glucose and IL-6 concentrations  
In vehicle controls, plasma ACTH was significantly higher during the active, dark phase, 
compared to rats killed during their inactive, light phase (Fig. 5A). In comparison, Cort-40 rats did not 
show the described diurnal pattern. Cort-100 and Cort-400 groups also lacked a diurnal variance, and 
their absolute plasma ACTH concentrations were decreased in a dose-dependent manner compared to 
vehicle controls (treatment, F(3, 60) = 46.16, p < 0.001; killing time point, F(1, 62) = 3.80, p = 0.05; 
interaction, F(3, 56) = 3.99, p < 0.05). 
 
Similarly, plasma CORT concentrations of vehicle and Cort-40 rats were significantly elevated in 
dark-phase compared to light-phase animals (Fig. 5B). This diurnal variation was absent in Cort-100 and 
Cort-400 animals (treatment, F(3, 57) = 8.98, p < 0.001; killing time point, F(1, 59) = 16.21, p < 0.001 
interaction, F(3, 53) = 9.46, p < 0.001). Cort-400 treatment resulted in light-phase plasma CORT 
concentrations that were elevated compared to all other groups at that time point, most likely reflecting 
excess exogenous CORT from the drinking water. 
 
In vehicle and Cort-40 rats, plasma glucose concentrations also varied diurnally (Fig. 5C), with 
elevated plasma glucose during the dark phase. Again, this diurnal pattern was abolished in the Cort-100 
and Cort-400 groups (treatment, F(3, 59) = 34.97, p < 0.001; killing time point, F(1, 61) = 6.96, p < 0.05; 
interaction, F(3, 55) = 2.71, p = 0.05). 
 
No treatment- or time-dependent differences were detected for plasma concentrations of IL-6 
(treatment, F(3, 60) = 0.49, p = 0.687; killing time point, F(1, 62) = 0.60, p = 0.444; interaction, F(3, 56) = 
0.97, p = 0.414; see Table A1 in Appendix A)). 
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Figure 5. Concentrations of adrenocorticotropin (ACTH; A), corticosterone (B), and glucose (C) in plasma 
sampled from adrenal-intact male rats during the light and dark phases after treatment with either vehicle 
(0.45% hydroxypropyl-beta-cyclodextrin) or 40, 100 or 400 µg/ml corticosterone (CORT) via the drinking 
water for 21 days. Half of each treatment group was killed during their inactive phase (2100 h, 2 h after 
lights on), the other half during their active phase (0900 h, 2 h after lights off). Corticosterone-drinking 
water bottles were replaced with vehicle bottles 90 min before the rats were sacrificed. All data are 
displayed as means + SEM. *p < 0.05, **p < 0.01 versus the corresponding light or dark phase value of 
(a) vehicle, (b) Cort-40, or (c) Cort-100. #p < 0.05, ##p < 0.01 versus the corresponding light phase value 
within the same treatment group, after post hoc analysis with Fisher’s Protected LSD test (vehicle-light, n 
= 8; vehicle-dark, n = 8; Cort-40-light, n = 8; Cort-40-dark, n = 8; Cort-100-light, n = 8, Cort-100-dark, n = 
8; Cort-400-light, n = 8; Cort-400-dark, n = 8).  
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4.9. Adrenal atrophy 
Table 1 summarizes the dose-dependent effects of CORT to induce adrenal atrophy. Three 
weeks of CORT treatment significantly reduced adrenal gland weight (F(3, 60) = 13.25, p < 0.001), 
diameter (F(3, 60) = 30.62, p < 0.001), and adrenal cortex width (F(3, 60) = 48.25, p < 0.001). Within the 
adrenal cortex, the strongest treatment effects on zone width (F(3, 60) = 51.95, p < 0.001) and cell 
density (increased: F(3, 60) = 48.62, p < 0.001) were detected within the zona fasciculata (Fig. 6), where 
most glucocorticoid-producing cells are located. The observed adrenal atrophy is most likely due to 
negative feedback regulation of HPA axis tissues by means of the exogenous CORT (Plaschke et al., 
2006). For a detailed description of the atrophy results see supplemental material in Appendix A). 
 
Table 1. Dose-dependent effect of corticosterone on pituitary and adrenal glands (1)  
 Vehicle Cort-40 Cort-100 Cort-400 
weight of pituitary (mg) 9.6 ± 0.4 10.1 ± 0.3 10.3 ± 0.7 9.9 ± 2.0 
weight of both adrenal glands (mg) 50.8 ± 2.1 38.4 ± 3.8**(a) 32.0 ± 3.4**(a) 25.0 ± 2.4**(a,b) 
diameter of entire adrenal gland (µm) 3661 ± 113 3365 ± 112*(a) 3022 ± 74*(b),**(a) 2382 ± 94**(a,b,c) 
 adrenal medulla diameter (µm) 1293 ± 90 1187 ± 71 1383 ± 79 1134 ± 78 
   adrenal cortex width (µm) 1184 ± 34 1089 ± 52 820 ± 28**(a,b) 624 ± 28**(a,b,c) 
         zona glomerulosa:     
                 width (µm) 102 ± 5 95 ± 5 89 ± 11 56 ± 4**(a,b,c) 
                 cell density (cells/(50 µm)2) 33.8 ± 3.0 38.2 ± 0.9 40.1 ± 1.4*(a) 46.8 ± 1.1*(c),**(a,b) 
         zona fasciculata:      
                 width (µm) 548 ± 18 409 ± 36*(a) 171 ± 9**(a,b) 135 ± 5**(a,b) 
                 cell density (cells/(50 µm)2) 17.3 ± 0.7 22 ± 1.3**
(a) 28.1 ± 1.6**(a,b) 36.2 ± 0.8**(a,b,c) 
         zona reticularis:     
                 width (µm) 534 ± 17 585 ± 38 560 ± 26 433 ± 24*(a),**(b,c) 
                 cell density (cells/(50 µm)2) 33.1 ± 1.7 34.6 ± 1.3 40.3 ± 0.7**
(a,b) 43.6 ± 0.6**(a,b) 
 
(1) Listed are the weights of the pituitary and both adrenal glands, as well as the average adrenal gland 
size, diameter of the adrenal gland and adrenal medulla, widths of the subregions of the adrenal cortex, 
and cell densities in each adrenocortical subregion of adult male rats that were either treated with vehicle 
(0.45% hydroxypropyl-beta-cyclodextrin) or 40, 100 or 400 µg/ml corticosterone (CORT) via the drinking 
water for 21 days. Data are displayed as means ± SEM. *p < 0.05, **p < 0.01 versus (a) Vehicle, (b) Cort-
40, and (c) Cort-100, after post hoc analysis with Fisher’s Protected LSD test (Vehicle, n = 16; Cort-40, n 
= 16; Cort-100, n = 16, Cort-400, n = 16).  
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Figure 6. Photomicrographs of adrenal gland sections that were stained with cresyl violet to visualize the 
diameter of the adrenal cortex (dashed double arrow) and its subdivisions. Adult, male rats were either 
treated with vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or 40, 100 or 400 µg/ml corticosterone 
(CORT) in the drinking water for 21 days. The borders between the three cortical subdivisions in each 
treatment group are indicated by dashed lines. The continuous double arrow indicates the diameter of the 
zona fasciculata, the principal region of glucocorticoid production. Abbreviations: ZG, zona glomerulosa; 
ZF, zona fasciculata; ZR, zona reticularis; M, adrenal medulla. Scale bar: 100 µm. 
 
 
4.10. tph2 mRNA expression in the DR 
CORT treatment significantly altered tph2 expression in the entire DR, meaning when all 
subregions of the DR (Fig. 7) were averaged for each individual (treatment, F(3, 60) = 3.05, p < 0.05; 
killing time point, F(1, 62) = 1.37, p = 0.242; interaction, F(3, 56) = 2.71, p < 0.01; Fig. 8). Specifically, the 
circadian difference (27%) in tph2 expression as observed between light and dark phase vehicle-animals 
(p = 0.002) was no longer present in any of the CORT-treated groups. Within the light phase, Cort-40 (p < 
0.05), Cort-100 (p < 0.01), and Cort-400 (p = 0.01) rats all expressed significantly more tph2 mRNA than 
vehicle controls (Fig. 8). No treatment-dependent differences in tph2 expression were detected in rats 
that were killed during their active, dark phase. 
 
With the exception of the DRI, this treatment effect of CORT was maintained throughout all DR 
subdivisions when analyzed separately, indicating a global, not circuit- or subregion-specific effect of 
CORT on basal tph2 expression. For subregional results of tph2 expression in the DRD, DRV, 
DRVL/VLPAG, DRC and DRI (Fig. A2, panels A-G), and for results of tph2 expression in the MnR (Fig. 
A3), please consult Appendix A). Appendix A) also contains correlation analyses of behavioral 
parameters with subregional and overall tph2 mRNA expression in the DR (Fig. A4, panels A-G). 
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Figure 7. Neuroanatomical atlas of rat tph2 mRNA expression used for analysis of the dorsal raphe 
nucleus (DR). Displayed (from top left to bottom right) are the sixteen coronal levels that were used to 
measure tph2 mRNA expression in all subregions of the dorsal raphe nucleus from rostral (–7.568 mm 
bregma, designated level +8) to caudal (–8.648 mm bregma, designated level –7). Photographs are 
autoradiographic images revealing the localization of bound 35-S-labeled cRNA probe complementary to 
tph2 mRNA. Abbreviations are applicable to each following level until indicated differently. Abbreviations: 
DRC, dorsal raphe nucleus, caudal part; DRD, dorsal raphe nucleus, dorsal part; DRI, dorsal raphe 
nucleus, interfascicular part; DRV, dorsal raphe nucleus, ventral part; DRVL, dorsal raphe nucleus, 
ventrolateral part; VLPAG, ventrolateral periaqueductal gray. Scale bar: 1 mm. 
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Figure 8. Average expression of tph2 mRNA (A; mean gray value) in the entire brainstem dorsal raphe 
nucleus, and (B) representative photomicrographs of light- and dark-phase tph2 mRNA expression in 
each treatment group at about —8.144 mm bregma. Adult, male rats were either treated with vehicle 
(0.45% hydroxypropyl-beta-cyclodextrin) or 40, 100 or 400 µg/ml corticosterone (CORT) for 21 days. Half 
of each treatment group was killed 2 h into the animals’ inactive, light phase, the other half 2 h into the 
rats’ active, dark phase. *p < 0.05, **p < 0.01 versus the corresponding light phase value of Vehicle. ##p 
< 0.01 versus vehicle-light phase, after post hoc analysis with Fisher’s Protected LSD test (vehicle-light, n 
= 8; vehicle-dark, n = 8; Cort-40-light, n = 8; Cort-40-dark, n = 8; Cort-100-light, n = 8, Cort-100-dark, n = 
8; Cort-400-light, n = 8; Cort-400-dark, n = 8). Scale bar: 1 mm. 
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5. Discussion 
Administration of CORT in the drinking water for three consecutive weeks dose-dependently 
altered body weight gain, induced despair- and anxiety-like behavior, flattened the diurnal HPA axis 
rhythm, and elevated tph2 expression in the DR of male rats. 
 
5.1. Depressive-like behavior in the FST 
Our results demonstrate that chronic glucocorticoid delivery to adrenal-intact rats is sufficient to 
induce despair-like behavior. This is consistent with recent studies reporting comparable behavioral 
effects after drinking-water-mediated corticosterone administration (Gourley et al., 2008b; Gourley et al., 
2008a; Gourley and Taylor, 2009; Lee et al., 2010a). Here, Cort-100 and Cort-400 rats responded with 
decreased climbing behavior and increased immobility in the FST, but showed no change in swimming 
behavior. Our results are inconsistent with a study in which adrenal-intact mice treated with corticosterone 
(35 μg/ml via the drinking water) for 7 weeks showed no differences in mobility in the FST (David et al., 
2009). The conflicting findings in the FST may be due to species differences, the time course of 
treatment, or methodology. For example, the murine FST only scores the final 4 minutes of the 5 min test 
session, while the majority of climbing behavior (60%-95% in this study) tends to occur during the first 
minute of the test. On the other hand, our findings are consistent with those of Brotto et al. (2001) who 
also found that chronic corticosterone (20 mg/kg, s.c., daily during the active, dark phase for 10 days) 
decreases climbing behavior, without affecting swimming behavior, in adrenal-intact male rats. An 
increase in swimming behavior is thought to be associated with serotonergic activity, while decreased 
climbing is correlated with adrenergic or dopaminergic intervention (Detke et al., 1995; Cryan et al., 
2005a; Perona et al., 2008). Indeed, chronic corticosterone treatment decreases hippocampal tyrosine 
hydroxylase mRNA and protein expression (Zhao et al., 2008). Consequently the corticosterone-induced 
decrease in climbing behavior observed in the FST in our study may be due to decreases in tyrosine 
hydroxylase mRNA and protein expression. This does not, however, preclude the possibility that 
elimination of the diurnal rhythm of tph2 mRNA contributes to specific symptoms in hypercortisolism-
induced depressive disorders (apart from those that might be reflected by reduced climbing behavior in 
the FST), such as increases in anxiety (Cloninger, 1990; Brady and Kendall, 1992; Kessler et al., 2005; 
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Godart et al., 2006) or disruption of circadian rhythms (Soria and Urretavizcaya, 2009; Westrich and 
Sprouse, 2010), manifesting, for example, in sleep problems (Pandi-Perumal et al., 2009). More 
mechanistic studies are necessary  to reveal whether or not the serotonergic system plays a crucial role 
in mediating the behavioral consequences of chronic glucocorticoid administration.  
 
5.2. Anxiety-like behavior in the OF, EPM, and SI test 
Concordant with previous studies (Ardayfio and Kim, 2006; Murray et al., 2008; Lee et al., 
2010a), chronic corticosterone treatment induced an anxiety-like state. In the SI and OF tests, increased 
anxiety-like behavior was only evident in Cort-400 rats. On the EPM, however, both Cort-100 and Cort-
400 produced a strong anxiogenic effect (e.g. percent time in the open arms), and the number of full open 
arm entries was reduced following all chronic doses of corticosterone. The EPM is thought to include both 
conflict anxiety and panic- or escape-like behaviors (Pellow et al., 1985; McNaughton and Zangrossi 
Junior, 2008), and the greater sensitivity of this test, compared to SI or OF, may reflect effects of 
corticosterone on specific anxiety-related neuronal circuits (Lowry et al., 2005; Hale et al., 2008a; Lowry 
et al., 2008c). In our study, we did not observe altered locomotor activity in the OF test, and the increased 
number of rears of all corticosterone treatment groups in the EPM test may simply be confounded by the 
fact that these rats also spent more time in the closed arms, where most of the explorative rearing 
behavior naturally occurs. Corticosterone’s effect on locomotion, however, remains controversial. In some 
studies (Veldhuis et al., 1982; Cador et al., 1993; Sandi and Guaza, 1994; Sandi et al., 1996a, b) acute or 
chronic corticosterone treatment has been reported to increase rat locomotor activity, while in others, 
chronic corticosterone administration had no effect on locomotion (Ehlers et al., 1992; Kalynchuk et al., 
2004; Marks et al., 2009).  
 
5.3. Elevated tph2 mRNA during the light phase and abolished diurnal variation of tph2 mRNA 
In our model, chronic administration of corticosterone elevated tph2 expression in the DR. In 
contrast, previous studies have found that tph2 expression is resistant to stress-induced increases in 
expression. For example, tph2 expression is unaltered following exposure of rats to social defeat 
(Gardner et al., 2009c), chronic restraint stress (Abumaria et al., 2008), or chronic social stress (Abumaria 
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et al., 2006). However, chronic unpredictable stress in adult male mice results in an increased 
corticosterone stress response and elevates tph2 mRNA expression in the DR (McEuen et al., 2008), 
suggesting that tph2 expression is only altered if habituation to a chronic stressor is prevented. In 
addition, studies in our laboratory have shown that adverse early life experience (e.g. maternal 
separation) creates a vulnerability to stress-induced increases in tph2 mRNA later in life, suggesting that 
interactions of development and environment are crucial in determining tph2 mRNA expression (Gardner 
et al., 2009c; Hale et al., 2011).  
 
Previous studies by Malek and colleagues revealed that the diurnal pattern of tph2 expression 
depends on the circadian rhythm of corticosterone (Malek et al., 2007). Here, we demonstrate that 
chronic corticosterone elevation abolishes the diurnal rhythm of the gene’s expression by enhancing tph2 
expression during the inactive phase, while no differences were detected during the active phase. In 
contrast, Clark et al. have identified a decrease in both tph2 expression in the DR and 5-HT synthesis in 
the frontal cortex after mice were exposed to 4 days of low dose dexamethasone (0.1 to 3 mg/kg, s.c. 
injection once per day), an effect that was blocked by co-administration of the glucocorticoid receptor 
antagonist mifepristone (Clark et al., 2005; Clark et al., 2008). Consistent with our findings, however, 
another study using the same species and delivery paradigm demonstrated that dexamethasone 
treatment of adrenalectomized rats via the drinking water increases Tph protein in the DR (Azmitia et al., 
1993). While rats normally consume most of their water during drinking bouts throughout the active, dark 
phase (Johnson and Johnson, 1990), it is possible that chronic corticosterone administration in our study 
disrupted the circadian rhythm of drinking behavior, particularly as disruption of tph2 mRNA rhythmicity 
may lead to disruption of Tph protein rhythmicity in the suprachiasmatic nucleus (SCN) (Barassin et al., 
2002), the predominant circadian pacemaker of the brain. Serotonergic function in the SCN plays an 
important role in the control of circadian rhythms ((for review see Lowry, 2002)), including perhaps the 
circadian pattern of drinking behavior (Edgar et al., 1997; Boer et al., 1998).  
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5.4. Correlation of tph2 expression and anxiety- and depressive-like behavior  
The fact that all doses of corticosterone treatment sufficiently abolished the normal diurnal 
variation in tph2 mRNA emphasizes the potential of tph2 mRNA diurnal rhythmicity as a sensitive 
biomarker for the development of depression. Yet, higher corticosterone doses were generally required to 
alter behavioral parameters, suggesting that together with altered serotonergic function, other 
glucocorticoid-sensitive brain circuitries are necessary to facilitate the behavioral phenotype of anxiety 
and depressive disorders.  
 
In our study, increased tph2 mRNA expression was associated with increased anxiety-related 
behavior and increased immobility in the FST. Our findings are seemingly inconsistent with previous 
reports that found increased tph2 expression in the DR to be associated with antidepressant-like or 
anxiolytic effects in rodent models.  For example, previous studies have found correlations between 
increased tph2 mRNA expression and antidepressant-like or anxiolytic behavior following chronic 
treatment with antidepressants, such as imipramine or fluoxetine (Shishkina et al., 2007; Heydendael and 
Jacobson, 2009; 2010), or with sex steroids (Hiroi et al., 2006; Donner and Handa, 2009). In contrast, our 
data are consistent with the finding that chronic treatment with selective serotonin reuptake inhibitors like 
citalopram and/or fluoxetine result in decreased tph2 mRNA (Shishkina et al., 2011) and Tph protein in 
the DR (MacGillivray et al., 2010), and that chronic citalopram decreases serotonin synthesis in DR target 
regions (Honig et al., 2009). In addition, our findings are consistent with studies of post-mortem tissues 
from depressed suicide patients, which have consistently found elevated tph2 mRNA and protein 
expression in the DR (Underwood et al., 1999; Boldrini et al., 2005; Bach-Mizrachi et al., 2006; Bonkale et 
al., 2006; Bach-Mizrachi et al., 2008; Underwood et al., 2010). 
 
5.5. Proposed mechanism of corticosterone action to regulate tph2 expression 
Based on the global increase in tph2 expression throughout all major subdivisions of the DR, we 
hypothesize that corticosterone acts directly on glucocorticoid or mineralocorticoid receptors within the 
DR to regulate tph2 gene expression rather than indirectly, for example, on CRF neurons in the central 
nucleus of the amygdala. Also, direct, chronic infusion of CRF into the DR is insufficient to significantly 
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alter tph2 expression (Clark et al., 2007). A potential role for CRF in the central nucleus of the amygdala 
in glucocorticoid-induced increases in tph2 expression would be supported by findings that 
glucocorticoids given chronically to adrenal-intact rats increase crf mRNA expression in the central 
nucleus of the amygdala (Makino et al. 1994). CRF neurons within the central nucleus of the amygdala 
project to the DR (Gray and Magnuson, 1992; Gray, 1993), and activate serotonergic systems in a 
glucocorticoid-dependent manner (Singh et al., 1990b; Singh et al., 1992; Forster et al., 2008). However, 
a stress challenge may be required to increase tph2 expression via this pathway, and would be expected 
to result in site-specific increases in tph2 expression, due to the fact that the central nucleus of the 
amygdala has topographically organized projections to the DR, mainly to the ventrolateral and dorsal 
parts (DRVL/VLPAG and DRD) ((for review see Hale and Lowry, 2011b)). Indeed, in previous studies 
involving models of chronic anxiety states and vulnerability to a depression-like syndrome, we have found 
site specific increases in tph2 expression in the DRVL/VLPAG and DRD regions after stress challenge 
((Gardner et al., 2009c); and unpublished observations). 
 
5.6. Importance of tph2-neuronal projections and rhythmicity for hypothalamic regulation of circadian 
function  
Barassin et al. (2002) reported that in addition to the diurnal variation in tph2 mRNA expression 
as observed in the control animals in our study, Tph protein also displays a significant light/dark variation 
in the median raphe nucleus (MnR), the SCN, and specifically the lateral wings (DRVL/VLPAG) of the DR, 
but not in other DR subdivisions nor in the entire DR combined. Interestingly, both midbrain raphe regions 
that were shown to have diurnal variation in Tph expression (MnR and DRVL/VLPAG) are known to 
project to the SCN (Lowry et al., 2008a). Thus, although tph2 mRNA expression varies in a diurnal 
manner throughout the entire DR, diurnal variations in Tph protein seem most pronounced in neural 
systems regulating circadian function, such as the SCN. This has important implications for patients 
suffering from affective disorders as many of them suffer from dysfunctions of circadian rhythms, including 
HPA axis rhythmicity (Deuschle et al., 1997; Gillespie and Nemeroff, 2005; Graeff, 2007; Wichers et al., 
2008b), sleep-wake cycles (Pandi-Perumal et al., 2009; Westrich and Sprouse, 2010), and body 
temperature (Rausch et al., 2003; Bunney and Potkin, 2008).  
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5.7. Abolished diurnal variation of plasma ACTH 
While not all depressed patients display HPA axis abnormalities, adverse early life experiences 
are most predictive of elevated HPA axis activity and development of affective disorders in adulthood 
(Sanchez et al., 2001; Heim and Nemeroff, 2002; Heim et al., 2008). Consistent with findings in 
depressed patients that display hypercortisolism (Deuschle et al., 1997; Weber et al., 2000b; Wichers et 
al., 2008a; Van den Bergh and Van Calster, 2009), chronic glucocorticoid elevation in this study also 
flattened the diurnal HPA axis rhythm. In our study, normal circadian variation of plasma ACTH was 
completely abolished by all doses of corticosterone. More specifically, ACTH concentrations were 
reduced during the active phase in Cort-40 rats, and further decreased during both the inactive phase and 
active phase in Cort-100 and Cort-400 animals. The basal elevation of glucocorticoids and flattening of 
the HPA axis rhythm in human depressed patients is thought to be due to increased cortisol release 
frequency during the nadir of HPA axis activity (Deuschle et al., 1997), and impaired negative feedback of 
HPA axis activity (Heuser et al., 1994), possibly due to reduced sensitivity of glucocorticoid receptors 
either peripherally at the pituitary or centrally at the level of the hypothalamus and limbic structures 
(Holsboer, 2000; Pariante and Miller, 2001; Pariante, 2009). In our study, corticosterone treatment 
resulted in a dose-dependent overall decrease in plasma ACTH, potentially indicative of intact negative 
feedback mechanisms within the HPA axis of our experimental rats, even though circadian HPA axis 
rhythmicity was lost. 
  
5.8. Metabolic effects of CORT 
In male rats, reduced body weight gain is commonly used to assess the efficacy of repeated or 
chronic glucocorticoid treatment (Conrad et al., 2007; Gourley and Taylor, 2009). Low doses of repeated 
glucocorticoid treatment are known to exert anabolic actions while chronic medium to high doses 
enhance catabolic processes including lipolysis and muscle protein breakdown (Tomas et al., 1979; 
Devenport et al., 1989; Santana et al., 1995). Meanwhile, chronic medium to high doses of 
glucocorticoids act, for example, on hypothalamic neuropeptide Y to increase food intake (Tempel and 
Leibowitz, 1994). Accordingly, Cort-100 and Cort-400 rats in our study gained much less weight or 
continuously lost weight, even though they ate and drank more, when corrected for body weight, than 
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vehicle controls after two and three weeks of treatment. Chronic corticosterone administration also 
flattened the diurnal rhythm of plasma glucose does-dependently, and resulted in decreased plasma 
glucose availability, an effect that seems counterintuitive given the anti-insulin actions of glucocorticoids 
(Warne et al., 2009). However, complex species-, dose-, and diet-dependent metabolic changes take 
place during chronic glucocorticoid exposure. For example, opposite effects of chronic corticosterone 
administration (25 or 100 µg/ml in the drinking water for 4 weeks) on weight gain have been reported in 
mice (Karatsoreos et al., 2010), and depressed, hypercortisolic human patients display elevated fasting 
plasma glucose (Roberge et al., 2007; Cassels, 2009), suffer from glucose and insulin resistance (Weber 
et al., 2000a), and have a higher prevalence for developing obesity, type 2 diabetes, or metabolic 
syndrome (Tsigos and Chrousos, 2002; Roberge et al., 2007; Anagnostis et al., 2009; Kyrou and Tsigos, 
2009; Cagampang et al., 2011).  
 
6. Conclusion 
In conclusion, our data suggest that chronic exposure to increased concentrations of 
glucocorticoids, as observed in various affective disorders (Plotsky et al., 1998b; Barden, 2004; Gillespie 
and Nemeroff, 2005; Graeff, 2007; Gunduz-Bruce et al., 2007), Cushing’s syndrome (Sonino et al., 1998; 
Michaud et al., 2009; Pereira et al., 2010), or after prolonged stress exposure (Leonard, 2005; Herman et 
al., 2008; McEuen et al., 2008; Kyrou and Tsigos, 2009), is sufficient to elevate tph2 expression, induce a 
depression-like syndrome, flatten the diurnal HPA axis rhythm, and alter both glucose metabolism and 
weight gain. Our results indicate that dysregulation of circulating glucocorticoid concentrations and 
rhythmicity, independent from exposure to external stressors, disrupt the diurnal pattern of serotonin 
synthesis, and thus contribute to the dysfunction of circadian rhythms symptomatic of many psychiatric 
disorders, specifically affective disorders. In addition, our data provide further rationale for continued 
exploration of the use of HPA-axis-targeting medication for patients suffering from affective disorders 
(O'Dwyer et al., 1995; Belanoff et al., 2002; Pariante et al., 2003; Young et al., 2004). 
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CHAPTER	III	
	
Chronic	glucocorticoid	intake	alters	the	diurnal	
pattern	of	slc6a4	and	htr1a	mRNA	expression	in	
anxiety‐related	subdivisions	of	the	midbrain	raphe	
complex		
 
1. Summary 
While research has demonstrated that the diurnal expression pattern of tph2, the gene encoding 
the rate-limiting enzyme for 5-HT synthesis, depends on the circadian GC rhythm, Chapter II described 
that chronic GC exposure is also sufficient to cause an anxiety- and depression-like phenotype 
associated with an abolished diurnal variation of tph2 expression. This diurnal disruption is due to 
increased tph2 expression during the inactive phase (light phase in rodents). We here hypothesized that 
slc6a4, the gene encoding the serotonin transporter (SERT), and htr1a, the gene encoding the 
autoinhibitory 5-HT1A receptor, are also expressed in a diurnal pattern that is altered by chronic GC 
exposure.  
 
To test this hypothesis, we conducted in situ hybridization histochemistry on two more series of 
brain sections from the previous chronic study, in which adrenal-intact adult, male rats had been 
subjected to 40, 100, or 400 μg/ml CORT or vehicle (0.45% 2-hydroxypropyl-β-cyclodextrin) via the 
drinking water for 21 days, to assess slc6a4 and htr1a mRNA expression within subregions of the 
serotonergic DR. 
 
We found that CORT-treatment affected slc6a4 and htr1a mRNA expression within specific DR 
subdivisions. In vehicle-treated rats, the anxiety-related dorsal DR (DRD) displayed a diurnal variation in 
slc6a4 expression that was abolished in CORT-treated rats by suppressing slc6a4 expression dose-
dependently during the rats’ active dark phase. CORT treatment also decreased dark-phase slc6a4 
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expression in the caudal part of the ventral DR (cDRV), an area that provides, among other brain regions, 
a dense innervation of the sensorimotor cortex, and that is consistently affected in chronic anxiety models 
that involve vulnerability to panic-like responses. Expression of htr1a occurred in a diurnal pattern within 
the anxiety-related caudal DR (DRC), a pattern that was, again, abolished by chronic CORT treatment. 
No other subdivisions displayed a diurnal expression pattern of either gene, suggesting an indirect effect 
of chronic CORT treatment on gene expression, possibly via alteration of afferent signaling from the 
extended amygdala complex. In addition, a novel serotonergic gene expression index was calculated by 
dividing the tph2 expression values by the sum of both slc6a4 and htr1a expression. If gene expression 
reflects functional changes in serotonergic neurotransmission, a larger serotonergic gene expression 
index would be expected to indicate an increase in serotonergic neurotransmission. The index confirmed 
and further corroborated the treatment effects on serotonergic gene expression in the DRD, DRV and 
DRC, and also indicated a large increase in the serotonergic gene expression index in the DRI, as 
represented by a dose-dependent 20-40% increase of index during the rats’ (active) dark phase. 
 
The observed changes in tph2, slc6a4 and htr1a expression may result in an increased activity of 
serotonergic systems (more 5-HT production, less 5-HT reuptake, and disrupted diurnal 5-HT1A-mediated 
autoinhibition) particularly within those DR subdivisions previously associated with control of anxiety-
related behavior, such as the DRD and the DRC, or within the DRI, and area associated with the control 
of depressive-like behavior. 
 
(The majority of the data in this study has been published in abstract form:  Mani S, Donner NC, Matti AJ, 
Wacker AJ, Lowry CA (2012). Chronic glucocorticoid intake abolishes the diurnal pattern of slc6a4 and 
htr1a mRNA expression in anxiety-related serotonergic systems. Annual Meeting of the Society for 
Neuroscience (SfN), New Orleans, LA, USA, October 2012.) 
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2. Background 
Chapter II (Donner et al., 2012a) summarized the effects of chronic CORT intake via the drinking 
water on emotionality and on the expression of tph2, encoding the rate-limiting enzyme for serotonin 
synthesis, of adult, male rats. In order to obtain a more comprehensive impression of serotonergic gene 
expression in the DR after chronic exposure to elevated concentrations of circulating GCs, slc6a4 and 
htr1a mRNA expression were also analyzed in our non-invasive chronic CORT paradigm. The slc6a4 
gene encodes SERT, a high affinity, low capacity transporter recycling 5-HT into the presynaptic terminal, 
and a major target of the antidepressant class of SSRIs (Wilson, 2007; Nierenberg et al., 2008). SERT is 
expressed and active in synaptic terminals both within the DR and in target regions of the DR (Horschitz 
et al., 2001). The htr1a gene encodes the autoinhibitory serotonin receptor 5-HT1A that inhibits both 5-HT-
neuronal firing (Sprouse and Aghajanian, 1987) as well as 5-HT release (Bonvento et al., 1992) when 
stimulated, and that is located mainly on the soma and dendrites of 5-HT neurons (Riad et al., 2000). 
While SERT is considered a serotonergic marker protein, 5-HT1A expression, however, is not restricted to 
5-HT neurons (Kuroda et al., 1994). Nevertheless, both proteins play an important role in the regulation of 
extracellular 5-HT, which controls the activity of serotonin neurons. 
 
Understanding the factors and mechanisms that control the diurnal pattern and the overall 
expression level of slc6a4 and htr1a mRNA is of biomedical importance because clinically, both SERT 
and 5-HT1A have been implicated in psychiatric disorders and treatment effects. Human and animal 
literature suggests a role for both SERT and 5-HT1A in anxiety (Zhuang et al., 1999; Holmes and Hariri, 
2003; Holmes et al., 2003a; Holmes et al., 2003b), depression (Owens and Nemeroff, 1994; Neumeister 
et al., 2006; Drevets et al., 2007; Savitz et al., 2009), and the actions of antidepressant and anxiolytic 
medication (Schloss and Williams, 1998; Blier, 2003; Lacivita et al., 2008). Over the past decade, 
extensive clinical attention has also been given to the association of genetic polymorphisms of SLC6A4 
(Maron et al., 2004; Gyawali et al., 2010; Kuzelova et al., 2010; Strug et al., 2010; Daniele et al., 2011) 
and HTR1A (Albert and Lemonde, 2004; Lemonde et al., 2004; Le Francois et al., 2008) with psychiatric 
disorders. 
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In animal models, both stress as well as glucocorticoid exposure without the experience of 
external stressors per se have been demonstrated to interact with the expression or functionality of 5-
HT1A. Fairchild et al. (2003) found reduced electrophysiological 5-HT1A autoinhibition in the DR after 
chronic intake of 50 µg/ml CORT in the drinking water, but did not use appropriate methodology and 
neuroanatomical resolution to accurately assess htr1a mRNA expression. Similarly, acute pretreatment 
with 30-100 nM CORT reduced the 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)-induced, 5-
HT1A-mediated autoinhibition of serotonergic neurons in rat midbrain sections ex vivo (Laaris et al., 1995), 
while 8 weeks of chronic mild stress markedly desensitized 5-HT1A receptors within the DR, leading to 
decreased autoinhibition (Lanfumey et al., 1999). 
 
Amongst other brain regions, the dorsal hippocampus has been studied most intensively for its 
interactions with GC hormones, and postsynaptic htr1a mRNA expression, as opposed to htr1c 
expression, appears to be under tonic negative control by endogenous GC hormones in this region. 
Adrenalectomy causes a 60–127 % increase in htr1a mRNA expression within 24 h of adrenal gland 
removal throughout major subdivisions of the dorsal hippocampus, an effect that becomes even more 
pronounced after 1 week of adrenal removal, and GC replacement restores and maintains the gene’s 
expression level (Chalmers et al., 1993). Others have found reduced hippocampal htr1a mRNA 
expression 24 h after a serve stressor (Lopez et al., 1999), and after chronic restraint (Watanabe et al., 
1993) or chronic unpredictable stress (Lopez et al., 1998), whereas the literature reports inconsistent 
results for chronic CORT administration alone (Meijer and de Kloet, 1994; Lopez et al., 1999). In a recent 
study, 5-HT1A protein expression in the DR remained unchanged 24 h after inescapable tail shock 
(Rozeske et al., 2011), while inescapable tail shock was found to reduce 5-HT-neuronal firing rate by 
desensitizing the 5-HT1A receptor.  
 
Little is known about the interactions of chronic GC exposure with slc6a4 mRNA expression 
(Kuroda et al., 1994), but light-phase SERT protein expression has recently been reported to be 
increased after chronic CORT intake via the drinking water (100 µg/ml in 2.4% EtOH). Concordantly, 
maternal separation, a manipulation that has been demonstrated to result in long-lasting changes towards 
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an increased CORT stress response (Kalinichev et al., 2002), together with social defeat in adulthood 
increased slc6a4 mRNA expression in the entire DR (Gardner et al., 2009b). In contrast, chronic food 
restriction, a condition that at the same time chronically elevated GCs in the circulation, was found to 
decrease slc6a4 expression in the DR (Jahng et al., 2007).  
 
For both slc6a4 and htr1a mRNA, however, no detailed analysis of subdivision- and light/dark-
phase-dependent mRNA expression levels have been conducted under control conditions or after 
chronic, non-invasive CORT treatment. Thus, to test the hypothesis that chronic GC exposure dose-
dependently alters the circadian pattern and amount of both slc6a4 and htr1a mRNA expression, we 
employed in situ hybridization histochemistry (ISHH), and evaluated the light- and dark-phase expression 
of both genes in the DR of adult, male rats after 21 days of vehicle or 40, 100 or 400 µg/ml CORT intake 
via the drinking water.  
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3. Materials and Methods 
3.1. Animals and treatment 
As described in Chapter II (Donner et al., 2012a), 64 adrenal-intact, adult male Sprague Dawley 
rats (Harlan, Indianapolis, IN, USA; 200-225 g) were kept with ad libitum access to vehicle or CORT 
solution, and to standard rat chow, on a reversed 12:12 h light/dark cycle (lights on at 1900 h). Rats were 
pair-housed according to treatment group, and treated for 21 days with CORT (11β, 21-dihydroxy-4-
pregnene-3, 20-dione, Cat. No. C2505, Sigma-Aldrich, St. Louis, MO, USA) or vehicle (tap water 
containing 0.45 % 2-hydroxypropyl-β-cyclodextrin, Cat. No. 332607, Sigma-Aldrich; n = 16). Rats in the 
experimental groups were either treated with 40 μg/ml CORT (Cort-40, approximately 7 mg/kg/day (David 
et al., 2009), n = 16), 100 μg/ml CORT (Cort-100, approximately 30 mg/kg/day (Gourley et al., 2008b), n 
= 16), or 400 μg/ml CORT (Cort-400, approximately 70-120 mg/kg/day (Conrad et al., 2007), n = 16).  
 
3.2. Experimental procedure  
To investigate diurnal variations in slc6a4 and htr1a gene expression, half of the rats in each 
treatment group were killed between 0830 h and 0930 h (approximately 2 h into the active, dark phase), 
the other half between 2030 and 2130 h (approximately 2 h into the inactive, light phase) via rapid 
decapitation on day 21 of treatment. CORT drinking bottles were replaced with vehicle 90 min before 
sacrifice to reduce individual variability in plasma hormone concentrations. Brains were removed 
immediately, fresh-frozen on dry ice, and stored at –80 °C until sectioning.  
 
3.3. In situ hybridization histochemistry (ISHH) assays 
Brains were cryosectioned at 12 µm in series of six between bregma –7.640 mm and –8.576 mm 
(Paxinos and Watson, 1998), thaw-mounted onto VistaVision HistoBond® microscope slides (VWR 
Scientific, West Chester, PA, USA). One series of sections was used in an in situ hybridization 
histochemistry (ISHH) assay with a synthetic 50-base cDNA probe (5′-ACT GCA GAG TAC CCA TTG 
GAT ATT TGG CTA GGC TCT GCC CTG TCC GCT GT-3′, Integrated DNA Technologies, Coralville, IA, 
USA), complementary to bases 207–256 of rat slc6a4 mRNA, as described previously (Donner et al., 
2012c), while another series of sections was used in an ISHH assay with a mixture of two synthetic cDNA 
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probes (5'-ACG AAG TTC CTA AGC TGG TGC CTG CTC CCT TCT TTT CCA CCT TCC TGA C-3' and 
5'-GCC TCA CTG CCC CAT TAG TGC ACG GAG TCC CCA CCG CCC TGT TCT CA-3') complementary 
to bases 810–858 and 923–969, respectively, of rat htr1a mRNA (Hansen and Mikkelsen, 1998). All 
oligonucleotide probes were labeled at the 3′–end with [35-S]-deoxyadenosine-5′-triphosphate (dATP, 
Cat. No. 5620001, MP Biomedicals, Santa Ana, CA, USA) using terminal deoxynucleotidyl transferase 
(TdT, 20 U/μl, Cat. No. EP0161, Fermentas, Glen Burnie, MD, USA) for 1 h at 37 °C in a water bath, 
cleaned using a QIAquick nucleotide removal kit (Cat. No. 28304, Qiagen, Valencia, CA, USA), and used 
in an ISHH assay as described previously (Gardner et al., 2009b). The hybridization temperature for the 
oligonucleotide complementary to slc6a4 mRNA and the oligonucleotide mixture complementary to htr1a 
mRNA was 37 °C. Air-dried slides were apposed to a BioMax MR autoradiography film (Cat. No. 871 
5187, Carestream Health, Rochester, NY, USA) for 11 (slc6a4) or 17 days (htr1a), respectively.  
 
3.4. Analysis of slc6a4 and htr1a mRNA expression 
 Digital autoradiography images were analyzed with ImageJ (NIH, Bethesda, MD, USA) while 
blinded to the treatment groups to measure “gray value x area” (equivalent to expression of the respective 
gene) using matrices in the shape of each subdivision of the brainstem DR. Area (mm2) was defined as 
the area (within each matrix) that fell above a gray value threshold that was kept consistent throughout 
each gene’s analysis. Based on Gardner et al. (Gardner et al., 2009c), Abrams et al. (Abrams et al., 
2004), and Paxinos & Watson (Paxinos and Watson, 1998), a total of 14 rostro-caudal levels between –
7.640 and –8.576 from bregma, containing seven anatomical and functional subdivisions of the DR 
(dorsal raphe nucleus, caudal part, DRC, –8.420 to –8.672 mm from bregma; caudal aspect of the dorsal 
raphe nucleus, dorsal part, cDRD, –8.000 to –8.336 mm from bregma; caudal aspect of the dorsal raphe 
nucleus, ventral part, cDRV, –8.000 to –8.504 mm from bregma; dorsal raphe nucleus, interfascicular 
part, DRI, –8.420 to –8.672 mm from bregma; dorsal raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal gray region, DRVL/VLPAG, –7.832 to –8.504 mm from bregma; rostral aspect of the 
dorsal raphe nucleus, dorsal part, rDRD, –7.580 to –7.916 mm from bregma; rostral aspect of the dorsal 
raphe nucleus, ventral part, rDRV, –7.580 to –7.916 mm from bregma) were analyzed. Please see Fig. 1, 
panel A and B, for details of the pattern and exact rostrocaudal location of slc6a4 and htr1a mRNA 
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expression within the midbrain DR. The individual background of every image was subtracted from each 
value. Background was either measured in the surrounding midbrain tegmentum for the (serotonergic 
marker) slc6a4 mRNA, or in the white matter of the medial longitudinal fasciculus (mlf) for the htr1a assay 
(since htr1a mRNA is not a serotonergic marker). An average value was computed for the DRVL/VLPAG 
using values from both the left and right hemisphere. Throughout the 14 rostrocaudal levels, values for 
each of the seven DR subdivisions were averaged, and average slc6a4 and htr1a mRNA expression 
levels in the entire DR were also calculated for each rat. Similarly, rostral and caudal DRD and DRV 
values were averaged to obtain an average value for the entire DRD or DRV. 
 
3.5. Calculation of a novel serotonergic gene expression index 
Based on the assumption that observed changes in tph2, slc6a4 and htr1a mRNA expression are 
likely to be reflected in the same way at the protein and functional levels, a simple, but novel serotonergic 
gene expression index was calculated to estimate overall serotonergic activity. Elevated tph2 mRNA 
presumably leads to elevated Tph2 protein levels, and thus more 5-HT synthesis, while increases in 
slc6a4 mRNA most likely result in reduced serotonergic signaling secondary to increased amounts of 5-
HT being recycled into presynaptic terminals. Similarly, increased htr1a mRNA expression would most 
likely result in increased autoinhibition of serotonergic neurons because of increased 5-HT1A receptor 
expression within the cell membrane of synapses and dendrites. The formula used for this index was 
“INDEX = tph2 / (slc6a4 + htr1a) because tph2 mRNA expression divided by the sum of slc6a4 and htr1a 
expression should be a generalized estimate of overall serotonergic activity; the higher the index, the 
more serotonergic activity. In order to calculate this index, all of the tph2 mRNA images from Chapter II 
were reanalyzed to match the image analysis method that was used for slc6a4 and htr1a mRNA in this 
Chapter, meaning a threshold function was applied and held constant throughout the analysis, before 
each gray value was multiplied with the area (above threshold) within the respective subdivision-specific 
matrix.  
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Figure 1. Neuroanatomic atlases of rat slc6a4 and htr1a mRNA expression. Displayed (from top left to 
bottom right of each panel) are 14 representative coronal sections (12 μm) that were used to measure (A) 
slc6a4 and (B) htr1a mRNA expression in all subdivisions of the midbrain dorsal raphe nucleus (DR) from 
rostral (–7.640 mm bregma, designated level +7) to caudal (–8.576 mm bregma, designated level –6). 
Photomicrographs are autoradiographic images revealing the localization of hybridized 35-S-labeled 
oligonucleotide probe(s) complementary to slc6a4 or htr1a mRNA. Abbreviations are applicable to each 
following level until indicated differently. cDRD, caudal aspect of the dorsal raphe nucleus, dorsal part; 
cDRV, caudal aspect of the dorsal raphe nucleus, ventral part; DRC, dorsal raphe nucleus, caudal part; 
DRI, dorsal raphe nucleus, interfascicular part; DRVL, dorsal raphe nucleus, ventrolateral part; VLPAG, 
ventrolateral periaqueductal gray; rDRD, rostral aspect of the dorsal raphe nucleus, dorsal part; rDRV, 
rostral aspect of the dorsal raphe nucleus, ventral part. Scale bar: 1 mm.  
A 
B 
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3.6. Statistical analysis 
Prior to statistical analysis using SPSS (version 20 for Windows, SPSS Inc., Chicago, IL, USA) 
outliers were identified (Grubbs, 1969) and removed from the data set in Microsoft Excel. Due to Grubbs’ 
outlier identification, 0.78 % of the slc6a4 data set (5 data points of 640 final data points in total), 0.94 % 
of the htr1a data set (6 data points of 640), and 1.72 % of the reanalyzed and reused tph2 data set from 
Chapter II (11 data points of 640) were excluded. This resulted in a 2.3 % loss of data points (15 data 
points of 640) for the serotonergic INDEX. Slc6a4 and htr1a mRNA expression, as well as the 
serotonergic INDEX data were analyzed using MMLA with treatment (4) and killing time point (2) as 
between-subjects factors and brain region (7) as the within-subjects factor. If a treatment- or time-point-
effect or an interaction of both factors was detected in the MMLA, individual DR subdivisions were further 
analyzed using a two-way ANOVA with treatment (4) and killing time point (2) as between-subjects 
factors, followed by Fisher’s Protected least significant difference (LSD) post hoc test where appropriate. 
Post hoc comparison results were obtained from the output of a one-way ANOVA with Fisher’s Protected 
LSD as the selected post hoc test, without considering or reporting the one-way ANOVA result itself. 
Average gene expression and the average of the serotonergic gene expression index in the DRD, DRV 
and in the entire DR were also analyzed with a two-way ANOVA. Significance was accepted at p < 0.05, 
and all results are shown as the mean + the standard error of the mean (SEM). Graphs were designed in 
SigmaPlot (version 11.0, Systat Software Inc., Evanston, IL, USA).    
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4. Results 
4.1. Effects of chronic CORT intake on slc6a4 mRNA expression  
Chronic CORT-treatment interacted with light/dark phase (killing time point) to suppress dark-
phase slc6a4 mRNA expression in a region-specific manner (Fig. 2; treatment, F(3, 60) = 2.65, p = 0.060; 
killing time point, F(1, 62) = 0.91, p = 0.344; treatment x killing time point, F(3, 56) = 3.23, p < 0.05; 
treatment x region, F(3, 60) = 1.51, p = 0.130; killing time point x region, F(1, 62) = 1.22, p = 0.316; 
interaction (treatment x killing time point x region), F(3, 56) = 1.86, p = 0.05). This effect was observed 
after treatment with all CORT doses, but was regionally restricted to the rostral and caudal DRD, and to 
the caudal DRV.  
 
The caudal DRD was the only subdivision with a diurnal variance in slc6a4 expression in vehicle-
treated rats. Dark-phase suppression of slc6a4 mRNA expression in the caudal DRD (treatment, F(3, 60) 
= 3.58, p < 0.05; killing time point, F(1, 62) = 0.18, p = 0.671; interaction, F(3, 56) = 0.99, p = 0.381) and 
in the entire DRD (treatment, F(3, 60) = 3.58, p < 0.05; killing time point, F(1, 62) = 0.18, p = 0.671; 
interaction, F(3, 56) = 0.99, p = 0.381), consequently resulted in an abolished diurnal variance of slc6a4 
expression in comparison to vehicle control rats. In the rostral DRD (treatment, F(3, 59) = 3.58, p < 0.05; 
killing time point, F(1, 61) = 0.18, p = 0.671; interaction, F(3, 55) = 0.99, p = 0.381) and in the caudal DRV 
(treatment, F(3, 60) = 3.58, p < 0.05; killing time point, F(1, 62) = 0.18, p = 0.671; interaction, F(3, 56) = 
0.99, p = 0.381) CORT also suppressed dark-phase slc6a4 expression in a dose-dependent manner, 
reducing overall slc6a4 expression by 15 to 20 % compared to vehicle controls. No other subdivisions of 
the DR displayed a treatment-dependent alteration of slc6a4 expression. 
 
4.2. Effects of chronic CORT intake on htr1a mRNA expression  
The effects of chronic CORT-treatment and light/dark phase on htr1a mRNA expression were 
restricted to the caudal DRD and to the DRC, and were statistically only apparent in form of a significant 
interaction between treatment and region (Fig. 3; treatment, F(3, 60) = 0.92, p = 0.442; killing time point, 
F(1, 62) = 1.72, p =0.198; treatment x killing time point, F(3, 56) = 0.36, p = 0.780; treatment x region, 
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F(3, 60) = 2.19, p < 0.05 ; killing time point x region, F(1, 62) = 0.61, p = 0.721; interaction (treatment x 
killing time point x region), F(3, 56) = 1.27, p = 0.260).  
 
Interestingly, the DRC was the only subdivision displaying a strong diurnal variance in htr1a 
mRNA expression in vehicle controls, and this diurnal variation was dose-dependently abolished by 
chronic CORT-treatment (treatment, F(3, 58) = 0.71, p =0.555; killing time point, F(1, 60) = 3.68, p < 0.05; 
interaction, F(3, 54) = 4.47, p < 0.05). Also, in the caudal DRD, chronic treatment with high-dose CORT 
(400 µg/ml) reduced htr1a expression during the (inactive) light phase compared to vehicle control rats, 
but only the tendency of a treatment effect was determined (p < 0.05). No other subdivisions of the DR 
displayed significant differences in diurnal htr1a expression or a treatment-dependent alteration in htr1a 
expression. 
 
4.3. Effects of chronic CORT intake on the serotonergic gene expression index  
A strong interaction of treatment and light/dark phase (killing time point) was detected after 
dividing the threshold-based reanalysis values of tph2 expression from Chapter II by the sum of slc6a4 
and htr1a values from the present chapter in order to receive a serotonergic gene expression index, (Fig. 
4; treatment, F(3, 60) = 3.15, p = 0.084; killing time point, F(1, 62) = 4.58, p < 0.05; treatment x killing time 
point, F(3, 56) = 5.94, p < 0.01; treatment x region, F(3, 60) = 2.51, p = 0.076; killing time point x region, 
F(1, 62) = 4.09, p < 0.05; interaction (treatment x killing time point x region), F(3, 56) = 2.31, p = 0.099).  
 
Two major effects were found. The most obvious effect was a tph2-driven index increase in the 
entire DR during the light phase after chronic CORT treatment, including all subdivisions except the 
DRVL/VLPAG. This pattern largely resembles the results of chronic CORT treatment on tph2 mRNA 
expression summarized in Chapter II. In the rostral DRD (treatment, F(3, 59) = 0.71, p =0.555; killing time 
point, F(1, 61) = 3.68, p < 0.05 ; interaction, F(3, 55) = 4.47, p < 0.05), in the caudal DRD (treatment, F(3, 
59) = 0.71, p =0.555; killing time point, F(1, 61) = 3.68, p < 0.05 ; interaction, F(3, 55) = 4.47, p < 0.05), 
and in the entire DR (treatment, F(3, 60) = 0.71, p =0.555; killing time point, F(1, 62) = 3.68, p < 0.05 ; 
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interaction, F(3, 56) = 4.47, p < 0.05), the observed light-phase index increase in CORT-treated rats 
resulted in a loss of normal diurnal variation of the index compared to vehicle control rats. 
 
A second, remarkable effect was that that chronic CORT-treatment dose-dependently induced a 
diurnal index variation in the DRC (treatment, F(3, 57) = 0.71, p =0.555; killing time point, F(1, 59) = 3.68, 
p < 0.05 ; interaction, F(3, 53) = 4.47, p < 0.05) and in the DRI (treatment, F(3, 59) = 0.71, p =0.555; 
killing time point, F(1, 61) = 3.68, p < 0.05 ; interaction, F(3, 55) = 4.47, p < 0.05), that was not present in 
vehicle control rats. The latter treatment effect was especially pronounced in the high-dose CORT group 
receiving 400 µg/ml CORT in the drinking water. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (next page). Average slc6a4 mRNA expression (gray value x area) measured in each dorsal 
raphe nucleus (DR) subdivision of male rats treated either with vehicle (0.45% hydroxypropyl-beta-
cyclodextrin) or with 40, 100 or 400 µg/ml corticosterone (CORT) for 21 days. Half of each treatment 
group was killed 2 h into the animals’ inactive (light) phase, the other half 2 h into their active, dark phase. 
(A,B,C) DRD, dorsal raphe nucleus, dorsal part; (E,F,G) DRV, dorsal raphe nucleus, ventral part; (H) 
DRVL, dorsal raphe nucleus, ventrolateral part / VLPAG, ventrolateral periaqueductal gray; (I) DRC, 
dorsal raphe nucleus, caudal part; (J) DRI, dorsal raphe nucleus, interfascicular part; (D) average of all 
values, representing the entire DR. l, (inactive) light phase; d, (active) dark phase. #p < 0.05, ##p < 0.01 
versus light phase value of the same treatment group; *p < 0.05, **p < 0.01 versus Vehicle-dark phase 
value; &p < 0.05 versus C40-dark phase value, after post hoc analysis with Fisher’s Protected LSD test 
(Vehicle-light, n = 8; Vehicle-dark, n = 8; C40-light, n = 8; C40-dark, n = 8; C100-light, n = 8, C100-dark, n 
= 8; C400-light, n = 8; C400-dark, n = 8).  
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Figure 3 (next page). Average htr1a mRNA expression (gray value x area) measured in each dorsal 
raphe nucleus (DR) subdivision of male rats treated either with vehicle (0.45% hydroxypropyl-beta-
cyclodextrin) or with 40, 100 or 400 µg/ml corticosterone (CORT) for 21 days. Half of each treatment 
group was killed 2 h into the animals’ inactive (light) phase, the other half 2 h into their active, dark phase. 
(A,B,C) DRD, dorsal raphe nucleus, dorsal part; (E,F,G) DRV, dorsal raphe nucleus, ventral part; (H) 
DRVL, dorsal raphe nucleus, ventrolateral part / VLPAG, ventrolateral periaqueductal gray; (I) DRC, 
dorsal raphe nucleus, caudal part; (J) DRI, dorsal raphe nucleus, interfascicular part; (D) average of all 
values, representing the entire DR. l, (inactive) light phase; d, (active) dark phase. #p < 0.05,  ##p < 0.01 
versus light phase value of the same treatment group; $p < 0.05 versus Vehicle-light phase value; ^p < 
0.05 versus C40-light phase value; after post hoc analysis with Fisher’s Protected LSD test (Vehicle-light, 
n = 8; Vehicle-dark, n = 8; C40-light, n = 8; C40-dark, n = 8; C100-light, n = 8, C100-dark, n = 8; C400-
light, n = 8; C400-dark, n = 8). 
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Figure 4 (next page). Novel serotonergic gene-expression index, integrating the expression of tph2, 
slc6a4 and htr1a mRNA in all subdivisions of the dorsal raphe nucleus (DR). The index uses the formula 
INDEX = tph2/(slc6a4 + htr1a) to estimate overall serotonergic activity. Each gene’s mRNA expression is 
entered into the formula using the arbitrary unit [gray value x area], resulting in a unitless index. Adult, 
male rats were treated either with vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or with 40, 100 or 400 
µg/ml corticosterone (CORT) for 21 days. Half of each treatment group was killed 2 h into the animals’ 
inactive (light) phase, the other half 2 h into their active, dark phase. (A,B,C) DRD, dorsal raphe nucleus, 
dorsal part; (E,F,G) DRV, dorsal raphe nucleus, ventral part; (H) DRVL, dorsal raphe nucleus, 
ventrolateral part / VLPAG, ventrolateral periaqueductal gray; (I) DRC, dorsal raphe nucleus, caudal part; 
(J) DRI, dorsal raphe nucleus, interfascicular part; (D) average of all values, representing the entire DR. l, 
(inactive) light phase; d, (active) dark phase. #p < 0.05,  ##p < 0.01 versus light phase value of the same 
treatment group; *p < 0.05, **p < 0.01 versus Vehicle-dark phase value; $p < 0.05, $$p < 0.01 versus 
Vehicle-light phase value; &p < 0.05 versus C40-dark phase value; @p < 0.05, @@p < 0.01 versus 
C100-dark phase value; !p < 0.05 versus C100-light phase value; after post hoc analysis with Fisher’s 
Protected LSD test (Vehicle-light, n = 8; Vehicle-dark, n = 8; C40-light, n = 8; C40-dark, n = 8; C100-light, 
n = 8, C100-dark, n = 8; C400-light, n = 8; C400-dark, n = 8).  
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5. Discussion 
The anxiety-related DRD and DRC, but no other DR subdivisions, displayed a diurnal variation in 
slc6a4 or htr1a mRNA, respectively, and chronic GC intake in the drinking water abolished this diurnal 
pattern in both regions by dose-dependently decreasing dark-phase slc6a4 mRNA expression in the 
DRD, and by elevating htr1a mRNA expression during the light phase in the DRC.  
 
5.1. Topographical significance of gene expression changes after chronic CORT intake  
Individual gene expression results of tph2 (Chapter II), slc6a4 and htr1a mRNA expression as 
well as the serotonergic gene expression index further support the hypothesis that chronically elevated 
GCs dose-dependently overactivate the serotonergic system, particularly in the anxiety-related DRD and 
DRC regions (Hale and Lowry, 2011b), and according to the serotonergic gene expression index also in 
the DRI, an area projecting to a distributed neural circuit that has been identified in human imaging 
studies as being dysfunctional in depressed patients (Drevets et al., 2008). Projection targets of the DRI, 
as traced in animal studies, include, but are not restricted to, the medial prefrontal cortex (Van Bockstaele 
et al., 1993), the orbitofrontal cortex (Porrino and Goldman-Rakic, 1982), the amygdala (Imai et al., 1986), 
and the hippocampus (Imai et al., 1986).  
 
5.2. Functional relevance of an overactive serotonergic system after chronic CORT intake 
Together with the behavioral and tph2 results from Chapter II, the observed changes in slc6a4 
and htr1a mRNA expression indicate an overactive DR-serotonergic system potentially amounting to 
elevated concentrations of 5-HT in the synaptic clefts and extracellular space within the DR. Functionally, 
increased synaptic 5-HT within the DR may have differential effects on neurotransmission and signaling 
in distal target areas of DR serotonergic neurons. Serotonergic neurotransmission may either be 
increased due to increased 5-HT availability, or decreased due to more 5-HT molecules acting on 
inhibitory 5-HT1A autoreceptors, which would lead to decreased 5-HT-neuronal firing. In addition, 
compensatory or pathological changes in pre- or postsynaptic receptor expression (Lopez et al., 1998) 
and receptor sensitivity may occur, as suggested by decreased 5-HT1A autoinhibiton in the DR after 
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chronic CORT intake (Fairchild et al., 2003), or after acute application of CORT onto midbrain slices of 
adrenalectomized rats. (Laaris et al., 1995). 
 
A major consequence of chronic CORT administration in our study was a decrease in slc6a4 
mRNA expression in the anxiety-related DRD and DRC. Models of chronic stress that involve chronically 
elevated GCs have also found evidence of decreases in slc6a4 mRNA expression. For example, in a rat 
model of chronic food restriction (Jahng et al., 2007) that was also found to increase immobility in the FST 
and anxiety-like behavior on the EPM, plasma CORT concentrations were elevated to 3-fold 
concentrations relative to the control group, and slc6a4 mRNA expression was significantly decreased 
(presumably measured during the light phase). In the same model, the ratio of 5-HIAA to 5-HT was 
decreased in the hypothalamus and in the hippocampus, indicating elevated serotonergic 
neurotransmission in those areas.  
 
Future studies will have to reveal whether the behavioral and gene expression changes observed 
in our chronic CORT paradigm are due to the actions of CORT on GR or MR locally within the DR, or 
within anxiety-circuits innervating the midbrain serotonergic systems, and whether or not part of the 
chronic CORT effect may be mediated indirectly by secondary, metabolic changes, as could also be the 
case in the study by Jahng et al. (2007). 
 
The gene expression data in my model indicates a potential GC-induced overactivity within 
serotonergic neurons of the DR that would consequently lead to more 5-HT in synaptic clefts and 
extracellular space within the DR if the treatment effects of chronic CORT hold true on the protein and 
functional levels. In that context, it a needs to be discussed that our results of downregulated slc6a4 
mRNA expression after chronic CORT intake are in contrast to a recent rat study by Zhang et al. (2012) 
that revealed increased light-phase SERT protein expression in the DR and in forebrain target areas of 
the DR after both chronic social defeat (which elevated endogenous plasma CORT concentrations) or 
chronic CORT intake of 100 µg/ml via the drinking water for 22 days, while ADX (with replacement of 25 
ug/ml CORT in the drinking water) normalized SERT expression. Zhang et al. (2012) further propose that 
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CORT actions on both GR and MR are responsible for the upregulation of SERT protein because daily 
systemic injections of either GR and MR antagonists alone, or a combination of both, all prevented the 
increase in SERT protein expression in the DR of chronically defeated rats. While slight differences in 
experimental design, such as a lack of distinction between functional and anatomical subdivisions of the 
DR and the use of 2.4% EtOH vehicle, may explain some of the discrepancy, the possibility exists that 
posttranscriptional or posttranslational changes occur, potentially in an attempt to overcompensate for 
decreased slc6a4 mRNA expression. Tph2, SERT and 5-HT1A protein expression have yet to be 
characterized in our model of chronic CORT intake. 
 
5.3. Functional relevance of an abolished diurnal variation in gene expression after chronic CORT 
intake 
The fact that chronic GC treatment abolishes overall serotonergic gene expression rhythmicity 
(Fig. 4) in the rostral and caudal DRD, while dose-dependently inducing a circadian rhythmicity in the 
DRC and DRI that is absent in vehicle controls (Fig. 4, panels I and J), may have important clinical 
implications as many patients that suffer from affective disorders also display a disrupted HPA axis 
rhythmicity (Deuschle et al., 1997; Gillespie and Nemeroff, 2005), altered sleep-wake cycles (Pandi-
Perumal et al., 2009; Westrich and Sprouse, 2010), and changes in thermoregulation and body 
temperature (Rausch et al., 2003; Rausch et al., 2006; Bunney and Potkin, 2008). Both studies by 
Rausch et al. also link elevated body temperature in affective disorders to 5-HT1A receptor dysfunction 
and polymorphisms in the SLC6A4 gene. The potential clinical implication is further corroborated by 
studies from our laboratory suggesting a role for the DRI in temperature sensitivity and thermoregulation 
(Hale et al., 2010a; Kelly et al., 2011). 
 
  
CHAPTER III 
63 
 
6. Conclusion 
Our results are novel, in that they identify, for the first time, a subdivision-specific diurnal 
expression pattern of slc6a4 and htr1a mRNA specifically in anxiety-related serotonergic systems, and 
that chronic exposure to elevated GCs is capable of disrupting this diurnal expression pattern in a dose-
dependent manner. Together with previous findings that chronic GC intake induces anxiety- and 
depressive-like behavior in association with an abolished diurnal variation in tph2 mRNA expression due 
to elevated light-phase tph2 expression (Donner et al., 2012a), these most recent findings are consistent 
with the hypothesis that diurnal variation of serotonergic gene expression plays an important role in the 
control of emotionality, that chronic GC exposure may in fact cause an overactive serotonergic system 
within the DR, and that anxiety- and depression-related serotonergic subdivisions of the DR are more 
sensitive to changes in circulating GC concentrations than other subdivisions.  
 
Furthermore, the fact that genetic carriage of the short, low-expressing allele of SERT is often 
associated with anxiety-traits and an increased prevalence of depression in human patient populations 
(Lotrich and Pollock, 2004; Gillespie et al., 2005) is consistent with the decreased slc6a4 expression 
observed in our rat model of depressive- and anxiety-like behavioral manifestations after chronic GC 
exposure. 
 
Based on our observations in this rat model of a GC-induced chronic anxiety- and depressive-like 
state, novel treatment strategies targeting specifically those serotonergic systems that send collateral 
projections to distal neuronal circuits involved in depression and anxiety, and thereby reducing the risk of 
side effects or delayed onset of the desired treatment effect, may emerge.  
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CHAPTER	IV	
	
Chronic	glucocorticoid	intake	increases	basal‐	and	
noise	stress‐induced	tryptophan	hydroxylase	activity	
in	anxiety‐related	serotonergic	systems	
 
1. Summary 
In Chapter II, I demonstrated that chronic administration of GCs to adrenal-intact adult, male rats 
elevates the expression of tph2, the gene encoding neuronal Tph, during the light phase, when rodents 
are commonly inactive.  
 
Here, we hypothesized that chronic GC exposure, without external stressors per se, alters both 
basal and stress-induced activity of Tph, the rate-limiting enzyme for 5-HT synthesis. To test this 
hypothesis, we treated adrenal-intact adult, male rats with 100 μg/ml CORT or vehicle (0.45% 2-
hydroxypropyl-β-cyclodextrin) via the drinking water for 21 days. We monitored weight gain and diurnal 
food and water consumption, and assessed the rats’ emotionality in the elevated plus-maze (EPM) and 
forced swim tests (FST) after two weeks. On day 21, all rats received injections of 100 mg/kg NSD-1015, 
an inhibitor of aromatic amino acid decarboxylase (AADC), to block the conversion of 5-
hydroxytryptophan (5-HTP) to 5-HT. Following the injection, rats were either exposed to acoustic startle 
stress (AS) for 30 min or remained in home cages until rapid decapitation. Post mortem, we assessed ex 
vivo adrenal functionality in a tissue culture assay, and measured 5-HTP accumulation, a readout of Tph 
activity, in the median raphe nucleus (MnR) and dorsal raphe nucleus (DR) subregions, and in anxiety-
related forebrain target areas, using high-pressure-liquid chromatography with electrochemical detection 
(HPLC-ED). 
 
Chronic CORT intake caused reduced weight gain, anxiety-like behavior on the EPM, increased 
immobility in the FST, an increased AS response, and adrenal insufficiency. The diurnal pattern and the 
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amount of food and water intake remained unchanged. Most importantly, chronic CORT elevated both 
basal and AS-induced Tph activity in the dorsal (DRD) and ventral DR (DRV), as well as basal Tph 
activity in the MnR. In the caudal DR (DRC), the infralimbic cortex (IL), the dorsal cornu ammonis region 
of the hippocampus (dCA1) and the caudal pontine reticular formation (PnC), AS elevated Tph activity 
only in CORT-, but not in vehicle-treated rats, indicating a permissive effect of chronic CORT. The 
increase of Tph activity in the PnC was strongly correlated with the magnitude of the AS response.  
 
Our results are novel, and suggest that GCs exert their chronic actions by creating either a basal 
hyperactivity or a hypersensitivity to an acute stressor in serotonergic circuitries that modulate anxiety-
related behavior. 
 
(This study has been published in abstract form: Donner NC, Siebler PH, Mani S, Lowry CA (2012). 
Chronic glucocorticoid intake increases basal- and stress induced tryptophan hydroxylase activity in 
anxiety-related serotonergic systems. Annual Meeting of the Society for Neuroscience (SfN), New 
Orleans, LA, USA, 2012.)  
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2. Background 
It is of clinical importance to learn more about how chronic or repeated exposure to elevated 
concentrations of GCs interact with the brain serotonergic systems. The clinical importance is suggested 
by 1) HPA axis dysfunction, often characterized by basally elevated GC levels throughout the day 
(Deuschle et al., 1997; Weber et al., 2000b), is a common feature of MDD (Plotsky et al., 1998a; 
Barden, 2004; Gillespie and Nemeroff, 2005) and other psychiatric disorders (Heuser et al., 1994; 
Graeff, 2007), 2) post mortem studies consistently show an upregulation of tph2 mRNA expression 
(Bach-Mizrachi et al., 2006; Bach-Mizrachi et al., 2008) and 3) TPH-positive neuron density and number 
(Underwood et al., 1999; Boldrini et al., 2005) within the DR of depressed suicides, and 4) as I 
demonstrated in Chapter II, chronic, non-invasive elevation of circulating GCs in rats is sufficient to 
cause an anxiety- and depressive-like phenotype along with an elevated light-phase expression of tph2 
mRNA that abolishes the natural diurnal pattern of the enzyme’s expression (Donner et al., 2012a). 
TPH2 is the rate-limiting enzyme for 5-HT synthesis in the brain (Walther et al., 2003), and is heavily 
expressed in the DR and MnR of the hindbrain, meaning the pons in humans, and the midbrain in 
rodents (Patel et al., 2004; Zhang et al., 2004). It is, however, largely unclear what neurophysiological 
consequences this upregulation of tph2 expression has, for example on the enzymatic activity of Tph2 
under basal conditions or under conditions of an acute stressor. 
 
In the study presented in this chapter, we used acoustic startle (AS) stress (Davis, 1980; Davis et 
al., 1980; Davis et al., 1982), a comparable mild stressor, as the acute stressor of choice following 
chronic treatment with vehicle or 100 µg/ml CORT via the drinking water (Donner et al., 2012a). 
Acoustic startle stress was chosen because the neuroanatomical circuitry of noise stress, including the 
AS reflex, is better understood (Leitner et al., 1981; Davis et al., 1982; Liang et al., 1992a) than that of 
many other, rather multimodal, stressors. A noise signal is transduced into physiological and behavioral 
responses in two categorically different ways. First, noise stress elicits a short-latency AS reflex, 
transduced from the cochlear nucleus, via the nucleus of the lateral lemniscus, to magnocellular 
neurons of the caudal pontine (reticular) nucleus (PnC), an integrative relay station, from where PnC 
neurons send projections to motor neuron cell bodies in the spinal cord that ultimately cause the 
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behavioral response to AS, namely the muscle twitching of the startle response (Prescott, 1998; 
Simons-Weidenmaier et al., 2006). Second, separate projections to subcortical nuclei such as, amongst 
others, the central amygdaloid nucleus (Ce), the locus coeruleus (LC), and the paraventricular nucleus 
of the hypothalamus (PVN) activate more complex neuronal networks (Liang et al., 1992a; Koyama et 
al., 1994; Cransac et al., 1998), including the serotonergic system of the brain (Singh et al., 1990a; 
Daugherty et al., 2001; Evans et al., 2009). The one that is most pertinent to the serotonergic system is 
a Ce-dependent network (Boadle-Biber et al., 1993; Spannuth et al., 2011). In the 1990s, the laboratory 
of Dr. Margaret Boadle-Biber contributed a series of elegantly designed experiments that identified that 
GCs are permissive for increased Tph activity for up to 24 h after both acute and repeated (3-5 days) 
acoustic startle (AS) stress, while they did not alter basal Tph activity (Singh et al., 1990a; Singh et al., 
1992; Singh et al., 1994). Later on, this GC-permissive effect was shown to be dependent on 
corticotropin-releasing factor (CRF) signaling within the Ce (Lee et al., 1994), but not on CRF-signaling 
within the PVN (Liang et al., 1992a; Liang et al., 1992b). Adrenalectomy, treatment with a GR 
antagonist, and amygdalar lesions all block, while DEX treatment of adrenalectomized rats recovers the 
effects of sound stress on in vitro Tph activity (Singh et al., 1990a; Singh et al., 1994). Other types of 
stressors also increase activation of serotonergic neurons (Grahn et al., 1999; Takase et al., 2004; Hale 
et al., 2008b; Hale et al., 2008a), 5-HT release (Amat et al., 1998a, b; Maswood et al., 1998; Amat et 
al., 2005). A recent study by Browne et al. (2011) found 5-HT turnover (measured as the ratio of 5-HIAA 
to 5-HT) to be increased in virtually all brain regions studied after exposure to acute restraint stress.  
 
While GCs, through actions of CRF, have been shown to be permissive for sound stress-induced 
increases in Tph activity, very little is known about the effects of chronic GC treatment on Tph activity. 
Therefore, we here measure light-phase Tph activity under control conditions and after 30 min of AS 
stress after 21 days of non-invasive treatment with vehicle (0.45% HBC in tap water) or 100 µg/ml 
CORT via the drinking water, hypothesizing that chronic exposure to elevated systemic concentrations 
of GCs increases both basal and stress-induced Tph activity in specific subdivisions of the DR and in 
anxiety-related target regions of the DR.   
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3. Materials and Methods 
3.1. Animals  
Thirty-two adult male Sprague Dawley rats (Harlan Labs, Indianapolis, IN; 200-225 g at arrival 
day) were pair housed according to the same treatment and killing time point. All rats were left intact (no 
adrenalectomy), and kept on a reversed 12:12 h light/dark cycle, with lights on at 0600 h. Rats were 
allowed to acclimate for three days prior to treatment start. Sixteen rats were treated with vehicle, and 
the other 16 rats were treated with 100 μg/ml CORT (CORT-100, 100 μg/ml) for 21 days. Fresh vehicle 
and treatment bottles were provided every four days.  
 
3.2. Assessment of body weight (BW) gain, and diurnal pattern of food and water intake  
The rat’s body weight (BW) gain was measured before treatment start (day 0), and on days 7, 14, 
and 21. To address the question whether chronic CORT intake alters diurnal activity patterns, such as 
food and water consumption, food and water intake was quantified before and after the 12 h dark phase 
and again after the 12 h light phase on days 0 (before treatment start), 7 (first week of treatment), 14 
(second week of treatment), and on day 20 (third week of treatment) by taking the weight of both the 
drinking water bottles and the remaining food pellets using a microscale, before refilling either supply. The 
difference in bottle weight was converted from grams (g) to milliliters (ml). 
 
3.3. Experimental design 
In Chapter II, a low (40 µg/ml), medium (100 µg/ml), and high dose (400 µg/ml) of CORT were 
used for the 21-day treatment period. While all doses abolished the diurnal variation of tph2 expression, 
only the medium and high doses exerted significant behavioral effects, and of the behavioral tests used, 
the EPM and the FST delivered the most robust results. Due to the supraphysiological nature of the 400 
µg/ml dose, only the 100 µg/ml dose was chosen in this experiment. Fig. 1 summarizes the experimental 
setup. The rats’ emotionality was assessed for 5 min on the EPM on day 16, and for 5 min in the FST on 
day 18, in an attempt to replicate our previous behavioral results (Donner et al., 2012a). During the last 
week of treatment, all rats were handled daily for about 30 s each to habituate them to the handling and 
i.p. injection on day 21. At 0230 h on day 21, all CORT-treatment bottles were 
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Figure 1. Illustration of the experimental design and timeline. Adult, male rats were treated with vehicle 
(0.45 % hydroxypropyl-beta-cyclodextrin, n = 16) or corticosterone (CORT, 100 µg/ml, n = 16) via the 
drinking water for 21 days. On day 16, the rats’ emotionality was assessed on the elevated plus-maze 
(EPM) for 5 min. On day 17, all rats were swim-trained for 15 min, and on day 18 tested for 5 min in the 
forced swim test (FST). In addition to days 16, 17 and 18, rats continued to be handled for 30 s per day 
on days 19 and 20 in order to habituate and prepare them for the injection on day 21. After CORT-water 
bottles were replaced with vehicle-bottles at 0230 h on day 21, all rats were injected with the 100 mg/kg 
of the aromatic L-amino acid decarboxylase inhibitor NSD-1015 (in 0.9 % saline) at 0330 h, before one 
half of each treatment group was subjected to unpredictable acoustic startle stress for 30 min, while the 
other half remained in their home cages as controls. Immediately after the termination of acoustic startle 
stress, at 0400 h, all rats were sacrificed via rapid decapitation to collect their brains, adrenal glands, 
thymi, and trunk blood. 
 
replaced with vehicle bottles, meaning 90 min before sacrifice. At 0330 h on day 21, all rats were given an 
intraperitoneal (i.p.) injection of NSD-1015 to inhibit aromatic amino acid decarboxylase (AADC)-
dependent conversion of 5-hydroxytryptophan (5-HTP) to 5-HT. Immediately following the injection, half 
of the rats of both treatment groups were subjected to acoustic startle stress (AS) for 30 min, while the 
other half remained in their home cages (HC) as controls without any acoustic stimulation. Immediately 
after removal from the AS chambers (at 0400 h), the rats were killed via rapid decapitation. The killing 
time point was decided upon based on findings by Malek et al. (2004; 2005; 2007) that peak Tph protein 
expression in the DR follows approximately 8 h after peak expression of tph2 mRNA. In Chapter II, we 
found that CORT elevated tph2 mRNA expression 2 h into the rats’ light phase compared to vehicle 
controls (Donner et al. 2012). To compare our results with our previous findings, we thus measured Tph 
protein activity 10 h into the rats’ light phase.  
Home cage or 
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Trunk blood was collected into sterile Falcon tubes containing 200 µl of 2% ethylene-diamine-
tetraacetic acid (EDTA; Cat. No. EDS, Sigma-Aldrich, St. Louis, MO, USA) in 0.05 M phosphate buffered 
saline. Blood samples were kept on ice until subsequent centrifugation in a microfuge (Beckman Coulter, 
Fullerton, CA, USA) for 15 min (6,000 rpm, 4 ºC). On ice, plasma samples from each rat were aliquoted 
and stored at ‒80 ºC. The thymus and adrenal glands were extracted, pruned from surrounding fat tissue, 
and their wet weight measured. Both left and right adrenal glands were then microdissected into two 
halves each using a microscope (Nikon Eclipse E200) and sterile technique, before entering the 
functional adrenal assay (see below). Brains were extracted, fresh-frozen on dry ice (with the dorsal side 
lying flat on a piece of dry ice), and stored at –80 ºC until microdissection.  
 
3.4. Treatment and intraperitoneal (i.p.) NSD-1015 injection 
The crystalline hormone corticosterone (CORT, 11β,21-dihydroxy-4-pregnene-3,20-dione; 
minimum ≥ 92 %; Cat. No. C2505) was obtained from Sigma-Aldrich. CORT was dissolved in vehicle, 
meaning tap water containing 0.45% 2-hydroxypropyl-β-cyclodextrin (HBC) from Sigma-Aldrich (Cat. No. 
332607), and treatment with vehicle or CORT began at 0600 h three days after the animals arrived in the 
facility. To prevent light-induced degradation of CORT, dark drinking bottles were used. On day 21, 100 
mg/kg NSD-1015 (3-hydroxybenzylhydrazine dihydrochloride, Cat. No.  54880, Sigma-Aldrich) in 0.9 % 
sterile saline was injected intraperitoneally (i.p.) to block AADC-dependent conversion of 5-HTP to 5-HT. 
Measuring 5-HTP accumulation in brain regions of interest was then used to assess Tph activity. 
 
3.5. Behavioral testing on the elevated plus-maze (EPM) and in the forced swim test (FST) 
Anxiety-like behavior was assessed for 5 min on the EPM on day 16 of treatment, while active 
versus passive stress-coping strategies were measured for 5 min in the FST on day 18, as previously 
described in Chapter II (Donner et al. 2012). Prior to the FST test, rats were trained in the forced swim 
tank under the same conditions for 15 min on day 17 as in previous studies (Kirby et al., 1995; Porsolt et 
al., 2001). Behavioral testing occurred during the dark phase between 0800 h and 1200 h, and was 
recorded under low red-light conditions either via a web-cam (Microsoft) mounted above the EPM, or 
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using a digital video camera recorder (Model DCR-DVD810, Sony, New York City, N.Y., USA) on a tripod 
positioned perpendicular to the swim tanks during the FST test. Behavioral analysis was conducted using 
EthoVision XT (version 5.0 Noldus Information Technologies, Tacoma, WA) for the EPM, and The 
Observer XT (version 5.0, Noldus Information Technologies) for the FST test. On the EPM, the latency 
until first open arm entry, the time spent in the open and closed arms, the number of closed and open arm 
entries (locomotor activity), the time spent grooming, and the number of fecal boli were monitored. The 
FST test was conducted using 25 °C  tap water at a water column height of 35 cm, and the time spent 
climbing (active stress-coping behavior: high-pace front leg paddling breaking the water surface at the 
wall of the tank, upright body position, strong hind leg strokes), the time spent swimming (also active 
stress-coping behavior: slow-pace front and hind leg movements that don’t break the water surface), the 
time spent immobile (passive stress-coping behavior: minimal leg movements; stiff, floating body 
posture), and the number of dives (active escape-seeking behavior) were quantified. While all behaviors 
may occur at any time, climbing behavior occurs preferentially during the first minute, while swimming and 
immobility are naturally more common during the last minutes of the test. 
  
3.6. Acoustic startle (AS) stress and behavioral recording 
The acoustic startle (AS) apparatus (Model No.  SM 100 version 4.1; Kinder Scientific, Poway, 
CA, USA) was described previously (Masini et al., 2008), and consists of a polymethyl methacrylate inner 
chamber (8 x 15 x 15 cm) inside a darkened box (59.7 x 38.1 x 38.1 cm). The apparatus has two 
speakers on the ceiling of the chamber that were used for constant administration of 60 dB background 
noise and unpredictable acoustic stimulation, adapting a protocol by the Boadle-Biber laboratory (Singh et 
al., 1990a). Briefly, 30 startling sounds of 100 ms duration, a sound intensity of 120 dB, and a frequency 
of 3.0 kHz were delivered in randomized intervals (average interval 1 min) over the time course of 30 
minutes.  
 
The floor of the chamber is equipped with an accelerometer linked to a Kinder Scientific software 
(StartleMonitor MFC, SM100, version 1) that recorded, amongst other parameters, the maximum acoustic 
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startle response (ASR) in Newtons (N) during the 200 ms time window following the onset of each 
acoustic stimulus. The ASRs of all 30 stimulus trials were averaged for each rat. 
 
3.7. Adrenal functionality assay (ex vivo) 
To reveal the consequences of chronic CORT treatment on the capability of adrenal cells to 
respond to stimulation with adrenocorticotropin (ACTH) in vitro, a stimulation protocol by Reber et al. 
(Reber et al., 2007) was adapted under sterile cell culture working conditions. After dissection of both 
adrenal glands into two halves (two halves from the left and two halves from the right adrenal), each half 
was incubated in 500 µl of DMEM-F12 medium (pH 7.4; Cat. No. 11320-033; Invitrogen, Carlsbad, CA, 
USA) containing 0.1 % bovine serum albumin (BSA Cat. No. A2153; Sigma-Aldrich) for 4 h at 37 °C in an 
atmosphere of 95 % O2 and 5 % CO2. Incubation of one half per well occurred in sterile 24-well cell 
culture plates (Cat. No. PIMWS2450; EMD Millipore, Billerica, MA, USA). After 4 h, the old medium was 
removed carefully, and replaced with a fresh volume of 475 µl DMEM-F12. At the same time, either 25 µl 
0.9 % saline (control) or 25 µl of rat ACTH (final concentration per well: 50 nM; Cat. No. EK-001-21; 
Phoenix Pharmaceuticals, Burlingame, CA, USA) was added to either half. Adrenal gland halves were 
incubated for another 6 h at 37 °C in an atmosphere of 95 % O2 and 5 % CO2. After the stimulation, the 
supernatant was collected and stored at –80 °C until analysis with a commercially available EIA kit to 
measure individual CORT release (Cat. No. ADI-900-097; Enzo Life Sciences, Plymouth Meeting, PA). 
Before being assayed in duplicates of 20 µl each, all samples were diluted 1:50 with DMEM-F12 medium.  
 
3.8. Brain sectioning and microdissection of fore- and hindbrain regions of interest 
Fresh-frozen brains were sectioned at 300 µm using a cryostat (Model CM1900; Leica, Wetzlar, 
Germany), and briefly thaw-mounted into microscope glass slides (Cat. No. 16004-420, VWR, West 
Chester, PA, USA) in preparation for microdissection and high pressure liquid chromatography with 
electrochemical detection (HPLC-ED) as previously described (Evans et al., 2009). After thaw-mounting, 
sections were again kept at –80 °C until microdissection at –10 ºC, using a cold plate (Model No. TCP-2, 
Cat. No. Z176664, Sigma-Aldrich) and blunt dissection needles ranging from 310 to 1000 μm in inner 
diameter (Fine Science Tools, Foster City, CA, USA). Rostrocaudal levels for microdissection were 
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verified using a stereotaxic atlas of the rat brain (Paxinos and Watson, 1998), and microdissected 
samples were placed in small Eppendorf tubes containing 100 μl acetate buffer (pH = 5.0; 992.7 mL 
HPLC grade H2O, 3.0 g sodium acetate, 4.3 ml glacial acetic acid), snap-frozen on dry ice, and stored at 
–80 °C until HPLC-ED analysis of 5-HTP.  
 
For a list of all brain regions chosen for microdissection, including their rostrocaudal distance from 
bregma, the number of samples pooled for each region, and the respective diameter of the blunt 
microdissection needles used, please see Table B1 in Appendix B). Six raphe subnuclei were 
microdissected within the hindbrain. The median raphe nucleus (MnR), the dorsal raphe nucleus, dorsal 
part, (DRD), and the dorsal raphe nucleus, ventral part (DRV) were all collected at –7.20, –7.50, –7.80, 
and –8.10 mm from bregma. The dorsal raphe nucleus, ventrolateral part / ventrolateral periaqueductal 
gray region (DRVL/VLPAG) was collected at –7.50, –7.80, and –8.10 mm from bregma, the  dorsal raphe 
nucleus, interfascicular part (DRI) was collected at –8.10, and –8.40 mm from bregma, and the dorsal 
raphe nucleus, caudal part (DRC) was collected at –8.40 and  –8.70 mm from bregma. In addition, 18 
brain regions that are either prominent target areas of the DR (Lowry et al., 2008a; Hale and Lowry, 
2011a), or part of known anxiety- or panic-circuitries (Lowry, 2002; Lowry et al., 2005; Lowry et al., 2008c; 
Lowry and Hale, 2010) were chosen for microdissection. This included the lateral (LO) and ventral orbital 
(VO) cortices at 4.20 mm bregma, the prelimbic (PrL) and infralimbic (IL) cortices at 2.70 mm bregma, the 
bed nucleus of the stria terminalis (BNST) at –0.30 mm bregma, the paraventricular nucleus (PVN) at –
1.80 mm bregma, the basolateral amygdaloid complex (BL) at –2.40, –2.70, and –3.00 mm bregma, the 
central amygdaloid nucleus (Ce) at –2.40 nd –2.70 mm bregma, the lateral hypothalamus plus the 
perifornical region of the hypothalamus (LH/PeF) at –3.00 and –3.30 mm bregma, the dorsomedial 
hypothalamus (DM) at –3.30 mm bregma, the dorsal hippocampus, cornu ammonis region 1 (dCA1) at  –
3.90 mm bregma, the ventral hippocampus, cornu ammonis region 1 (vCA1) and the ventral subiculum 
(VS) at –6.00 mm bregma, the interpeduncular nucleus (IP) at –6.30, –6.60, and –6.90 mm bregma, the 
entorhinal cortex (Ent) at –6.90, –7.50, and –8.10 mm bregma, the dorsomedial periaqueductal gray 
(DMPAG) and the dorsolateral and lateral periaqueductal gray (DLPAG/VLPAG) at –7.50,  –7.80, and –
8.10 mm bregma, and the caudal pontine (reticular) nucleus (PnC) at –9.00, –9.30, and –9.60 mm 
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bregma. The dorsomedial caudate putamen (dmCPu, 0.60 and 0.30 mm bregma) was used as a negative 
control region, in which only minimal amounts of 5-HTP were detected (< 0.5 pg/µg). 
 
3.9. Measuring 5-hydroxytryptophan (5-HTP) accumulation as a readout of tryptophan hydroxylase 
(Tph) activity  
Injection of the AADC inhibitor NSD-1015 was used to prevent the conversion of 5-HTP to 5-HT 
in all rats. To analyze 5-HTP accumulation, an index of Tph activity in the presence of NSD-1015, the 
microdissected samples were thawed and centrifuged at 13,000 rpm for 5 min at 4 ºC, and 50 µl of the 
supernatant from each sample were placed in an ESA 542 autosampler (ESA Analytical Ltd., Huntington, 
UK) to be analyzed for 5-HTP content using HPLC-ED. During the procedure, samples were maintained 
at 4 °C, while the column oven temperature remained at 29 °C, the flow rate at 1.50 ml, and the pressure 
between 175 and 195 bar. The remaining supernatant (~50 μl) was stored at –80 °C as a back-up 
sample, and the tissue-sample pellet was reconstituted with 175 μl of 0.2 M NaOH and assayed for total 
protein content using Bradford-reaction-based commercially available kit (Micro BCA Protein Assay Kit, 
Thermo Scientific, Rockford, IL, USA). 5-HTP concentrations are expressed as a ratio of total 5-HTP (in 
pg) and the total amount of protein per sample (μg). 
 
3.10. Statistical analysis 
Prior to statistical analysis using SPSS (version 20 for Windows, SPSS Inc., Chicago, IL, USA) 
outliers were identified (Grubbs, 1969) and removed from the data set in Microsoft Excel. Due to Grubbs’ 
outlier identification, 3.13 % of the plasma CORT and NE data sets (one data point each of 32 in total),  
9.38% of the TNFα data set (3 of 32 data points), 6.25% of the IL-1β data set (2 of 32 data points), 6.25% 
of the FST data set (8 of 128 data points), 2.34% of the EPM data set (6 of 256 data points), and 1.92% 
of the 5-HTP data set (16 of f832 data points) were excluded.  
 
Food and water consumption were analyzed using a mixed model linear analysis (MMLA) with 
treatment (2) as the between-subjects factor, and day (4) and light/dark phase (2) as within-subjects 
factors. Similarly, BW gain was analyzed using a MMLA with treatment (2) as the between-subjects 
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factor, and day (3) as the within-subjects factor. Adrenal functionality values (CORT concentration in 
supernatant) were first compared using a MMLA with treatment (2) and stress (2) as the between-
subjects factors, and ACTH (2) and left/right (2) as the within-subjects factors. Due to unequal variances, 
post hoc comparisons were conducted using non-parametric Mann-Whitney-U tests. A two-way analysis 
of variance (ANOVA) with treatment (2) and stress (2) as between-subjects factors was performed for 
plasma NE, IL-1β, and TNFα concentrations, followed by Fisher’s Protected least significant difference 
(LSD) post hoc testing where appropriate (post hoc test readout of a one-way ANOVA, disregarding the 
one-way ANOVA result itself). Due to unequal variances, CORT concentrations of both the blood plasma 
samples were also compared using non-parametric Mann-Whitney-U tests. Thymus and adrenal weights 
were compared with Student’s t-tests. Behavioral parameters from EPM and FST testing (time or number 
of events), the number of dives during the FST, the number of fecal boli in the swim tank, and the 
difference in rectal temperature from before and after the FST were compared using Student’s t-tests. 
From the acoustic startle data set, only the maximum ASR was compared using a Student’s t-test. 
  
Due to different neuroanatomical properties, two different sets of MMLAs with treatment (2) and 
stress (2) as between-subjects factors, and region as the within-subjects factor were performed to 
compare the 5-HTP content in all of the 25 microdissected brain regions: The first analysis compared the 
5-HTP content in all 6 midbrain raphe subnuclei (DRD, DRV, DRVL/VLPAG, DRC, DRI, and MnR), the 
second analysis compared the 5-HTP content in projection regions including the LO, VO, PrL, IL, dmCPu, 
BNST, PVN, BL, Ce, LH/PeF, DM, dCA1, vCA1, VS, Ent, IP, DMPAG, DLPAG/LPAG, and PnC. 5-HTP in 
the entire DR was analyzed using a two-way ANOVA with treatment (2) and stress (2) as between-
subjects factors.  
 
If a general treatment- or stress-effect or an interaction of both factors was detected in any of the 
MMLAs, individual physiological end points, behaviors, brain regions, or subdivisions of the DR were 
further analyzed using a two-way ANOVA with treatment (2) and stress (2) as between-subjects factors, 
followed by Fisher’s Protected LSD post hoc test where appropriate (obtained from the post hoc readout 
of a one-way ANOVA, disregarding the one-way ANOVA result itself). Significance was accepted at p < 
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0.05, and all results are shown as the mean + the standard error of the mean (SEM) in figures, and ± the 
SEM in tables. Graphs for our figures and correlations were designed in Microsoft Excel or SigmaPlot 
(version 11.0, Systat Software Inc., Evanston, IL, USA).   
 
For a description of plasma stress hormone and cytokine assays please refer to Appendix B). 
  
CHAPTER IV 
77 
 
4. Results 
4.1. Effects of chronic CORT on body weight (BW) gain and food and water consumption 
Chronic CORT-treatment significantly reduced BW gain, with vehicle-treated control rats gaining 
an average of 74 g, and CORT-treated rats gaining only about 26 g throughout the 21 days of treatment 
(Fig. 2, panel A; treatment, F(1, 30) = 78.76, p < 0.001; day, F(2, 29) = 173.97, p < 0.001; treatment x 
day, F(2, 26) = 40.29, p < 0.001). With the exception of increased water intake during the dark phase on 
day 20, neither the BW-corrected water consumption nor the diurnal pattern of water intake was altered 
by chronic CORT-treatment compared to vehicle controls, indicating that the rats’ overall activity pattern 
was not significantly altered by chronic CORT treatment (Fig. 2, panel B; treatment, F(1, 30) = 0.279, p = 
0.604; day, F(3, 28) = 25.40, p < 0.001; light/dark phase, F(1, 30) = 189.11, p < 0.001; treatment x day, 
F(3, 24) = 7.35, p < 0.01; treatment x light/dark phase, F(1, 28) = 0.66, p = 0.429; light/dark phase x day, 
F(3, 24) = 99.57, p < 0.001; treatment x light/dark phase x day, F(1, 16) = 4.07, p = 0.025). Similarly, with 
the exception of the light phase on day 7, the overall food consumption and the diurnal pattern of food 
consumption remained unaltered by chronic CORT treatment (Fig. 2, panel C; treatment, F(1, 30) = 1.24, 
p = 0.283; day, F(3, 28) = 10.14, p < 0.01; light/dark phase, F(1, 30) = 1270.56, p < 0.001; treatment x 
day, F(3, 24) = 0.64, p = 0.60; treatment x light/dark phase, F(1, 28) = 2.05, p = 0.154; light/dark phase x 
day, F(3, 24) = 5.91, p < 0.01; treatment x light/dark phase x day, F(1, 16) = 0.71, p = 0.558). 
 
4.2. Effects of chronic CORT on anxiety-like behavior on the elevated plus-maze (EPM) 
Most of the effects of chronic CORT-treatment on emotionality that we had found in Chapter II 
were reproduced in the present study. On the EPM, CORT-treated rats displayed increased anxiety-like 
behavior (Fig. 3) as they spent more time exploring the closed (p < 0.05) than the open arms compared to 
vehicle-treated rats (p < 0.001). CORT-treated rats also reared more often at the walls of the closed arms 
(p < 0.05), and accumulated less full entries into the exposed, open arms of the maze (p < 0.05) 
compared to vehicle-treated controls. 
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Figure 2. Cumulative body weight (BW) 
gain (A), and BW-corrected water (B) 
and food intake (C) of adrenal-intact, 
adult, male rats during treatment with 
either vehicle (0.45% hydroxypropyl-
beta-cyclodextrin) or corticosterone 
(CORT, 100 µg/ml) via the drinking 
water for 21 days. On days 0, 7, 14 and 
20, water and food intake were 
monitored during both the 12 h light 
(inactive) phase, and during the 12 h 
dark (active) phase. All data are 
displayed as means + SEM. *p < 0.05, 
**p < 0.01 versus Vehicle, after post hoc 
analysis with Fisher’s Protected LSD test 
(Vehicle, n = 16; CORT, n = 16).
A 
B 
C 
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Figure 3. Anxiety-related behavioral parameters of all rats, assessed on the elevated plus-maze (EPM) 
on day 16 of treatment with either vehicle (0.45 % hydroxypropyl-beta-cyclodextrin) or corticosterone 
(CORT, 100 µg/ml). The test was performed during the rats’ active (dark) phase. Panel (A) depicts the 
percent time the rats spent either in the closed arms, the open arms, or in the neutral middle-square of 
the elevated plus-maze. The number of closed, open, and full open arm entries, and the number of rears 
at the walls are indicated in panel (B). Data are displayed as means + SEM. *p < 0.05, **p < 0.01 versus 
Vehicle (Vehicle, n = 16; CORT, n = 16). 
 
4.3. Effects of chronic CORT on depressive-like behavior in the forced swim test (FST) 
In the FST, CORT-treated rats spent more time immobile (p < 0.05), while both climbing and 
swimming time were in tendency reduced. Also, vehicle-treated rats clearly displayed a more active 
escape-seeking behavior by diving more often to the bottom of the tank, while CORT-treatment prevented 
active exit-seeking behavior in the form of dives (Fig. 4, panel B; p < 0.05). No treatment effect of CORT 
was detected on the number of boli left in the swim tank or on delta rectal temperature (Fig. 4, panels C 
and D). 
 
4.4. Effects of chronic CORT on thymus weight, adrenal gland weights, and adrenal functionality 
Thymus (p < 0.001) and adrenal gland weights (p < 0.001; average of left and right adrenal) were 
markedly decreased by chronic CORT-treatment (Table 1). Both the left (p < 0.001) and the right adrenal 
gland (p < 0.001) were affected by chronic CORT treatment with regard to their wet weight. 
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Figure 4. The rats’ stress coping behavior as assessed in the forced swim test (FST) for 5 min on day 18 
of treatment with vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or corticosterone in the drinking water 
(CORT, 100 µg/ml). Shown in panel (A) is the percentage of time the rats spent either climbing or 
swimming (active coping behavior), or immobile (passive coping behavior). Panels (B, C, D) display the 
number of dives (proactive escape seeking behavior), the number of fecal boli left in the tank after the 
FST, and the difference in rectal temperature (delta temperature, °C) from before and after the FST for 
each treatment group. Data are displayed as means + SEM. *p < 0.05, versus Vehicle (Vehicle, n = 16; 
CORT, n = 16). 
 
 
 
 
Table 1. Adrenal gland & thymus weights after chronic corticosterone treatment (1) 
 Vehicle  CORT 
Thymus weight (mg) 420.14 ± 21.47  209.46 ± 11.50 ** 
Left adrenal gland weight (mg) 24.07 ± 1.68  14.28 ± 0.57 ** 
Right adrenal gland weight (mg) 21.91 ± 1.31  13.96 ± 1.03 ** 
Average adrenal gland weight (mg) 22.99 ± 1.35  14.12 ± 0.70 ** 
 (1) Listed are the thymus and adrenal gland weights of adult, male rats that were either treated with 
vehicle (0.45 % 2-hydroxypropyl-β-cyclodextrin) or corticosterone (CORT, 100 µg/ml) via the drinking 
water for 21 days. Data are displayed as means ± SEM. **p < 0.01, versus Vehicle (Vehicle, n = 16; 
CORT, n = 16). 
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The application of ACTH onto adrenal halves in the in vitro assay demonstrated that the adrenals 
of CORT-treated rats had not only shrunk in size, but that chronic exogenous CORT had induced adrenal 
insufficiency (Fig. 5), meaning that the adrenals of CORT-treated rats released significantly less CORT 
both basally and after stimulation with ACTH, compared to vehicle-controls (treatment, F(1, 126) = 56.27, 
p < 0.001; stress, F(1, 126) = 0.25, p = 0.623; ACTH/saline, F(1, 126) = 16.51, p < 0.001; left/right, F(1, 
126) = 0.88, p = 0.355; treatment x stress, F(1, 124) = 0.37, p = 0.550; treatment x left/right F(1, 124) = 
0.40, p = 0.534; stress x left/right, F(1, 124) = 0.036, p = 0.850; ACTH/saline x left/right, F(1, 124) = 0.06, 
p = 0.805; treatment x stress x left/right F(1, 120) = 0.04, p = 0.848). Interestingly, the left adrenal gland 
retained some ACTH-responsiveness in CORT-treated rats, while in vitro CORT release of the right 
adrenal gland was unaffected by ACTH application. In vehicle-treated rats, the left adrenal gland of the 
stressed rats had already released a significant amount of CORT during AS, resulting in a blunted CORT 
release after ACTH-stimulation ex vivo. 
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Figure 5. Adrenal functionality after chronic treatment with vehicle or corticosterone, as assessed ex vivo 
in a tissue culture assay. Immediately after rapid decapitation and organ extraction, the left (l) and the 
right (r) adrenal gland of each rat was microdissected into two halves, and each half placed into its own 
well, containing culture medium. The basal (non-stimulated) corticosterone (ng/ml) release was measured 
by applying 0.9 % saline ( ̶ ACTH) to one adrenal half, while the responsiveness to ACTH was measured 
by applying a stimulus of 50 nM ACTH in 0.9 % saline (+ ACTH) to the other adrenal half. (a) designates 
the average corticosterone secretion of both the left and right adrenal half. Rats had either been treated 
with vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or corticosterone in the drinking water (CORT, 100 
µg/ml) for 21 days. On day 21, half of each rat treatment group was subjected to acoustic startle stress 
(Stress), while the other half of the rats remained in their home cages as controls (Control). Data are 
displayed as means + SEM. *p < 0.05, **p < 0.01 versus respective  ̶ ACTH group; #p < 0.05 versus 
respective Vehicle-Control group; $$ p < 0.01 versus respective Vehicle groups; &p < 0.05 versus left-
side adrenal half; after post hoc analysis with Mann-Whitney-U tests (Vehicle-Control, n = 8; Vehicle-
Stress, n = 8; CORT-Control, n = 8; CORT-Stress, n = 8).  
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4.5. Effects of chronic CORT on the activity of tryptophan hydroxylase (Tph) in serotonergic systems 
Two major effects of chronic CORT-treatment on Tph activity (5-HTP accumulation) were 
detected within midbrain serotonergic systems (Fig. 6). In the DRD (Fig. 6, panel A; treatment, F(1, 29) = 
15.50, p < 0.01; stress, F(1, 29) = 8.86, p < 0.01; interaction, F(1, 27) = 0.92, p = 0.347), in the DRV (Fig. 
6 , panel B; treatment, F(1, 29) = 10.66, p < 0.01; stress, F(1, 29) = 7.65, p < 0.05; interaction, F(1, 27) = 
0.01, p = 0.944) and in the MnR (Fig. 6, panel G; treatment, F(1, 28) = 8.54, p < 0.01; stress, F(1, 28) = 
13.18, p < 0.01; interaction, F(1, 26) = 0.05, p = 0.832), CORT-treatment elevated the basal activity of 
Tph. Second, while AS stress in vehicle-treated rats increased Tph activity only in the DRV and MnR, 
chronic CORT-treatment sensitized specific subdivisions of the DR to AS stress, resulting in significant 
stress-induced increases of Tph activity in the DRD and DRC (Fig. 6, panel D; treatment, F(1, 29) = 0.92, 
p = 0.347; stress, F(1, 29) = 6.90, p < 0.05; interaction, F(1, 27) = 0.012, p = 0.913) in addition to 
increasing Tph activity in the MnR (treatment, F(1, 30) = 8.37, p < 0.01; stress, F(1, 30) = 9.17, p < 0.01; 
treatment x stress, F(1, 28) = 1.24, p = 0.277; treatment x region, F(1, 30) = 4.59, p < 0.01; stress x 
region F(1, 30) = 0.58, p = 0.714; interaction, F(1, 28) = 1.13, p = 0.370). No other subdivisions of the DR 
displayed altered Tph activity in response to chronic CORT treatment or stress.  
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Figure 6. Graphs illustrating the amount of 5-hydroxytryptophan (5-HTP, pg/µg total protein) measured in 
the (G) median raphe nucleus (MnR) and in each functional subdivision (A-E) of, and in the entirety of the 
dorsal raphe nucleus (DR, F). Adult, male rats were treated with vehicle (0.45% hydroxypropyl-beta-
cyclodextrin) or corticosterone in the drinking water (CORT, 100 µg/ml) for 21 days. On day 21, half of 
each rat treatment group was subjected to acoustic startle stress (S), while the other half of the rats 
remained in their home cages as controls (C). Prior intraperitoneal (i.p.) administration of the aromatic L-
amino acid decarboxylase inhibitor NSD-1015 (in 0.9 % saline) allowed for accumulation of 5-HTP, a 
readout of tryptophan hydroxylase (Tph) activity. (A) DRD, dorsal raphe nucleus, dorsal part; (B) DRV, 
dorsal raphe nucleus, ventral part; (C) DRVL, dorsal raphe nucleus, ventrolateral part / VLPAG, 
ventrolateral periaqueductal gray; (D) DRC, dorsal raphe nucleus, caudal part; (E) DRI, dorsal raphe 
nucleus, interfascicular part; (F) average 5-HTP content in entire DR. Data are displayed as means + 
SEM. *p < 0.05, stress effect within the same treatment group; #p < 0.05, ##p < 0.01 treatment effect 
versus respective vehicle group, after post hoc analysis with Fisher’s Protected LSD test (Vehicle-Control, 
n = 8; Vehicle-Stress, n = 8; CORT-Control, n = 8; CORT-Stress, n = 8). 
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4.6. Effects of chronic CORT on tryptophan hydroxylase (Tph) activity in relevant DR target regions 
Many target areas of the DR, including the LO, PrL, the BNST, the BL, the Ce, the Ent, and the 
DLPAG/LPAG showed an increase in Tph activity in vehicle-treated rats after exposure to AS stress (Fig. 
7, Panels A, C, E, G, H, N and P; treatment, F(1, 30) = 5.46, p < 0.05; stress, F(1, 30) = 13.56, p < 0.01; 
treatment x stress, F(1, 28) = 0.01, p = 0.959; treatment x region, F(1, 30) = 1.74, p = 0.144; stress x 
region F(1, 30) = 3.41, p = 0.01; interaction, F(1, 28) = 3.55, p = 0.01). In the VO (Fig. 7, panel B; 
treatment, F(1, 28) = 1.39, p = 0.249; stress, F(1, 28) = 12.81, p < 0.01; interaction, F(1, 26) = 0.45, p = 
0.507) and IL (Fig. 7, panel D; treatment, F(1, 29) = 2.72, p = 0.111; stress, F(1, 29) = 9.75, p < 0.01; 
interaction, F(1, 27) = 0.40, p = 0.535), chronic CORT-treatment was permissive for the stress-induced 
increase in Tph activity. In contrast, chronic CORT treatment abolished this stress-induced increase in 
Tph activity in the BL (Fig. 7, panel G; treatment, F(1, 30) = 2.44, p = 0.129; stress, F(1, 30) = 18.87, p < 
0.001; interaction, F(1, 28) = 2.19, p = 0.150) and in the Ent (Fig. 7, panel P; treatment, F(1, 28) = 0.13, p 
= 0.725; stress, F(1, 28) = 2.70, p = 0.112; interaction, F(1, 26) = 9.55, p < 0.01). In the Ent, this was due 
to a CORT-induced basal increase in Tph activity. The most remarkable treatment effects, however, were 
found in the dCA1 (Fig. 7, panel J; treatment, F(1, 30) = 0.56, p = 0.462; stress, F(1, 30) = 15.62, p < 
0.001; interaction, F(1, 28) = 3.58, p = 0.069) and in the PnC (Fig. 7, panel R; treatment, F(1, 29) = 30.59, 
p < 0.001; stress, F(1, 29) = 21.70, p < 0.001; interaction, F(1, 27) = 10.32, p < 0.01), where chronic 
CORT-treatment allowed for a highly significant stress-induced increase in Tph activity that was not 
present in vehicle-treated rats. 
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Figure 7 (next two pages). Graphs illustrating the amount of 5-hydroxytryptophan (5-HTP, pg/µg total 
protein) measured in a series of forebrain and hindbrain target regions of the dorsal raphe nucleus (DR) 
that have been shown to play a role in emotionality and stress-coping behavior. Adult, male rats had been 
treated with vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or corticosterone in the drinking water 
(CORT, 100 µg/ml) for 21 days. On day 21, half of each rat treatment group was subjected to acoustic 
startle stress (S), while the other half of the rats remained in their home cages as controls (C). Prior 
intraperitoneal (i.p.) administration of the aromatic L-amino acid decarboxylase inhibitor NSD-1015 (in 
0.9% saline) allowed for accumulation of 5-HTP, a readout of tryptophan hydroxylase (Tph) activity. (A) 
LO, lateral orbital cortex; (B) VO, ventral orbital cortex; (C) PrL, prelimbic cortex; (D) IL, infralimbic cortex; 
(E) BNST, bed nucleus of the stria terminalis; (F) PVN, paraventricular nucleus of the hypothalamus; (G) 
BL, basolateral amygdaloid complex; (H) CE, central amygdaloid nucleus; (I) DM, dorsomedial 
hypothalamic nucleus; (J) dCA1, cornu ammonis region 1, dorsal hippocampus; (K) vCA1,  cornu 
ammonis region 1, ventral hippocampus; (L) VS, ventral subiculum; (M) DMPAG, dorsomedial 
periaqueductal gray; (N) DLPAG, dorsolateral periaqueductal gray / LPAG, lateral periaqueductal gray; 
(O) IP, interpeduncular nucleus; (P) Ent, entorhinal cortex; (Q) LH, lateral hypothalamus / PeF, 
perifornical region; (R) PnC, caudal pontine nucleus. Data are displayed as means + SEM. *p < 0.05, **p 
< 0.01 stress effect within the same treatment group; #p < 0.05, ##p < 0.01 treatment effect versus 
respective Vehicle group, after post hoc analysis with Fisher’s Protected LSD test (Vehicle-Control, n = 8; 
Vehicle-Stress, n = 8; CORT-Control, n = 8; CORT-Stress, n = 8).  
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4.7. Effects of chronic CORT on the acoustic startle response (ASR) 
Chronic exposure to CORT in the drinking water caused the rats to startle more during the AS 
procedure, as reflected by an increased maximum ASR compared to vehicle controls (Fig. 8, panel A; p < 
0.001). Furthermore, a strong correlation of 5-HTP in the PnC and the maximum ASR was found, when 
the values of both vehicle- and CORT-treated rats were plotted (Fig. 8, panel B; r = 0.882, r2 = 0.777, p < 
0.001, N = 16). 
 
 
 
Figure 8. Acoustic startle response as measured during the 30 min exposure to acoustic startle stress 
(AS) on day 21, and correlation of 5-hydroxytryptophan (5-HTP) measured in the caudal pontine nucleus 
(PnC) and the maximum startle response. Startle response was measured during the 30 min exposure to 
acoustic startle (AS) stress on day 21. Panel (A) shows the maximum acoustic startle response (ASR; in 
Newton, N) of adult male rats that were chronically treated with either vehicle (0.45% hydroxypropyl-beta-
cyclodextrin) or corticosterone (CORT, 100 µg/ml) via the drinking water. Panel (B) displays the 
correlation between the 5-hydroxytryptophan (5-HTP) content measured in the PnC and the maximum 
ASR. Data are displayed as means + SEM. **p < 0.01, versus Vehicle (Vehicle, n = 8; CORT, n = 8). 
 
 
For the effects of stress and chronic CORT treatment on plasma stress hormone and cytokine 
concentrations please refer to Appendix B). 
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5. Discussion 
Chronic delivery of CORT via the drinking water for 21 days caused an anxiety- and depressive-
like phenotype, an increased ASR, adrenal insufficiency, and reduced BW gain, but did not alter the 
circadian pattern of food and water consumption. Most importantly, chronic CORT potentiated AS-induced 
Tph activity in the anxiety-related DRD, while it elevated basal Tph activity in the DRD, DRV, and MnR. In 
the DRC, IL, dCA1, and PnC, CORT-treatment was required to elicit a significant AS-induced increase in 
Tph activity, and Tph activity in the PnC was strongly correlated with ASR magnitude. 
 
5.1. Anxiety- and depressive-like behavior, and increased acoustic startle response (ASR) after 
chronic CORT 
Both the anxiety- and depressive-like effects of our non-invasive chronic CORT-paradigm that 
were described in Chapter II (Donner et al., 2012a) were reproduced in this study. Concordant with 
results from other groups, using both mice and rats (Ardayfio and Kim, 2006; Murray et al., 2008; Lee et 
al., 2010a; Diniz et al., 2012), chronic CORT exposure exerted anxiogenic effects on both the number of 
full entries into, and time spent in, the open arms of the EPM. The EPM includes components of both 
conflict (approach)- and panic (escape)-like behaviors (Pellow et al., 1985; McNaughton and Zangrossi 
Junior, 2008). An increased number of rears in the closed arms of the EPM may either indicate 
glucocorticoid-mediated enhancement of locomotion, as found in some (Veldhuis et al., 1982; Cador et 
al., 1993; Sandi and Guaza, 1994) but not in other studies (Ehlers et al., 1992; Kalynchuk et al., 2004), or 
simply be confounded by the fact that the rats spent more time in the closed arms, where most of the 
rearing behavior naturally occurs. The latter interpretation is supported by the fact that the number of 
entries into the closed arms of the EMP, usually regarded to as a measure of locomotor activity (Pellow et 
al., 1985), was not altered by CORT-treatment in our study. 
 
 In the FST, CORT-treated rats spent, again (Donner et al., 2012a), more time immobile, and also 
failed to display any diving behavior. Immobility is interpretable as a passive stress-coping strategy 
(Porsolt et al., 2001; Neumann et al., 2011), while diving is clearly a measure of escape-seeking, active 
stress-coping (Detke et al., 1995). Increased immobility was due to a tendency for decline in both 
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climbing in swimming behavior, suggesting an interaction of altered serotonergic, noradrenergic and 
dopaminergic signaling (Detke et al., 1995; Cryan et al., 2005a; Perona et al., 2008). Our findings are 
concordant with passive stress-coping behaviors found in other models of chronic CORT administration 
via the drinking water or using injections (Gourley et al., 2008b; Gourley et al., 2008a; Zhao et al., 2008; 
Lee et al., 2010a; Wu et al., 2012), with the exception of a study by David et al. (2009) that found no 
effect of a lower dose of chronic CORT in the drinking water (35 µg/ml) on immobility in the FST. Since 
the comparable 40 µg/ml dose in our initial study (Donner et al., 2012a), also failed to induce despair-like 
behavior, behavioral effects of chronic GC elevation may depend largely on the amount and duration of 
GC elevation, whereas the expression of the tph2 gene appears to be sensitive to comparably smaller 
changes in circulating GC concentrations. More research should focus on the neurobiology of diving 
behavior in the FST. To this date, it is considered an unreliable and inconsistent behavioral parameter. 
 
The observation that chronic CORT-treatment increased the average ASR during the 30 min of 
AS stress stands in contrast to findings in adult male Wister rats by other groups (Lee et al., 1994; Czyrak 
et al., 2003; Tanke et al., 2008). All of these, however, either used injections once or twice per day, or 
sustained delivery via a pellet, instead of a non-invasive oral paradigm with pulsatile bouts of CORT 
intake, meaning that the pulsatility of the stimulation may in fact be crucial to elicit an increased ASR after 
chronic GC treatment. In mice, chronic sustained CORT treatment using s.c. pellets or a drinking water 
paradigm also rather tends to decrease the ASR (Stevens et al., 2001; Ardayfio and Kim, 2006). In 
general, the literature is either inconsistent or suggests little to no correlation between exploratory tasks, 
such as the EPM, and startle reactivity (Paterson et al., 2001; Yilmazer-Hanke et al., 2004). Another 
potential explanation for the discrepancy is a bimodal effect of GCs on startle reactivity. Human literature 
suggests that low doses of exogenous cortisol enhance, while high cortisol doses attenuate acoustic 
startle reactivity (Buchanan et al., 2001). Similarly, severe depression, which is often associated with 
elevated plasma cortisol (Weber et al., 2000b), has been shown to be associated with lower startle 
responses than moderate depression (Kaviani et al., 2004). 
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5.2. Chronic-CORT-induced sensitization of the dorsal and caudal DR  to acoustic startle (AS) stress 
Consistent with findings by Singh et al. (1990a) that describe how 3 to 5 days of intraperitoneal 
injections of DEX, a synthetic GR-specific GC, can restore the increase of noise-stress induced Tph 
activity in adrenalectomized rats, chronic CORT treatment in our study was permissive for an AS stress-
induced increase in Tph activity, in particular within the anxiety-related DRD and DRC. The subdivision-
specificity resembles that of a previous study from our group (Evans et al., 2009). Evans et al. 
demonstrated that one 30 min session of unpredictable noise stress, as well as ex vivo CRF-treatment of 
midbrain slices was sufficient to increase Tph activity selectively in the DRC, but not in other serotonergic 
regions. Our findings relate to clinical post mortem results in that elevated tph2 mRNA and protein 
expression appear to be restricted to specific subdivisions of the DR, including the DRD of alcohol-
dependent depressed suicides (Bonkale et al. 2006), and the DRC in drug-free depressed suicides 
(Bach-Mizrachi et al. 2006, 2008). Anatomical tracing studies in primates and rodents revealed that dorsal 
and caudal subdivisions of the DR contain populations of serotonergic neurons that project to forebrain 
circuits controlling anxiety states, affective conditions, and cognitive functions (Lowry et al., 2008c; Lowry 
et al., 2008b).  
 
In addition to the CORT-induced sensitization of the DRD and DRC to AS stress, chronic CORT 
treatment elevated basal Tph activity in the DRD, DRV, and MnR. While acute increases in Tph activity 
cannot be explained by transcriptional modifications, the basal, chronic effect is most likely due to 
increased tph2 mRNA and Tph protein expression. Indeed, my studies demonstrate that chronic CORT-
treatment elevates (light-phase) tph2 mRNA expression in all of those subdivisions (Fig. A2, Appendix 
A)), including the MnR (Fig. A3, Appendix A)).  
 
The DRV, amongst other target regions, gives rise to projections to the barrel field cortex 
(Kirifides et al., 2001), sensorimotor cortex (Waterhouse et al., 1986), orbitofrontal cortex (Coffield et al., 
1992), and motor cortex (Waterhouse et al. 1986). Chronic GC elevation could thus, through increased 
serotonergic neurotransmission emerging from the DRV, contribute to the development of certain 
sensorimotor impairments often observed in psychiatric disorders (Canbeyli, 2010).  
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Given the strong correlation of Tph activity and the magnitude of the ASR in CORT-treated rats, 
chronic GC exposure may potentiate 5-HT-neurotransmission in the PnC resulting in stimulatory actions 
on the startle reflex. Since 5-HT synthesis itself was blocked using NSD-1015, this could be due to a 
stress-induced stimulation of 5-HT release from vesicular neurotransmitter stores in the synaptic 
terminals. Alternatively, GCs may potentiate the stress-sensitivity and CRF-related signaling in collateral 
branches from the Ce that innervate, amongst other targets, the PnC. In comparison, Davis et al. 
demonstrated in the 1980s that 5-HT can have a dose-dependent enhancing function on the ASR when 
injected into the spinal cord, while intracerebroventricular administration of 5-HT results in dose-
dependent suppression of the ASR (Davis et al., 1980), possibly via 5-HT1A autoreceptor-dependent 
inhibition of serotonergic neurons with descending projections to the PnC. 
 
Projections from the DR may travel both to and through the MnR (Tischler and Morin, 2003). 
Consistent with potential DR/MnR interactions, Forster et al. showed that increases in 5-HT release in the 
mPFC following stimulation of the DR can be prevented by inhibition of the MnR (2008). The MnR 
innervates important hypothalamic areas (Vertes et al., 1999), many of which are likely to provide 
negative γ-amino butyric acid (GABA)ergic feedback to the PVN, and are thus capable of regulating HPA 
axis activity (Lowry, 2002). The MnR is also thought to be involved in stress attenuation or resilience 
(Graeff et al., 1996), and in the control of various behavioral and physiologic functions, such as food and 
water intake, control of hippocampal theta rhythm, and circadian rhythmicity in general (Wirtshafter and 
Trifunovic, 1988; Vertes et al., 1994; Morin, 1999; Wirtshafter, 2001). A GC-induced increase in 
serotonergic neurotransmission from the MnR may thus contribute to altered ingestive behavior 
(Anagnostis et al., 2009), disrupted sleep/wake rhythms or sleep impairments commonly observed in 
stress-related psychiatric disorders (Boivin, 2000). 
 
Acute, as opposed to basal, increases in Tph activity are probably attributable to phosphorylation 
of the enzyme by protein kinase A (Makita et al., 1990; Vrana et al., 1994; Johansen et al., 1995). Based 
on earlier findings that GCs are acting through CRF signaling in the Ce to permit increases in stress-
induced, but not basal, Tph activity (Singh et al., 1990a; Singh et al., 1990b; Liang et al., 1992a; Singh et 
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al., 1992; Lee et al., 1994; Singh et al., 1994), and based on the subdivision-specific treatment- and 
stress-effects in this study, we propose that chronically elevated GCs affect a neuronal circuit related to 
generalized (approach/conflict) anxiety rather than a panic-circuitry. For example, chronic GC exposure 
may result in altered crf mRNA (Makino et al., 1994a, b) and CRF protein expression within the Ce and 
subsequently in the BNST, as local infusions of CORT into the Ce elevate crf mRNA expression in the 
BNST (Shepard et al., 2006). GC-induced plasticity in DR-innervating CRF neurons from the BNST, 
which is associated with anxiety-like behavior (Shepard et al., 2009), may then lead to increased release 
of CRF onto CRFR-expressing GABAergic neurons in the inhibitory surround of the DR, or onto 
GABAergic interneurons located in dorsal and caudal subdivisions of the DR. The DRD- and DRC-
specific sensitization of Tph activity to an acute stressor, together with the elevated anxiety in the EPM 
strongly indicates plasticity within an anxiety-related network, because the dorsal and caudal DR, but not 
other subdivisions, are activated by anxiogenic drugs (Abrams et al., 2005), the CRF-like peptide 
urocortin 2 (Staub et al., 2005; Staub et al., 2006; Hale et al., 2010b), and by fear-, anxiety-, and stress-
related stimuli (Gardner et al., 2005; Spannuth et al., 2011). Most recently, Sink et al. (2012) 
demonstrated that overexpression of CRF within the BNST increased crfr2 mRNA expression in the DRD 
corroborating the existence of an anxiety-related BNST-DR circuit.  
 
5.3. Chronic-CORT-induced sensitization of serotonergic systems to acoustic startle (AS) stress in 
cortical, hippocampal, and pontine brain regions  
Glucocorticoid-mediated sensitization of the VO, IL, dCA1, and PnC to AS stress is consistent 
with recent findings by Wu et al. (2012) who found increased 5-HT content in the hippocampus of 
chronically CORT-treated rats (daily s.c. injections, 40 mg/kg). The fact that neither chronic CORT-
treatment nor AS stress significantly elevated Tph activity in the DMPAG, an area thought to control fight- 
or flight- and panic-like responses, such as tachycardia and hypertension (Bandler et al., 2000; Keay and 
Bandler, 2001), further supports the differentiation between panic- and anxiety-circuitries. In contrast, AS 
stress significantly increased Tph activity within the DLPAG / LPAG regions, where local injections of 
excitatory amino acids have been shown to elicit passive stress-coping strategies or depressive-like 
behavior, including hyporesponsiveness to the environment, bradycardia, and hypotension (Bandler et al., 
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1991; Bandler et al., 2000). Dorsal and caudal subdivisions of the DR may preferentially innervate the 
DLPAG / LPAG rather than the DMPAG, and thus control passive stress-coping strategies, while the 
lateral wings of the DR (DRVL / VLPAG) may preferentially project to the DMPAG, controlling panic-like 
responses (Graeff, 2004; Donner et al., 2012c). The seemingly contradictory effect of chronic CORT on 
Tph activity in the BL, a major input region for the Ce and a contributor to the development of chronic 
anxiety states (Sanders and Shekhar, 1995b, a), and in the Ent, a hub for memory formation and 
navigation (Hasselmo et al., 2002; Eichenbaum and Lipton, 2008; Lipton and Eichenbaum, 2008) as well 
as the control of anxiety states (Hale et al., 2008a), remains to be explained. In both regions, chronic 
CORT attenuated the stress-induced increase in Tph activity. The enhanced stress-sensitivity in the 
orbitofrontal (VO) and mPFC (IL) may shed light on how chronically elevated GCs alter serotonergic 
neurotransmission in cortical areas important for reward-based decision-making (Rolls and Grabenhorst, 
2008; Schultz et al., 2011) and for the perception of control (Maier and Watkins, 2010). 
 
5.4. Correlation of acoustic startle response (ASR) and tryptophan hydroxylase (Tph) activity in the 
caudal pontine nucleus (PnC) 
This study is the first to demonstrate a strong positive correlation of the maximum ASR and Tph 
activity within the PnC, an important relay station within the midbrain reticular formation to control the 
startle response upon acoustic stimulation (Simons-Weidenmaier et al., 2006). Our findings are 
consistent with highly elevated 5-HIAA concentrations in the PnC of adult, male rats 2 h after they were 
acutely treated with intracerebroventricular CRF (Fig. B1, Appendix B), unpublished data), and suggest a 
direct CRF-mediated role for serotonergic neurotransmission in the control of the acoustic startle reflex. 
Interestingly, Tph activity in the PnC remained unchanged by AS stress in vehicle-treated rats, suggesting 
a permissive role for chronically elevated GCs to influence the ASR at the level of the PnC through 
actions of CRF. 
 
5.5. Adrenal insufficiency after chronic CORT 
As expected and in part described in Chapter II, the adrenal glands of chronically CORT-treated 
rats were atrophied in size, and highly impaired in their functionality. Adrenal halves of vehicle-treated 
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control rats released about 12 times more endogenous CORT after in vitro stimulation with ACTH than 
the adrenal halves of CORT-treated rats. Stimulation with ACTH is also used clinically to assess adrenal 
insufficiency in vivo (Oberfield et al., 1990; Corrias et al., 2012) in patients. Interestingly, the (in tendency) 
lighter left, but not the (in tendency) heavier right, adrenal glands of the CORT-group maintained the 
capacity to release a significant amount of endogenous CORT upon ACTH stimulation, while non-
stimulated endogenous CORT release was lower in the left adrenal gland of CORT-treated rats. Few 
reports of adrenal asymmetry in functionality or size are available (Gerendai and Halasz, 1997; Sullivan 
and Gratton, 1999; Engeland and Arnhold, 2005), and it has yet to be determined whether this difference 
is due to differential vascular supply or differential innervation (Toth et al., 2008). Toth et al., for example, 
found that the left adrenal gland is more heavily innervated by supraspinal projections from brain regions 
in the hypothalamus and in the brainstem raphe magnus, raphe obscurus, and raphe pallidus than the 
right adrenal.  
 
5.6. Altered metabolism, but maintenance of diurnal activity patterns after chronic CORT 
Chronic CORT-induced attenuation of BW gain in rats has been characterized previously (Conrad 
et al., 2007; Gourley and Taylor, 2009). Our data show that CORT-treated rats ate and drank just as 
much as vehicle-controls, when their BW was taken into account, suggesting that an elevated metabolism 
prevented proper weight gain in the CORT group. Anabolic versus catabolic effects of CORT are highly 
dose- (Tomas et al., 1979; Devenport et al., 1989) and species-dependent. While 100 µg/ml CORT is 
considered a medium to high, catabolic dose in rats, mice receiving the same CORT concentration via the 
drinking water gain more BW than controls (Karatsoreos et al., 2010; Cassano et al., 2012). Another 
potential indicator of an elevated metabolism in the CORT group in our study, their drop in rectal 
temperature from before to after the FST closely resembled that of vehicle-treated controls (3.7 ºC), 
although CORT-treated rats weighed much less than vehicle-control rats at day 21, and would thus be 
expected to lose more body heat during the FST. 
 
For a brief discussion of the interaction of AS stress and chronic CORT treatment on plasma 
stress hormone and cytokine concentrations please refer to Appendix B).  
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6. Conclusion 
In conclusion, these results elucidate how one component of repeated or chronic stress, namely 
elevated concentrations of circulating GCs, may contribute to the etiology of anxiety- and depressive 
symptoms by altering serotonergic activity within source- and target-regions of serotonergic signaling, 
without altering diurnal activity patterns. The identification of specific GC-sensitive serotonergic regions 
and GC-sensitive circuitries may aid in the development of target-specific treatments or preventative 
measures to avoid psychiatric illness, for example in patients with hypercortisolemia, such as Cushing’s 
disease, or in people that are known to enter predictably chronic stressful situations. 
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CHAPTER	V	
	
Midbrain	CRF	receptor	systems	differentially	control	
noise	stress‐induced	tryptophan	hydroxylase	activity	
after	chronic	glucocorticoid	exposure	
 
1. Summary 
In Chapter II, I demonstrated that chronic GC exposure elevates tph2 mRNA expression, and in 
Chapter IV it was found that chronic GC exposure enhances AS-induced in vivo Tph activity selectively 
within the DRD and DRC subdivisions of the DR. Other researchers have also described that exposing 
rats to unpredictable noise stress increases the in vivo Tph activity selectively within the caudal DR. 
Likewise, different types of stressors, as well as the CRFR2-selective ligand urocortin 2 and anxiogenic 
drugs increase c-Fos expression selectively in serotonergic neurons within the caudal DR, while electrical 
stimulation of the Ce increases extracellular 5-HT concentrations in limbic forebrain sites that are 
innervated by the caudal DR. The latter effects can be prevented by microinjection of the CRFR2 receptor 
antagonist antisauvagine-30 (ASV-30) directly into the caudal DR. Studies have also demonstrated that, 
in contrast to the rather ubiquitously distributed CRFR1, the expression pattern of CRFR2 is much more 
limited to specific brain regions, with the mid-rostrocaudal to caudal DR being one of the areas of highest 
CRFR2 mRNA expression and immunoreactivity, while CRFR1 is generally expressed in comparably low 
levels within the DR, but is expressed at high levels in the immediate surround of the DR.  
 
We thus hypothesize that chronic GC exposure sensitizes anxiety-related subdivisions of the DR 
to subsequent stress exposure by increasing CRF mRNA and protein expression in the Ce and in the 
BNST, leading to enhanced stress-induced release of CRF and thus activation of CRFR1 within the 
immediate inhibitory surround of the DR, and of CRFR2 specifically within the dorso-caudal subdivisions 
of the DR, namely the DRD and DRC. To test this hypothesis we acutely blocked either CRFR2 or 
CRFR1, using specific antagonists, within the caudal DR and its immediate surround 10 min before 
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exposure to AS stress in rats previously treated with chronic CORT, and measured both basal (home 
cage control) and acoustic startle-induced Tph activity within the DR and within anxiety-, panic- or stress-
coping-related target areas of the DR. All rats received 100 µg/ml CORT in 0.45% HBC non-invasively for 
21 days via the drinking water to sensitize the DR to AS stress. Immediately prior to entering the AS 
chamber, all rats (including the home cage controls) were injected with 100 mg/kg NSD-1015, an inhibitor 
of AADC, to block the conversion of 5-HTP to 5-HT. 5-HTP accumulation was measured, as a readout of 
Tph activity, using HPLC-ED. 
 
We found that, with the exception of the median raphe nucleus (MnR) and the interfascicular part 
of the DR (DRI), pharmacological blockade of CRFR1 potentiated AS-induced Tph activity in average by 
23% throughout the entire DR, most likely due to inhibition of CRFR1-mediated stimulation of GABAergic 
afferents to the DR. In contrast, CRFR2 blockade prevented the AS-induced increase in Tph activity 
within anxiety-related DR subdivisions, namely the DRD and DRC. Furthermore, CRFR1 blockade 
increased the maximum acoustic startle response (ASR), and the maximum ASR was strongly correlated 
with the 5-HTP content in the PnC, a major relay station of the acoustic startle reflex. 
 
These findings suggest competing roles for CRFR1 and CRFR2 in control of stress-induced 
serotonergic activity, namely that CRFR2 activation stimulates stress-induced serotonergic activity within 
the anxiety-related DRD and DRC, while CRFR1 activation inhibits it in the DRD and DRC, but also in the 
DRV. 
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2. Background 
In Chapter IV, chronic GC intake was found to sensitize the activity of Tph, the rate-limiting 
enzyme during brain 5-HT synthesis, in response to 30 min of acoustic startle (AS) stress, specifically in 
the dorsal and caudal regions of the DR. Glucocorticoid-treated rats also displayed increased anxiety- 
and depressive-like behavior, and an increased behavioral startle response, even though exposure to AS 
stress occurred only once. Repeated or chronic exposure to GCs is known to increase anxiety-related 
behaviors in rodent models (Ardayfio and Kim, 2006; Shepard et al., 2009; Sterner and Kalynchuk, 2010), 
and glucocorticoids are thought to enhance fear conditioning (Corodimas et al., 1994; Thompson et al., 
2004) through actions of CRF within the extended amygdala complex (Lee et al., 1994; Schulkin et al., 
1998). With respect to fear conditioning, repeated systemic CORT delivery for several days up to 2 h 
before, but not after, exposure to a contextual fear-conditioning test increases fear-conditioned freezing 
behavior in rats (Thompson et al., 2004), indicating a sensitizing effect of glucocorticoids for later memory 
consolidation of a fearful stimulus. Chronic systemic elevations of GCs have also been demonstrated to 
increase basal CRF mRNA expression specifically in anxiety-related brain regions of the extended 
amygdala complex, such as the central nucleus of the amygdala (Ce) and in the bed nucleus of the stria 
terminalis (BNST) (Makino et al., 1994a, b; Makino et al., 1995) and CRF release in the Ce and in the 
medial prefrontal cortex (Merali et al., 2008) in response to an acute stressor. Local delivery of CORT into 
the Ce has furthermore been shown to potentiate stress-induced CRF mRNA expression in the BNST 
(Shepard et al., 2006) and to increase anxiety-like emotional and colonic responses (Myers et al., 2005), 
while systemic administration of a CRFR1 antagonist blocks these behavioral responses (Myers et al., 
2005). Since previous in vitro and in vivo studies have established that CRF mediates the stimulating 
effect of sound stress on Tph activity (Singh et al., 1990b; Singh et al., 1992; Evans et al., 2009), we now 
believe that altered CRF signalling may mediate the subdivision-specific effects of chronic GC treatment, 
most likely through altered afferent input from anxiety-related brain regions, such as the BNST or the Ce, 
to the DR. In an early study by Singh et al. (1990a) adrenalectomy, treatment with a glucocorticoid 
receptor antagonist, and amygdalar lesions all blocked, while prior systemic, repeated injection of 
dexamethasone into adrenalectomized rats recovered, the effects of sound stress on in vitro Tph activity, 
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indicating a permissive effect of glucocorticoids on sound stress-induced increases in Tph activity that 
may be dependent on input from the extended amygdala.  
 
One possibility is that chronic GC exposure sensitizes anxiety-related subdivisions of the DR to 
subsequent stress exposure by increasing CRF mRNA and protein expression in the Ce and BNST, 
leading to enhanced stress-induced release of CRF acting on CRFR1 in the immediate surround of the 
DR, and on CRFR2 specifically within the caudal part of the dorsal DR (cDRD) and in the DRC. 
Collectively, those two regions will be referred to as the caudal DR in the remainder of the Chapter. This 
hypothesis is supported by previous studies demonstrating that a) exposing rats to AS stress increases 
the in vivo activity of Tph selectively within caudal DR (Evans et al., 2009), b) different types of stressors 
(Gardner et al., 2005; Johnson et al., 2005; Johnson et al., 2008), the CRFR2-selective ligand urocortin 2 
(Staub et al., 2005; Staub et al., 2006) and anxiogenic drugs (Abrams et al., 2005) all increase c-Fos 
expression (a marker of neuronal activation) in serotonergic neurons selectively within the caudal DR, c) 
electrical stimulation of the Ce increases extracellular 5-HT concentrations in limbic forebrain sites that 
are innervated by the caudal DR (Forster et al., 2008) and d) the latter effects can be prevented by 
microinjection of the CRFR2 antagonist antisauvagine-30 (abbreviated as ASV-30 or A30) (Rivier et al., 
2002) directly into the caudal DR (Forster et al., 2008). Studies have also demonstrated that, in contrast 
to the rather ubiquitously distributed CRFR1, the expression pattern of CRFR2 within the brain is much 
more limited to specific brain regions, with the mid-rostrocaudal to caudal DR constituting one of the 
areas of most concentrated CRFR2 mRNA expression (Day et al., 2004) and immunoreactivity (Lukkes et 
al., 2011), while CRFR1 is generally expressed in comparably low levels within the DR, but higher levels 
in the immediate surround. 
 
We hypothesized that the enhanced startle response observed after chronic exposure to elevated 
GCs is simultaneously and differentially regulated by CRFR1 and CRFR2, with CRFR2 acting directly on 
serotonergic neurons to increase Tph activity within the caudal DR, and CRFR1 acting within the 
inhibitory surround of the DR to prevent overactivation of Tph. To test our hypothesis, we blocked either 
CRFR2 or CRFR1 pharmacologically within the caudal DR 10 min before exposure to AS stress, and 
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measured both basal and AS-induced Tph activity within the DR and within anxiety-related target areas of 
the DR in adult, male rats that received 21 days of non-invasive CORT treatment via the drinking water. 
Tph activity was assessed by measuring the amount of 5-HTP accumulation using HPLC-ED after 
chemically blocking AADC.  
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3. Materials and Methods 
3.1. Animals  
Sixty adult, male Sprague Dawley rats (Harlan Laboratories, Indianapolis, IN, USA; 225-250 g at 
the arrival day, 275-300 g at the day of surgery) were single-housed with ad libitum access to food and 
CORT-water for the entire duration of the experiment (post-surgery), and kept on a reversed 12:12 h 
light/dark cycle for consistency with the design of previous studies. Fresh CORT drinking bottles were 
provided every four days. During the last week of treatment, all rats were handled for 30 s per day to 
habituate them for the handling and injections on day 21. 
 
3.2. Experimental design 
Fig. 1 summarizes the timeline of the experimental design. Seven days after arrival, all rats 
received stereotaxic surgery for implantation of a unilateral guide cannula (sealed with a dummy stylet 
and a screw-cap). Non-traumatic ear bars were used to preserve the tympanic membranes since 
accurate hearing was essential for later exposure to AS stress. After the surgery, rats were allowed to 
recover for four days before being treated with 100 μg/ml CORT via the drinking water for 21 days. No 
control group receiving vehicle in the drinking water was included because we demonstrated in Chapter 
IV that chronic CORT is required for an AS-induced increase in Tph activity in the DRD and DRC, and 
because the objective of the study was to elucidate the underlying mechanism for this observation, not to 
compare CORT- to vehicle-treated rats. On day 21 after treatment start, the dummy stylets were 
removed, and the rats received unilateral intracranial microinjections of vehicle (n = 20), antisauvagine-30 
(abbreviated as ASV-30 or A30, n = 20), or antalarmin (Ant, n = 20) 10 min (at 0320 h) before a 30 min 
exposure to home cage control conditions or to AS stress (0330 h to 0400 h). Immediately before the start 
of AS, all rats (including the home cage control rats) received an i.p. injection of the AADC inhibitor NSD-
1015 (100 mg/kg). After AS stress, all rats were rapidly decapitated, and their brains fresh-frozen on dry 
ice (dorsal side facing downward on a piece of dry ice) before being stored at ‒80 °C until further 
processing. The experiment was run in alternating, pseudo-randomized blocks. As explained in Chapter 
IV, the killing time point was decided upon based on findings by Malek et al. (2004, 2005, 2007) that peak 
Tph protein expression in the DR follows approximately 8 h after peak expression of tph2 mRNA. 
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Figure 1. Illustration of the experimental design and timeline. Adult, male rats (N=60) received stereotaxic 
implants of a unilateral guide cannula targeting the caudal dorsal raphe nucleus (DR). After four recovery 
days, all rats were chronically treated with corticosterone (CORT, 100 µg/ml in 0.45% hydroxypropyl-beta-
cyclodextrin, n = 60) via the drinking water for 21 days. During the last 7 days of treatment, rats were 
handled daily for 30s each to habituate and prepare them for the injection procedures at the end of the 
study. On day 21, CORT-water bottles were replaced with vehicle-bottles at 0230 h, before the rats either 
received an intra-cranial microinjection of vehicle (2% EtOH/ 2% Cremophor EL/ artificial cerebrospinal 
fluid (aCSF); n=20), antalarmin (n=20) or anti-sauvagine 30 (ASV-30, n=20) at 0320 h, and subsequently 
100 mg/kg of the aromatic L-amino acid decarboxylase inhibitor NSD-1015 (in 0.9% saline) 
intraperitoneally (i.p.) at 0330 h. Half of each treatment group was then subjected to unpredictable 
acoustic startle stress for 30 min, while the other half remained in their home cages as controls. 
Immediately after the termination of acoustic startle stress, at 0400 h, all rats were sacrificed via rapid 
decapitation to collect their brains and trunk blood. 
 
In Chapter II, we found that CORT elevated tph2 mRNA expression 2 h into the rats’ light phase 
compared to vehicle controls (Donner et al., 2012a). To compare our results with our previous findings, 
we thus measured Tph protein activity 10 h into the rats’ light phase.  
 
3.3. Surgery and verification of cannula placement 
A permanent, unilateral guide cannula was stereotaxically implanted above the caudal DR, and 
was sealed with a dummy stylet until insertion of the injection cannula on day 21 of the experiment. 
Briefly, rats were anesthetized in an induction chamber using 5% isoflurane (Vedco, Saint Joseph, MO, 
USA), and the top of their head was shaved, before being positioned and locked into the stereotaxic 
frame using non-traumatic ear bars with the incisor bar set at ‒3.3 mm (Paxinos and Watson, 1998). 
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During surgery, isoflurane anesthesia was delivered at a 2–3% concentration through a nose-cone. After 
sterilizing the shaved area with 70% EtOH, a 1.5–2.0 cm rostro-caudal skin incision was made, and the 
skull was cleared of connective tissue until bregma and lambda were clearly visible. To avoid the sagittal 
sinus and the mesencephalic aqueduct, the guide cannula (Cat. No. C315GA/SPC, 26 ga, Plastics One 
Products, Roanoke, VA, USA) was implanted at a 32.0 ° angle (in reference to the midline), using the 
following coordinates: + 4.00 mm lateral from bregma, –8.30 mm caudal from bregma (anterior-posterior 
coordinate), and –6.65 mm (depth from the skull surface to the tip of the guide cannula along the cannula 
track). These coordinates were selected so that the tip of the injection cannula (Cat. No. C315IA/SPC, 33 
ga, Plastics One Products) would extend exactly 1 mm beyond the guide cannula, targeting the 
immediate (right side) caudal DRD and the DRC areas and adjacent surround. The guide cannula was 
secured with four 2 x 4 mm stainless steel screws (Bolt Depot, Weymouth, MA, USA) anchored in the 
skull, and with a head cap of dental cement (Cat. No. 51458; Stoelting, Wood Dale, IL, USA), and sealed 
with a dummy stylet including a plastic screw-on top (Cat. No. C315DC/SPC (small), Plastics One 
Products). Rats recovered from surgery and anesthesia in a clean cage on top of a 37 °C heating pad. 
Post-surgery, rats received a subcutaneous (s.c.) injection of 5 mg/kg Meloxicam (Metacam®, Cat. No. 
16397, Medi-Vet, Mandeville, LA, USA), an analgesic, and 5 mg/kg of the antibiotic enrofloxacin (Baytril®, 
Cat No. 10228, Medi-Vet). The same dose of Baytril was injected once daily for 2 days post-surgery (3 
days total) to prevent infections. After surgery, rats were single-housed for the remainder of the study.  
 
The placement of each injection cannula tip was verified post mortem in 25 μm sections of the 
DR that had been mounted on glass microscope slides (Cat. No. 16004-382; VWR, West Chester, PA, 
USA) and subjected to a nuclear cresyl violet (Cat. No. C5042; Sigma-Aldrich) staining protocol (12 min in 
0.5% cresyl violet, followed by 3 min differentiation in H2O, 2 min dehydration steps in an ascending EtOH 
series, and 5 min in xylene before coverslipping). The tips of the injection cannulae tracks were then 
mapped by comparing the sections with a rat brain atlas (Paxinos and Watson, 1998). Due to guide 
cannula tip placement outside a radius of 0.5 mm from the target, 21.66 % of the rats were removed from 
further analysis.  Fig. 2 depicts the location of all injection cannula tips that were considered on-target.  
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Figure 2. Verification and mapping of 
cannulae placements. Unilateral stereotaxic 
placements of guide and injection cannulae 
were verified via histochemistry and 
comparison with the rat brain atlas by Paxinos 
and Watson (1998). (A) Depicted are those 
injection sites between  ̶ 8.10 mm and  ̶ 8.70 
mm from bregma that were considered within 
target, namely within the midbrain dorsal 
raphe nucleus (DR) or its immediate surround. 
Thirteen out of 60 cannula placements in total 
were considered anatomical outliers, and thus 
not included in the analysis. The orientation of 
the brain sections matches the orientation of 
the viewer (left hemisphere on the left, right 
hemisphere on the right). (B) Representative 
photomicrograph of guide and injection 
cannula tracks and of an injection site itself 
at  ̶ 8.40 mm from bregma in a 25 µm thick 
brain section stained histochemically with 
cresyl violet. The vertical scales in panel (A) 
and (B) indicate the dorsoventral coordinates 
in millimeters. Abbreviations: 2, second 
cerebellar lobule; Aq, mesencephalic 
aqueduct; DRD, dorsal raphe nucleus, dorsal 
part; DRV, dorsal raphe nucleus, ventral part; 
DRVL/VLPAG, dorsal raphe nucleus, 
ventrolateral part / ventrolateral 
periaqueductal gray; DRC, dorsal raphe 
nucleus, caudal part; DRI, dorsal raphe 
nucleus, interfascicular part; DTgP, dorsal 
tegmental nucleus, pericentral part; mlf, 
medial longitudinal fasciculus; scp, superior 
cerebellar peduncle; xscp, decussation of the 
superior cerebellar peduncle (Veh-HC, n = 8; 
Veh-AS, n = 7; Ant-HC, n = 8; Ant-AS, n = 7; 
A30-HC, n = 8; A30-AS, n = 9). Scale bar, 500 
µm. 
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3.4. CORT treatment, drugs, and dosage of intra-cranial antagonist microinjections 
The crystalline hormone corticosterone (CORT, 11β,21-dihydroxy-4-pregnene-3,20-dione; 
minimum ≥ 92 %; Cat. No. C2505) was obtained from Sigma-Aldrich. CORT was dissolved in tap water 
containing 0.45 % 2-hydroxypropyl-β-cyclodextrin (HBC) from Sigma-Aldrich (Cat. No. 332607), and 
treatment with CORT-water began at 0600 h on day 0 (four days after surgery). To prevent light-induced 
degradation of CORT, dark drinking bottles were used.  
 
Immediately prior to the onset of AS stress on day 21, all rats received an i.p. injection of 100 
mg/kg NSD-1015 (3-hydroxybenzylhydrazine dihydrochloride, Cat. No. 54880, Sigma-Aldrich) in 0.9 % 
sterile saline to block AADC-dependent conversion of 5-HTP to 5-HT. Measuring 5-HTP accumulation in 
brain regions of interest was then used to assess Tph activity. Ten min prior to the onset of AS stress, 
rats received microinjections of vehicle (2% EtOH/ 2% Cremophor EL/ artificial cerebrospinal fluid 
(Bledsoe et al., 2011), n = 20), 50 ng of the selective CRFR1 receptor antagonist antalarmin (Cat. No. 
A8727, Sigma-Aldrich, n = 20) in 0.5 µL vehicle, or 2 µg (Forster et al., 2008) of the selective CRFR2 
antagonist anti-sauvagine 30 (Cat. No. A4727, ASV-30, Sigma-Aldrich) in 0.5 μL vehicle into the DR or its 
immediate surround at bregma –8.30 mm. The dosage of antalarmin was based on the finding that similar 
doses (25 and 50 ng) have been shown to be sufficient to block CRF receptor-mediated increases in 
extracellular 5-HT within the nucleus accumbens (Lukkes et al., 2008). Similarly, when injected into the 
DR, 2 µg of ASV-30 has been shown to block increases in extracellular 5-HT within the medial prefrontal 
cortex (mPFC), that are usually observed after electrical stimulation of the Ce (Forster et al., 2008). 
Hammack et al. furthermore demonstrated that intra-DR microinjection of 1.82 μg ASV-30 reduced, and 
3.65 μg ASV-30 blocked, the behavioral manifestations of inescapable stress, namely exaggerated fear 
conditioning and escape deficits in the shuttlebox measured 24 h later in a model of learned helplessness 
(Hammack et al., 2003b).  The microinjections were performed using procedures described previously 
(Spiga et al., 2006; Forster et al., 2008), connecting the 33 ga injection cannula via polyethylene tubing 
(Cat. No. 313CT, Plastics One Products) to a blunt-tip syringe of 10 μl total volume (Cat. No. 80365; 
Hamilton, Reno, NV) and a precision-pump (Model PhD 2000; Harvard Apparatus, Holliston, MA, USA). 
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3.5. Acoustic startle (AS) stress and behavioral recording 
The AS stress procedure was exactly the same as previously described in Chapter IV. Briefly, 30 
sound pulses of 100 ms duration each, a sound intensity of 120 dB, and a frequency of 3.0 kHz were 
delivered in randomized intervals (average interval: 1 min) over the time course of 30 minutes. A constant 
background noise of 60 dB was delivered in between each AS trial. The protocol closely resembles the 
one used by the Boadle-Biber laboratory (Singh et al. 1990). The maximum acoustic startle response 
(ASR) in Newtons (N) was recorded during the 200 ms time window following the onset of each of the 30 
AS trials, and individual trial ASRs were later averaged per rat. 
 
3.6. Brain sectioning and microdissection of fore- and hindbrain regions of interest 
Sections from the DR region (–7.50 mm to –9.00 mm bregma) were collected by alternating one 
100 µm section with two 25 µm sections (sectioning pattern: 100 µm, 25 µm, 25 µm, 100 µm, 25 µm, 25 
µm, 100 µm…) in order to verify injection cannula placement; the rest of the brain was sectioned at 300 
µm. Sections were collected using a cryostat (Model CM1900; Leica, Wetzlar, Germany), and were then 
thaw-mounted onto microscope glass slides (Cat. No. 16004-420, VWR, Westchester, PA, USA) in 
preparation for microdissection and HPLC-ED as previously described (Evans et al., 2009). After briefly 
thaw-mounting the sections, sections were again kept at –80 °C until microdissection at –10 ºC, using a 
cold plate (Model No. TCP-2, Cat. No. Z176664, Sigma-Aldrich) and blunt dissection needles ranging 
from 310 to 1000 μm in inner diameter (Fine Science Tools, Foster City, CA, USA). Rostrocaudal levels 
for microdissection were verified using a stereotaxic atlas of the rat brain (Paxinos and Watson, 1998), 
and microdissected samples were placed in small Eppendorf tubes containing 100 μl acetate buffer (pH = 
5.0; 992.7 mL HPLC grade H2O, 3.0 g sodium acetate, 4.3 ml glacial acetic acid), snap-frozen on dry ice, 
and stored at –80 °C until HPLC-ED analysis of 5-HTP.  
 
All brain regions that were chosen for microdissection, including their rostrocaudal distance from 
bregma, the number of samples pooled for each region, and the respective diameter of the blunt 
microdissection needles used, are included in Table B1 in Appendix B). Again, six subregions of the 
midbrain raphe nuclei were microdissected within the hindbrain. The MnR, the DRD, and the DRV were 
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all collected at –7.20, –7.50, –7.80, and –8.10 mm from bregma. The DRVL/VLPAG was collected at –
7.50, –7.80, and –8.10 mm from bregma, the DRI was collected at –8.10, and –8.40 mm from bregma, 
and the DRC was collected at –8.40 and  –8.70 mm from bregma. Only the 15 of the original 18 target 
regions of midbrain serotonergic systems chosen in Chapter IV were microdissected in the present study. 
This included the LO and VO at 4.20 mm bregma, the PrL and IL at 2.70 mm bregma, the BNST at –0.30 
mm bregma, the PVN at –1.80 mm bregma, the BL at –2.40, –2.70, and –3.00 mm bregma, the Ce at –
2.40 and –2.70 mm bregma, the dCA1 at  –3.90 mm bregma, the vCA1 and the VS at –6.00 mm bregma, 
Ent at –6.90, –7.50, and –8.10 mm bregma, the DMPAG and the DLPAG/VLPAG at –7.50,  –7.80, and –
8.10 mm bregma, and the PnC at –9.00, –9.30, and –9.60 mm bregma. The dorsomedial caudate 
putamen (dmCPu, 0.60 and 0.30 mm bregma) was used as a negative control region, in which only 
minimal amounts of 5-HTP were detected (< 0.5 pg/µg).  
 
3.7. Measuring 5-hydroxytryptophan (5-HTP) accumulation as a readout of tryptophan hydroxylase 
(Tph) activity  
Injection of the AADC inhibitor NSD-1015 was used to inhibit the conversion of 5-HTP to 5-HT in 
all rats. To analyze 5-HTP accumulation, an index of Tph activity in the presence of NSD-1015, the 
microdissected samples were thawed and centrifuged at 13,000 rpm for 5 min at 4 ºC, and 50 µl of the 
supernatant from each sample were placed in an ESA 542 autosampler (ESA Analytical Ltd., Huntington, 
UK) to be analyzed for 5-HTP content with HPLC-ED. During the procedure, samples were maintained at 
4 °C, while the column oven temperature remained at 29 °C, the flow rate at 1.50 ml, and the pressure 
between 175 and 195 bar. The remaining supernatant (~50 μl) was stored at –80 °C as a back-up 
sample, and the tissue-sample pellet was reconstituted with 175 μl of 0.2 M NaOH and assayed for total 
protein content using a Bradford-reaction-based commercially available kit (Micro BCA Protein Assay Kit, 
Thermo Scientific, Rockford, IL, USA). 5-HTP concentrations are expressed as a ratio of total 5-HTP (in 
pg) and the total amount of protein per sample (μg). 
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3.8. Statistical analysis 
Prior to statistical analysis using SPSS (version 20 for Windows, SPSS Inc., Chicago, IL, USA) 
outliers were identified (Grubbs, 1969) and removed from the data set in Microsoft Excel. Due to Grubbs’ 
outlier identification, 1.92% of the 5-HTP data set (16 data points of 832) was excluded. Due to 
neuroanatomical properties, two different sets of mixed model linear analyses (MMLAs) with treatment (3) 
and stress (2) as between-subjects factors and region as the within-subjects factor were performed to 
compare the 5-HTP content in all of the 25 microdissected brain regions. The first analysis compared the 
5-HTP content in all 6 subregions of the midbrain raphe complex (DRD, DRV, DRVL/VLPAG, DRC, DRI, 
and MnR), the second analysis compared the 5-HTP content in projection regions including the LO, VO, 
PrL, IL, dmCPu, BNST, PVN, BL, Ce, dCA1, vCA1, VS, Ent, DMPAG, DLPAG/LPAG, and PnC. 5-HTP in 
the entire DR was analyzed using a two-way ANOVA with treatment (3) and stress (2) as between-
subjects factors.  
 
If a general treatment- or stress-effect or an interaction of both factors was detected in any of the 
MMLAs, individual brain regions, or subdivisions of the DR were further analyzed using a two-way 
ANOVA with treatment (3) and stress (2) as between-subjects factors, followed by Fisher’s Protected LSD 
post hoc test where appropriate (obtained from the post hoc read-out of a one-way ANOVA, disregarding 
the one-way ANOVA result itself). The maximum ASR was compared between treatment groups using a 
one-way ANOVA, followed by a Fisher’s Protected LSD post hoc test where appropriate. Significance 
was accepted at p < 0.05, and results are shown as the mean + the standard error of the mean (SEM). 
Graphs for the figures and correlations were designed in SigmaPlot (version 11.0, Systat Software Inc., 
Evanston, IL, USA).      
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4. Results 
4.1. Effects of chronic CORT on the activity of tryptophan hydroxylase (Tph) in serotonergic systems 
As found in in Chapter IV, AS stress exposure again increased Tph activity selectively in the DRD 
(Fig. 3, panel A; microinjection, F(2, 42) = 11.77, p < 0.001; stress, F(1, 43) = 0.67, p = 0.420; interaction, 
F(1, 39) = 14.97, p < 0.001), in the DRC (Fig. 3, panel D; microinjection, F(2, 43) = 4.26, p < 0.05; stress, 
F(1, 44) = 0.38, p = 0.543; interaction, F(1, 40) = 6.03, p < 0.01), and in the MnR (Fig. 3, panel G; 
microinjection, F(2, 43) = 4.78, p < 0.05; stress, F(1, 44) = 1.13, p = 0.293; interaction, F(1, 40) = 4.00, p 
< 0.05) of vehicle-microinjected rats, while Tph activity in other DR subdivisions remained unaltered by 
exposure to AS stress (microinjection, F(2, 44) = 13.45, p < 0.001; stress, F(1, 45) = 0.36, p = 0.553; 
microinjection x stress, F(2, 41) = 9.14, p < 0.01; microinjection x region, F(2, 44) = 0.81, p = 0.620; stress 
x region F(1, 45) = 2.04, p = 0.093; interaction, F(1, 41) = 1.61, p = 0.139). Microinjection of the CRFR1 
antagonist antalarmin markedly potentiated the stress-induced increase in Tph activity in the DRD, and 
was permissive for AS stress to increase Tph activity in the DRV (Fig. 3, panel B; microinjection, F(2, 44) 
= 6.71, p < 0.01; stress, F(1, 45) = 1.37, p = 0.248; interaction, F(1, 41) = 3.97, p < 0.05) and in the entire 
DR (Fig. 3, panel F; microinjection, F(2, 44) = 4.25, p < 0.05; stress, F(1, 45) = 1.26, p = 0.378; 
interaction, F(1, 41) = 3.99, p < 0.05), compared to home cage controls of the same intra-cranial 
microinjection. In the DRD and DRC, microinjection of the CRFR2 antagonist antisauvagine-30 prevented 
the stress-induced elevation of Tph activity that was observed in vehicle-treated rats. No treatment or 
stress effect was detected in the DRVL/VLPAG region. 
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Figure 3. Graphs illustrating the amount of 5-hydroxytryptophan (5-HTP) measured in the median raphe 
nucleus (MnR, G) and in each functional subdivision (A-E) of, and in the entirety of the dorsal raphe 
nucleus (DR, F). Adult, male rats were treated with 100 µg/ml corticosterone (CORT) in the drinking water 
for 21 days before receiving an intracranial microinjection of vehicle (Veh), antalarmin (Ant) or 
antisauvagine-30 (A30) immediately prior to home cage (HC) control conditions or 30 min of acoustic 
startle (AS) stress. Prior intraperitoneal (i.p.) administration of the aromatic L-amino acid decarboxylase 
inhibitor NSD-1015 (in 0.9 % saline) allowed for accumulation of 5-HTP, a read-out of tryptophan 
hydroxylase (Tph) activity. (A) DRD, dorsal raphe nucleus, dorsal part; (B) DRV, dorsal raphe nucleus, 
ventral part; (C) DRVL, dorsal raphe nucleus, ventrolateral part / VLPAG, ventrolateral periaqueductal 
gray; (D) DRC, dorsal raphe nucleus, caudal part; (E) DRI, dorsal raphe nucleus, interfascicular part; Data 
are displayed as means + SEM. #p < 0.05, ##p < 0.01 stress effect versus the HC control-group of the 
same intracranial injection; *p < 0.05, **p < 0.01  treatment effect versus the AS stress-group that 
received an intracranial injection of vehicle, after post hoc analysis with Fisher’s Protected LSD test (Veh-
HC, n = 8; Veh-AS, n = 7; Ant-HC, n = 8; Ant-AS, n = 7; A30-HC, n = 8; A30-AS, n = 9).  
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4.2. Effects of chronic CORT on tryptophan hydroxylase (Tph) activity in relevant target regions  
Many target regions of the DR displayed a significant stress-induced increase in Tph activity in 
vehicle-treated rats (Fig. 4, panels A, B, C, E, F, G, H, I, N, and O; microinjection, F(2, 44) = 9.01, p < 
0.01; stress, F(1, 45) = 8.45, p < 0.01; microinjection x stress, F(2, 41) = 10.14, p < 0.001; microinjection 
x region, F(2, 44) = 3.52, p < 0.01; stress x region F(1, 45) = 1.61, p = 0.171; interaction, F(1, 41) = 2.28, 
p < 0.05), while a microinjection of antalarmin was required to cause this stress-induced elevation of Tph 
activity in the VS (Fig. 4, panel K; microinjection, F(2, 44) = 5.08, p < 0.05; stress, F(1, 45) = 0.47, p = 
0.497; interaction, F(1, 41) = 0.63, p = 0.537) and Ent (Fig. 4, panel L; microinjection, F(2, 42) = 1.43, p = 
0.251; stress, F(1, 43) = 0.25, p = 0.618; interaction, F(1, 39) = 3.79, p < 0.05). In the LO (Fig. 4, panel A; 
microinjection, F(2, 44) = 1.95, p = 0.156; stress, F(1, 45) = 1.87, p = 0.180; interaction, F(1, 41) = 3.59, p 
< 0.05), in the VO (Fig. 4, panel B; microinjection, F(2, 44) = 4.58, p < 0.05; stress, F(1, 45) = 11.86, p < 
0.01; interaction, F(1, 41) = 2.36, p < 0.109), and in the BNST (Fig. 4, panel E; microinjection, F(2, 43) = 
4.46, p < 0.05; stress, F(1, 44) = 0.99, p = 0.326; interaction, F(1, 40) = 5.14, p < 0.01), microinjections of 
both antagonists prevented the stress-induced elevation of Tph activity observed in the vehicle-stress 
group, but the effect was strongest in the two orbitofrontal regions. In the PVN (Fig. 4, panel F; 
microinjection, F(2, 44) = 5.55, p < 0.01; stress, F(1, 45) = 0.18, p = 0.675; interaction, F(1, 41) = 6.45, p 
< 0.01) and in the DLPAG/LPAG (Fig. 4, panel N; microinjection, F(2, 42) = 3.72, p < 0.05; stress, F(1, 
43) = 1.73, p = 0.196; interaction, F(1, 39) = 2.89, p = 0.067), microinjection of antisauvagine-30 
prevented the stress-induced increase of Tph activity, compared to vehicle-microinjected rats. No 
treatment or stress effect was detected in the IL, vCA1 and DMPAG.   
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Figure 4 (next page). Graphs illustrating the amount of 5-hydroxytryptophan (5-HTP) measured in a 
series of forebrain and hindbrain target regions of the dorsal raphe nucleus (DR) that have been shown to 
play a role in emotionality and stress-coping behavior. Adult, male rats were treated with 100 µg/ml 
corticosterone (CORT) in the drinking water for 21 days before receiving an intracranial microinjection of 
vehicle (Veh), antalarmin (Ant) or antisauvagine-30 (A30) immediately prior to home cage (HC) control 
conditions or 30 min of acoustic startle (AS) stress. Prior intraperitoneal (i.p.) administration of the 
aromatic L-amino acid decarboxylase inhibitor NSD-1015 (in 0.9 % saline) allowed for accumulation of 5-
HTP, a read-out of tryptophan hydroxylase (Tph) activity. (A) LO, lateral orbital cortex; (B) VO, ventral 
orbital cortex; (C) PrL, prelimbic cortex; (D) IL, infralimbic cortex; (E) BNST, bed nucleus of the stria 
terminalis; (F) PVN, paraventricular nucleus of the hypothalamus; (G) BL, basolateral amygdaloid 
complex; (H) CE, central amygdaloid nucleus; (I) dCA1, cornu ammonis region 1, dorsal hippocampus; (J) 
vCA1,  cornu ammonis region 1, ventral hippocampus; (K) VS, ventral subiculum; (L) Ent, entorhinal 
cortex; (M) DMPAG, dorsomedial periaqueductal gray; (N) DLPAG, dorsolateral periaqueductal gray / 
LPAG, lateral periaqueductal gray; (O) PnC, caudal pontine nucleus. Data are displayed as means + 
SEM. #p < 0.05, ##p < 0.01 stress effect versus the HC control-group of the same intracranial injection; 
*p < 0.05, **p < 0.01  treatment effect versus the AS stress-group that received an intracranial injection of 
vehicle, after post hoc analysis with Fisher’s Protected LSD test (Veh-HC, n = 8; Veh-AS, n = 7; Ant-HC, 
n = 8; Ant-AS, n = 7; A30-HC, n = 8; A30-AS, n = 9).  
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4.3. Effects of chronic CORT on the acoustic startle (AS) response  
Intra-cranial microinjection of the CRFR1 antagonist antalarmin significantly increased the 
maximum ASR compared to vehicle-microinjected control rats (Fig. 5, panel A; F = 4.16, p < 0.05). 
Furthermore, again, a strong correlation of 5-HTP in the PnC and the maximum ASR was found, when 
the values of all intra-cranial microinjection groups were plotted (Fig. 8, panel B; r = 0.862, r2 = 0.743, p < 
0.001, N = 22). 
 
 
 
Figure 5. (A) Acoustic startle response as measured during the 30 min exposure to acoustic startle stress 
(AS) on day 21, and (B) correlation of 5-hydroxytryptophan (5-HTP) measured in the caudal pontine 
nucleus (PnC) with the maximum startle response. Adult, male rats were treated with 100 µg/ml 
corticosterone (CORT) in the drinking water for 21 days before receiving an intraperitoneal (i.p.) injection 
of the aromatic L-amino acid decarboxylase inhibitor NSD-1015 (in 0.9 % saline) and an intracranial 
microinjection of either vehicle (Veh), antalarmin (Ant) or antisauvagine-30 (A30) immediately prior to 30 
min of acoustic startle (AS) stress (Veh, n = 7; Ant, n = 7; A30, n = 9). 
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5. Discussion 
Local, pharmacological blockade of CRFR1 within the caudal DR region, including the DRD, 
DRC, and the adjacent surround, markedly increased AS-induced Tph activity in the DRD and DRV, and 
potentiated the maximum ASR. In contrast, CRFR2 blockade prevented the AS-induced increase in Tph 
activity in the anxiety-related DRD and DRC regions, as well as in the PVN and DLPAG/VLPAG. In the 
LO and VO, both CRFR1 and CRFR2 antagonism within the caudal DR prevented the AS-induced 
increase in Tph activity. 
 
5.1. Proposed CRFR1-mediated inhibition of Tph activity during acute stress 
All of the rats were chronically treated with CORT in the drinking water. Because chronic stress 
and chronic systemic elevation of CORT are known to increase crf mRNA in the Ce and BNST, especially 
in the dorsolateral BNST (Makino et al., 1994a, b), and because local delivery of GCs into the Ce 
potentiate stress-induced crf mRNA expression in the BNST (Shepard et al., 2006), projections from the 
BNST (or Ce) to the DR are likely to release more CRF during an acute challenge such as AS. Altered 
BNST-mediated CRF signaling is also likely in our chronic CORT paradigm because chronic delivery of 
CORT directly into the BNST has been shown to produce an anxiety-like phenotype (Shepard et al., 
2009), similar to the one observed in our model.  
 
In the adjacent surround of the mid-rostrocaudal to caudal DR, crfr1 mRNA is strongly expressed, 
while no or minimal expression levels of crfr1 mRNA are detected in the rostral to mid-rostrocaudal 
surround of the DR, and almost none in the DR itself (Day et al., 2004). At the same time, according to 
Day et al. (2004), expression of both gad65 and gad67, encoding the two glutamic acid decarboxylase 
isoforms GAD65 and GAD67 that are active in GABAergic neurons, is most pronounced in the caudal 
surround or the DR, at about –8.40 mm to –8.60 mm bregma, and CRFR1 has been shown previously to 
be localized on GABAergic neurons in this area using immunohistochemical methods (Roche et al., 
2003). CRF released from BNST- and/or Ce-derived afferents is thus expected to act on CRFR1 on 
GABAergic neurons to increase GABAergic inhibition towards serotonergic neurons in the DR under 
circumstances of an acute stress exposure, a hypothesis that is supported by electrophysiological studies 
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measuring decreased DR discharge after local stimulation with low doses of CRF (Kirby et al., 2000). The 
data also suggest that CRFR1 does not hold serotonergic neurons under tonic inhibition under basal, 
non-stress conditions otherwise HC control rats injected with antalarmin would be predicted to show an 
increase in Tph activity as well. 
 
5.2. Proposed CRFR2-mediated stimulation of Tph activity during acute stress 
Conversely, CRF is also expected to act on CRFR2 receptors both directly on serotonergic 
neurons within the caudal DRD and DRC, and also on GABAergic cells in the adjacent surround of the 
caudal DR. Day et al. (2004) described expression of crfr2 mRNA within the serotonergic DR at all 
bregma levels, but caudally crfr2 mRNA was often found in clusters of immediately DR-adjacent 
GABAergic neurons. In addition, Lukkes et al. (2011) found that the DRD contained the highest density of 
serotonergic neurons that were also immunoreactive (ir) for CRFR2 protein. The increased density of 
CRFR2-ir neurons in the dorsal and caudal DR (Lukkes et al., 2011) together with intra-DR injections 
studies using CRF and the CRFR2 agonist urocortin 2 (Hammack et al., 2002; Hammack et al., 2003b) 
suggest that CRF is exerting some of its anxiogenic effects within the DR selectively through actions on 
the more dorsally and caudally expressed CRFR2. While rostral intra-DR injections of CRF failed to cause 
behavioral changes, CRF and urocortin 2 only interfered with escape behavior and the potentiation of fear 
conditioning when injected into the caudal DR region (Hammack et al., 2002; Hammack et al., 2003a), 
while CRFR2 antagonists injected into the caudal DR region blocked the behavioral consequences of 
inescapable shock (Hammack et al., 2003b). 
 
5.3. Effects of CRFR-antagonism on AS-induced Tph activity in the orbitofrontal cortex, the PVN, and 
the DLPAG / LPAG  
The exact mechanism of how CRFR2 antagonism prevented the AS-induced increase in Tph 
activity in the PVN and in the DLPAG/LPAG is unclear. Given the location of the injection sites used in 
this study, and the efferent targets of the DRD and DRC regions (Hale and Lowry, 2011a), it is likely that 
collateral projections from the DRD to the hypothalamus and to the DLPAG / LPAG inhibited the stress-
induced increases in Tph activity in this region. Likewise, it is possible that serotonergic innervation from 
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the DRI to the orbitofrontal cortex (Porrino and Goldman-Rakic, 1982), including the LO and VO, 
mediated the inhibitory effect on Tph phosphorylation (Johansen et al., 1996) in these regions. 
 
5.4. Correlation of the maximum acoustic startle response and Tph activity in the PnC 
The average maximum ASR was elevated by injection of CRFR1, but not CRFR2 antagonist into 
the caudal DR and its immediate surround immediately prior to AS stress. However, the AS-induced 
increase in Tph activity within the PnC was not significantly potentiated by CRFR1 antagonism, potentially 
indicating either actions of 5-HT in other parts of circuit or regulatory actions of other neurotransmitter 
systems that are known to interact with the startle response upon acoustic stimulation, such as 
noradrenergic signaling from the locus coeruleus (Davis et al., 1977; Anisman et al., 2000; Samuels et al., 
2007). Interestingly, a noticeable variance in maximum ASR existed amongst antalarmin-injected rats. 
This variance was not correlated with the rostrocaudal placement if the injection cannula tip. Thus, 
individual differences before or upon chronic GC exposure and acute CRFR1 blockade may underlie the 
increased variance. 
 
In addition, we were able to reproduce the finding from Chapter IV that a strong positive 
correlation exists between the maximum ASR and Tph activity within the PnC, an important relay station 
within the midbrain reticular formation to control the startle response upon acoustic stimulation (Simons-
Weidenmaier et al., 2006). Our findings are consistent with highly elevated 5-HIAA concentrations in the 
PnC of adult, male rats 2 h after they were acutely treated with intracerebroventricular CRF (Fig. B1, 
Appendix B), unpublished data), and suggest a direct CRF-mediated role for serotonergic 
neurotransmission in the control of the acoustic startle reflex. Since 5-HT synthesis was blocked by NSD-
1015 injection in our experiment it could be that 5-HT release from vesicular stores in 5-HT-synaptic 
terminals within the PnC is potentiated by acute stress and by a permissive function of chronic GC 
exposure.  
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6. Conclusion 
Our results provide novel evidence for competing actions of CRFR1 and CRFR2 signaling onto 
brain serotonergic systems during exposure to an acute stressor, and indicate an interaction of both 
receptor types in the control of 5-HT synthesis in the DRD, DRV and DRC, but not in the DRVL or DRI. 
Clinically, blockade of CRFR2 or stimulation of CRFR1 within the caudal DR and its adjacent surround 
may open opportunities for new anxiolytic treatment strategies. Future studies will have to reveal the 
behavioral or physiological consequences of elevated Tph activity in each of brain regions studied. 
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CHAPTER	VI	
	
GENERAL	DISCUSSION	&	FUTURE	DIRECTIONS	
 
1. Brief summary and interpretation of most important treatment effects 
In attempt to shed light on the role of elevated concentrations of GCs during chronic or repeated 
stress exposure, and in particular on how chronically elevated GCs act on brain serotonergic systems, I 
developed a non-invasive rat model delivering various doses of GCs chronically to adrenal-intact, adult 
male rats via the drinking water. Chronic exposure to systemically elevated circulating concentrations of 
GCs resulted in an anxiety- and depressive-like behavioral state, altered diurnal patterns of serotonergic 
gene expression in anxiety- and depression-related serotonergic systems, enhanced sensitivity of 
anxiety-related serotonergic systems to a novel stressor, abolished diurnal rhythms of plasma glucose 
and HPA axis hormones, functional adrenal insufficiency, and reduced weight gain.  
 
A final mechanistic study furthermore revealed that CRFR1 and CRFR2 exert opposing actions in 
modulating the sensitivity of serotonin synthesis to a novel, acute stressor. Generally speaking, CRFR1 is 
likely to maintain an adequate serotonergic stress response, in form of controlled stress-induced 
phosphorylation of Tph within serotonergic neurons, while CRFR2 appears to promote sensitization of 
stress-induced serotonin synthesis within anxiety-related serotonergic systems. Based on the literature 
describing dense crfr1 mRNA expression in the adjacent surround of the caudal DR region, also revealed 
using immunohistochemistry (see Fig. D1), and crfr2 mRNA and CRFR2 protein expression within 
serotonergic neurons, we hypothesize that CRFR1 functions to stimulate GABAergic inhibition of anxiety-
related subdivisions of the DR, while CRFR2 is postulated to stimulate Tph phosphorylation directly in 
serotonergic neurons of the anxiety-related caudal DR region. It remains to be addressed whether the 
functional aspects of CRFR1- versus CRFR2-mediated modulation of serotonin synthesis are only 
present in situations of chronic GC exposure, or also under normal conditions.  
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2. Future directions 
First, in order to assess serotonergic gene expression in my chronic GC model in a more 
comprehensive way, mRNA expression of slc6a4 and htr1a in the MnR will also be quantified. Recent 
unpublished data by colleagues suggest that a) depression and suicide are psychologically partially 
overlapping, but in their molecular serotonergic manifestation different psychiatric conditions, and that b) 
TPH2 mRNA expression in the MnR is especially relevant for depression.  
 
Second, while it is likely that chronically elevated GCs act either on GR or MR to increase crf 
mRNA and CRF protein expression within the extended amygdala complex, the possibility of local GC 
actions within the DR or its adjacent surround needs to be adressed, for example by using local infusion 
of GCs directly into the dorsal DR region, or local treatment with GR or MR antagonist during chronic 
systemic CORT treatment via the drinking water.  
 
 
 
Figure D1. Photomicrograph displaying immunohistochemical staining of glutamic acid decarboxylase 67 
(GAD67) in the adjacent surround of the dorsal raphe nucleus (DR) at –8.45 mm bregma. 30 µm-thick 
sections of the DR were obtained from an adult rat after transcardial perfusion with 4% 
paraformaldehyde, and used for immunohistochemical detection of cytoplasmic GAD67 (brown). The 
brown color is based on a 3-3’-diaminobenzidine tetrachloride (DAB)-based reaction product. The purple-
black background color stems from a subsequent, here irrelevant, immunohistochemical staining. Aq, 
mesencephalic aqueduct; DRC, dorsal raphe nucleus, caudal part; DRI, dorsal raphe nucleus, 
interfascicular part; mlf, medial longitudinal fasciculus. Scale bar, 500 µm. 
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In addition, it would be of functional and biomedical interest to address whether or not GR 
chaperoning within serotonergic neurons of the DR is altered in my model. Espallergues et al. (2012), for 
example, propose that the effects of GCs on socioaffective behaviors are critically regulated via reversible 
acetylation of heat-shock protein 90 (HSP90), a key component of the GR chaperone complex, within 
serotonergic neurons. Within the brain, the lysine deacetylase HDAC6 is most densely expressed in 
serotonergic neurons, and has by now been demonstrated to control HSP90 acetylation, thereby 
modulating HSP90-GR interactions, as well as hormone- and stress-induced GR translocation, GR 
downstream signaling, and behavior. Espallergues et al. found that site-specific deletion of HDAC6 in 
serotonin neurons reduces acute anxiogenic effects of GCs in the OF, EPM, and SI test, blocks social 
avoidance in mice exposed to chronic social defeat, and prevents electrophysiological and morphological 
changes induced by chronic social defeat.  
 
The ideal design of an experiment addressing GR chaperoning would be the deletion or 
downregulation of HDAC6 expression, or a reduction of its activity, in exactly those anxiety-related 
serotonergic subdivisions that were sensitized by chronic GC treatment in my model, in an attempt to 
restore control levels of emotionality and serotonergic function.  
 
However, to perform subdivision- or subpopulation-targeted intervention studies, we first have to 
identify specific markers of functionally related serotonergic subpopulations. Laser-microdissection of all 
the topographically organized, morphologically and functionally distinct subpopulations of serotonergic 
neurons, followed by a gene expression microarray study to identify subpopulation-specific markers and 
potential drug targets would be a first step into the right direction. 
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Appendix	
 
A) Supplemental material to Chapter II  
 
1. Supplemental materials and methods 
1.1. Supplemental information for ANIMALS & EXPERIMENTAL SETUP 
Rats were kept at 23 °C and were allowed to acclimate to the reversed light/dark cycle and the 
new facility for at least seven days after arrival and prior to their use in the experiment. The bedding 
(7093 Teklad Shredded Aspen Bedding, Harlan Laboratories, Indianapolis, IN, USA) was exchanged 
every four days. On day 20, one representative rat of each treatment group was photographed with a 
digital camera (Canon Powershot SD1000; Canon, Lake Success, NY, USA) mounted above to visualize 
obvious treatment effects on physical appearance such as abdominal diameter. To avoid variability due to 
the one hour time window for the killings, the rapid decapitations on day 21 of treatment were performed 
in randomized blocks such that four rats of each treatment group were killed during the animals’ active 
(lights off) and inactive (lights on) phases on two consecutive days. In addition to measuring the absolute 
amount of water and food consumed, we also divided the cumulative amount of food and water 
consumed by two rats per cage by the combined body weight per cage to analyze the relative food and 
water consumption. All animal procedures were approved by the University of Colorado Boulder IACUC 
committee, and were consistent with the NIH Guide for the Care and Use of Laboratory Animals, 1996.  
All efforts were made to minimize the number of animals used and their suffering. 
 
1.2. Tph2 riboprobe preparation  
As previously described (Donner and Handa, 2009), a 583 bp fragment of tph2 cDNA was 
transcribed and radioactively labeled to create a cRNA (ribo-) probe complementary to bases 761 to 1343 
of rat tph2 mRNA. To obtain an appropriate template for transcription, the pCRII-TOPO plasmid 
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(Invitrogen, Carlsbad, CA, USA) containing the cDNA sequence, was cut with two restriction enzymes, 
BlpI and XbaI (New England Biolabs, Ipswich, MA, USA) at 37 °C for 2 h. In the presence of [35-S]-UTP 
and under RNase-free conditions, the sense control cRNA probe was then transcribed at 40 °C for 1 h, 
using Sp6 RNA-polymerase (Promega, Madison, WI, USA), while the anti-sense cRNA probe was 
produced with T7 RNA-polymerase (Promega) at 37 °C for 1 h. Template DNA was then removed by 
digestion with DNase I (Sigma-Aldrich) for 10 min at 37 °C. The probe was precipitated with –20 °C 100% 
ethanol in the presence of Glycoblue (Cat. No. AM9515, Ambion, Austin, TX, USA), stored at –80 °C 
overnight, centrifuged and washed with 70% –20 °C ethanol, and then re-dissolved in ribonuclease-free 
water. The incorporation percentage (55%), and the activity of the final probe (7 x 106 in 1 µl) was 
measured in a liquid scintillation beta counter, model LS 3801 (Beckman, Brea, CA, USA). The antisense 
probe specifically detected tph2, but not tph1 mRNA, since no hybridization was observed in the pineal 
gland (Patel et al., 2004; Malek et al., 2005). The sense control probe did not hybridize with any specific 
areas in the brain. 
 
1.3. Tph2 in situ hybridization histochemistry 
Tissue sections were briefly thawed at room temperature, fixed with 4% paraformaldehyde in 0.05 
M phosphate buffered saline (PBS) for 10 min, and rinsed three times in 2X standard saline citrate buffer 
(SSC) for 10 min each. Ninety µl hybridization solution (0.4 µg/ml radiolabeled probe, 25 mM Tris, pH 7.4, 
40% deionized formamide, 500 µg/ml single-stranded salmon sperm DNA, 250 µg/ml transfer RNA, 1X 
Denhardt’s solution, 4 mM EDTA, 5 mM sodium chloride, 10% dextran sulfate) was dispensed on each 
slide, avoiding air bubbles and resulting in about 1 x 106 cpm of radiolabeled probe per slide. Rectangular 
parafilm pieces were used as coverslips on each slide, and slides were incubated overnight in a 
humidified chamber at 55 °C. The next day coverslips were removed before all slides were washed once 
in 2X SSC and three times in 1X SSC, for 10 min each. Slides were then incubated in “ribonuclease A” 
solution (0.05 M Tris–Cl, 0.025 M EDTA, 0.5 M NaCl and 20 µg/ml RNase A) for 1 h at 37 °C. After this, 
slides were washed in 1X SSC/1 ml/L beta-mercaptoethanol for 30 min at room temperature, and then in 
1X SSC/1 ml/L beta-mercaptoethanol for 30 min at 60 °C. The latter three steps were intended to remove 
riboprobe and riboprobe fragments that have the potential to bind nonspecifically within the tissue. Lastly, 
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slides were desalted in 0.5X and 0.1X SSC/1 ml/L beta-mercaptoethanol for 10 min each, and then 
gradually dehydrated in 50%, 70%, 90% and 100% ethanol containing 0.3 M ammonium acetate. After 
air-drying for 20 min, all slides were apposed to the same Kodak BioMax autoradiography film 
(PerkinElmer, Waltham, MA) for 7 days. 
 
1.4. Imaging and semi-quantitative densitometry of tph2 in situ hybridization autoradiograms 
Autoradiographic images of the probe bound to tph2 mRNA together with 14-C-labeled standards 
were measured using a computer-assisted image analysis system. All slides from the study had been 
apposed to the same film, allowing us to use a single set of 14-C-labeled standards for reference. 
Analysis was performed on a PC using the publicly available NIH-developed image analysis software 
ImageJ. Virtual matrices in the shape of the respective DR subregions were created, overlaid with the 
image, and the “optical density x area” within each matrix measured. All measurements were taken while 
blinded to the treatment groups. During the entire analysis a constant threshold function was applied, 
which determined the area that was actually measured within each matrix. Thus, all pixels with a gray 
density below threshold were automatically excluded. In addition, the individual background of each 
image was measured and subtracted from each value. A rostrocaudal analysis atlas for tph2 expression 
in the DR was created by comparing the image of the tissue sections with a stereotaxic rat brain atlas 
(Paxinos and Watson, 1998) and with tph2 mRNA expression topography as reported by Gardner et al. 
(Gardner et al., 2009c). According to Gardner et al. (Gardner et al., 2009c) and Tph immunostaining 
(Abrams et al., 2004), each rostrocaudal level was further divided into respective subregions of the DR. 
Throughout all rostrocaudal levels, the values for each subdivision were then averaged for each individual 
rat, and the average tph2 expression in the entire DR for each rat was also calculated depending on 
treatment group and killing time point. A total of 16 rostro-caudal levels were studied throughout the 
midbrain, extending from bregma –7.568 mm to –8.648 mm. The subdivisions studied were summarized 
into the following functional subregions of the DR: dorsal raphe nucleus, caudal part (DRC; –8.432, –
8.504, –8.576, and –8.648 mm bregma), dorsal raphe nucleus, dorsal part (DRD; –7.568, –7.640, –7.712, 
–7.784, –7.856, –7.928, –8.000, –8.072, –8.144, –8.216, –8.288, and –8.360 mm bregma), dorsal raphe 
nucleus, interfascicular part (DRI; –8.432, –8.504, –8.576, and –8.648 mm bregma), dorsal raphe 
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nucleus, ventral part (DRV; –7.568, –7.640, –7.712, –7.784, –7.856, –7.928, –8.000, –8.072, –8.144, –
8.216, –8.288, –8.360, –8.432, and –8.504 mm bregma), left and right dorsal raphe nucleus, ventrolateral 
part/ventrolateral periaqueductal gray region (left and right DRVL/VLPAG; –7.784, –7.856, –7.928, –
8.000, –8.072, –8.144, –8.216, –8.288, –8.360, –8.432, and –8.504 mm bregma). 
 
1.5. Supplemental information for MORPHOLOGICAL ANALYSIS OF THE ADRENAL GLANDS 
As primary targets of HPA axis regulation, the wet weights of the adrenal glands and pituitary 
gland were measured on a micro-scale immediately after dissection from the surrounding tissue. Original 
and body weight-corrected organ weights were calculated. Excess surface liquids were absorbed with a 
Kim® wipe. Two pituitaries were lost due to improper dissection. The organs were then post-fixed 
overnight in 0.1 M sodium phosphate buffer with 4% paraformaldehyde, rinsed twice in 0.1 M sodium 
phosphate buffer for 12 h each, and lastly placed in 0.1 M sodium phosphate buffer with 30% sucrose (pH 
7.4) until saturated. Until further processing, they were stored at ‒80 °C in cryoprotectant (30% ethylene 
glycol, 20% glycerol, 0.05 M sodium phosphate buffer, pH 7.4). The cryo-sectioned and mounted adrenal 
glands were dipped in water, submersed in 0.5% filtered cresyl violet solution for 20 min, differentiated in 
water for 3 min, and then dehydrated in an ascending alcohol series of 50%, 70%, 95%, and 100% 
ethanol. Lastly, the sections were immersed in xylenes (Cat. No. X5-500, Fisher Scientific, Fair Lawn, NJ, 
USA) for 5 min before the slides were preserved with cover slips using Entellan mounting medium (Cat. 
No. 14802, EMS, Hatfield, PA, USA).  
 
To identify potential atrophic effects of the chronic corticosterone treatment within the adrenal 
medulla and each subregion of the adrenal cortex, photomicrographs of medial adrenal sections were 
taken both at 40- and 100-fold magnifications under a Nikon light microscope (Nikon Eclipse 90i) linked to 
a digital camera DS-Fi1 and the image-capturing software NIS-Elements AR 3.0 (A.G. Heinze Inc., Lake 
Forest, CA, USA). The zona glomerulosa was identified as a group of densely arranged ovoid cells. The 
zona fasciculata (under non-atrophied conditions) was identified as cells laden with lipid-droplets 
arranged in radial columns, while the zona reticularis was identified as a loose meshwork of darkly 
stained nuclei. Because the zona fasciculata lost its distinct transparency and column pattern under 
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assumed atrophied conditions in our medium and high corticosterone groups, it was also identified via the 
exclusion principle after both the zona glomerulosa and zona reticularis were identified. All adrenocortical 
zone-specific width measurements were summed into a total width for the adrenal cortex, and the adrenal 
cortex width was then doubled and added to the medullary diameter to calculate the diameter of the entire 
adrenal gland. Zone identifications and morphological specifications were based on Vinson (Vinson, 
2003). All measurements were performed while blinded to the treatment groups. Since we found no 
significant treatment effect on the weight of the pituitaries, no histochemical analysis was performed.  
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2. Supplemental results 
2.1. Absolute food & water consumption 
  In contrast to weight-corrected food intake, absolute food intake (Fig. A1, panel A) was reduced in 
both the Cort-100 and the Cort-400 group after two and three weeks of treatment, compared to vehicle 
controls and Cort-40 rats (treatment, F(3, 28) = 3.33, p < 0.05; time, F(2, 29) = 1214.57, p < 0.001, interaction, 
F(6, 20) = 5.44, p < 0.001). At the same time, the rats’ water consumption (Fig. A1, panel B), revealed that 
the Cort-400 group drank less water than all other treatment groups in absolute terms (treatment, F(3, 28) = 
17.24, p < 0.001; time, F(2, 29) = 2547.48, p < 0.001; interaction, F(6, 20) = 3.63, p < 0.01).  
 
 
Figure A1. Absolute food consumption (A) and water intake (B) of adrenal-intact male rats during 
treatment with either vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or 40, 100 or 400 µg/ml 
corticosterone via the drinking water for 21 days. All data points represent cumulative values, meaning 
the difference compared to day 0 of the experiment. All data are displayed as means + SEM. *p < 0.05, 
**p < 0.01 versus (a) Vehicle, (b) Cort-40, and (c) Cort-100, after post hoc analysis with Fisher’s 
Protected LSD test (Vehicle, n = 16; Cort-40, n = 16; Cort-100, n = 16, Cort-400, n = 16). 
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2.2. Plasma concentration of IL-6 
No treatment- or time-dependent differences were detected for plasma concentrations of IL-6 
(treatment, F(3, 60) = 0.49, p = 0.687; killing time point, F(1, 62) = 0.60, p = 0.444; interaction, F(3, 56) = 0.97, p 
= 0.414; Table A1). 
 
Table A1. Plasma IL-6 concentrations after chronic corticosterone treatment (1)
 
Vehicle Cort-40 Cort-100  Cort-400 
light dark light dark light dark light dark 
IL-6 76.36 72.01 67.81 73.00 70.86 71.63 68.14 73.94 
(pg/ml) ± 4.26 ± 5.44 ± 3.25 ± 2.69 ± 2.86 ± 3.06 ± 1.97 ± 0.98 
 (1) Listed are interleukin-6 (IL-6) plasma concentrations of adult male rats that were either treated with 
vehicle (0.45% hydroxypropyl-beta-cyclodextrin) or corticosterone (40, 100 or 400 µg/ml) via the drinking 
water for 21 days. Half of each treatment group was killed 2 hours into their inactive (light) phase, the 
other half two hours into their active (dark) phase. No significant differences based on treatment or killing 
time point were detected. Data are displayed as means ± SEM. 
 
2.3. tph2 mRNA expression in the median raphe nucleus (MnR) and in DR subdivisions  
In the DRD (Fig. A2, panel A), corticosterone treatment significantly elevated tph2 mRNA 
expression during the light phase, but not during the dark phase (treatment, F(3, 60) = 3.35, p < 0.05; killing 
time point, F (1, 62) = 0.30, p = 0.580; interaction, F(3, 56) = 3.21, p < 0.05). In rats sacrificed during their 
inactive (light) phase, tph2 mRNA expression was higher after three weeks of Cort-40 (p < 0.05) and 
Cort-100 (p < 0.01) treatment compared to vehicle-treated controls. Only vehicle-treated rats showed a 
significant difference in tph2 expression between the light and the dark phase within the DRD (p < 0.01). 
 
In the DRV (Fig. A2, panel B), tph2 expression in all corticosterone-treated rats sacrificed in either 
the light- or dark-phase resembled tph2 expression in vehicle-treated rats sacrificed during the dark 
phase. Even though no statistical overall treatment effect, interaction, or effect of killing time point was 
detected (treatment, F(3, 60) = 1.77, p = 0.156; killing time point, F(1, 62) = 2.31, p = 0.131; interaction, F(3, 56) 
= 1.87, p = 0.138), pairwise comparisons revealed the circadian variation in gene expression between the 
light and the dark phase in vehicle-treated rats (p < 0.01), and a significant elevation of light-phase tph2 
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expression in the Cort-40 (p < 0.05), Cort-100 (p < 0.05), and Cort-400 group (p < 0.05), compared to 
vehicle controls.  
 
Both the left and the right DRVL/VLPAG, as well as both sides combined (Fig. A2, panels C, D, 
and E) displayed in tendency a similar light-dark variation in tph2 expression within the vehicle group (p = 
0.084), but the effects of treatment, killing time point or treatment x killing time point did not reach 
significance (left and right DRVL / VLPAG combined: treatment, F(3, 60) = 1.05, p = 0.369; killing time point, 
F(1, 62) = 3.29, p = 0.071; interaction, F(3, 56) = 0.45, p = 0.719).  
 
Average tph2 mRNA expression levels in the DRC (Fig. A2, panel F) revealed a significant 
treatment and killing time point effect (treatment, F(3, 60) = 3.89, p = 0.050; killing time point, F(1, 62) = 4.42, p 
< 0.05; interaction, F(3, 56) = 2.21, p = 0.113). Only the vehicle control rats (p < 0.05) and Cort-400 (p < 
0.05) rats displayed a significant light-dark difference, with higher tph2 mRNA expression during the dark 
phase. Also, Cort-40 (p < 0.05), Cort-100 (p < 0.01), and Cort-400 (p < 0.05) groups all expressed more 
tph2 mRNA during the light phase than vehicle controls. 
 
In the DRI (Fig. A2, panel G), no significant effect of treatment, killing time point, or treatment x 
killing time point on tph2 mRNA expression was found (factor treatment, F(3, 60) = 1.37, p = 0.275; killing 
time point, F(1, 62) = 0.31,  p = 0.581; interaction, F(3, 56) = 0.86, p = 0.473).  
 
 
 
 
 
Figure A2 (next page). Average tph2 mRNA expression (optical density x area) measured in each 
subdivision of the dorsal raphe nucleus (DR). Adult, male rats were treated either with vehicle (0.45% 
hydroxypropyl-beta-cyclodextrin) or corticosterone (40, 100 or 400 µg/ml) for 21 days. Half of each 
treatment group was killed 2 h into the animals’ inactive (light) phase, the other half 2 h into their active, 
dark phase. (A) DRD, dorsal raphe nucleus, dorsal part; (B) DRV, dorsal raphe nucleus, ventral part; 
(C,D,E) DRVL, dorsal raphe nucleus, ventrolateral part / VLPAG, ventrolateral periaqueductal gray; (F) 
DRC, dorsal raphe nucleus, caudal part; (G) DRI, dorsal raphe nucleus, interfascicular part. *p < 0.05, **p 
< 0.01 versus (a) Vehicle-light phase; #p < 0.05, ##p < 0.01 versus the corresponding light phase value 
within the same treatment group, after post hoc analysis with Fisher’s Protected LSD test (Vehicle-light, n 
= 8; Vehicle-dark, n = 8; Cort-40-light, n = 8; Cort-40-dark, n = 8; Cort-100-light, n = 8, Cort-100-dark, n = 
8; Cort-400-light, n = 8; Cort-400-dark, n = 8).  
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Similar to the DRD, DRV, and DRC, chronic CORT treatment abolished the diurnal variation in 
average tph2 mRNA expression in the entire MnR (Fig. A3, panel C) by elevating light-phase tph2 
expression in a dose-dependent manner (factor treatment, F(3, 60) = 3.57, p = 0.025; killing time point, F(1, 
62) = 2.89,  p = 0.099; interaction, F(3, 56) = 1.48, p = 0.239). This effect was mainly due to treatment effects 
in the rostral MnR (factor treatment, F(3, 60) = 4.32, p = 0.012; killing time point, F(1, 62) = 3.46,  p = 0.072; 
interaction, F(3, 56) = 1.79, p = 0.17)., but not in the caudal MnR. 
 
2.4. Weight of pituitary and adrenal glands  
Chronic corticosterone treatment reduced the weight of the adrenal glands in a dose-dependent 
manner (F(3, 60) = 13.25, p < 0.001). This adrenal atrophy effect is likely due to negative feedback 
regulation of the HPA axis by exogenous corticosterone at the level of the pituitary and adrenal glands 
(Plaschke et al., 2006). The weight of the pituitary was not significantly altered by any dose of 
corticosterone treatment (F(3, 58) = 0.071, p = 0.975). For both the adrenals and the pituitary, all data from 
rats of the same treatment that were killed during the light or dark phase were pooled because no 
differences due to killing time point were detected. 
 
2.5. Adrenal gland morphology 
The average diameter of the adrenal gland was significantly decreased by all corticosterone 
doses (F(3, 60) = 30.62, p < 0.001). Compared to vehicle controls, the diameter of the adrenal medulla 
remained unaltered after chronic corticosterone treatment (F(3, 60) = 1.94, p = 0.133). However, the width 
of the adrenal cortex was significantly reduced in Cort-100 and Cort-400 rats (F(3, 60) = 48.25, p < 0.001), 
suggesting that the atrophy took effect mainly within the adrenal cortex, not in the medulla. To determine 
which part of the adrenal cortex displayed the highest level of atrophy, we measured the average width 
and cell density of each adrenocortical zone (zonae glomerulosa, fasciculata, and reticularis).  
 
We found that the zona fasciculata decreased most dramatically, to 75% of the width observed in 
vehicle controls in the Cort-40 group, to 31% in the Cort-100 group, and to 25% in the Cort-400 group (F(3, 
60) = 51.95, p < 0.001). In the Cort-400 group, the widths of the zona glomerulosa (F(3, 60) = 9.52, p < 
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Figure A3. Average tph2 mRNA expression (optical density x area) measured in the rostral (A), caudal 
(B), and entire (C) median raphe nucleus (MnR). Adult, male rats were treated either with vehicle (0.45% 
hydroxypropyl-beta-cyclodextrin) or corticosterone (40, 100 or 400 µg/ml) for 21 days. Half of each 
treatment group was killed 2 h into the animals’ inactive (light) phase, the other half 2 h into their active, 
dark phase. *p < 0.05, **p < 0.01 versus (a) Vehicle-light phase or (b) Cort-40-light phase; #p < 0.05 
versus the corresponding light phase value within the same treatment group, after post hoc analysis with 
Fisher’s Protected LSD test (Vehicle-light, n = 8; Vehicle-dark, n = 8; Cort-40-light, n = 8; Cort-40-dark, n 
= 8; Cort-100-light, n = 8, Cort-100-dark, n = 8; Cort-400-light, n = 8; Cort-400-dark, n = 8). 
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0.001) and zona reticularis (F(3, 60) = 6.06, p = 0.001) were also significantly smaller compared to the 
vehicle-, Cort-40 and Cort-100 groups. 
 
The cell density within each of the cortical zones was elevated after chronic corticosterone 
treatment (zona glomerulosa, F(3, 60) = 8.82, p < 0.001; zona fasciculata, F(3, 60) = 48.62, p < 0.001; zona 
reticularis, F(3, 60) = 17.03, p < 0.001). Adrenocortical cells from corticosterone groups appeared generally 
smaller and atrophied, thus resulting in a higher cell count per area. Again, this effect was most prominent 
within the zona fasciculata, the zone that contains most of the glucocorticoid-producing cells. 
 
2.6. Correlation of behavioral parameters with tph2 mRNA expression 
Average tph2 mRNA expression in the entire DR (light and dark phase values of each treatment 
group combined) was found to be positively correlated with time spent immobile in the OF (r = 0.481, 
r2=0.231, p < 0.001, Fig. A4, panel A), and negatively with percent time spent in the open arms of the 
EPM (r = −0.253, r2=0.064, p < 0.05, Fig. A4, panel B), as well as number of entries into those open arms 
(r = −0.295, r2=0.087, p < 0.05, Fig. A4, panel C).  
  
With respect to functional subdivisions of the DR, immobility in the OF was positively correlated 
with tph2 mRNA expression in the DRD (r = 0.302, r2=0.091, p < 0.05, Fig. A4, panel D) and DRI (r = 
0.313, r2=0.098, p < 0.05, Fig. B4, panel E). Similarly, tph2 expression in the DRI was associated with 
immobility behavior during the FST (r = 0.266, r2=0.071, p < 0.05, Fig. A4, panel F). Open arm entries on 
the EPM, in contrast, were negatively correlated with tph2 mRNA expression in the DRV (r = 0.253, 
r2=0.064, p < 0.05, Fig. A4, panel G). Social interaction was not found to be associated with tph2 
expression. 
Figure A4 (next page). Behavioral parameters that were found to be significantly correlated with tph2 
mRNA expression. Adrenal-intact, adult, male rats were treated with either vehicle (0.45% hydroxypropyl-
beta-cyclodextrin) or corticosterone (40, 100 or 400 µg/ml) via the drinking water for 21 days. Individual 
data pairs are labeled according to treatment group, and plotted around the corresponding regression 
line. The graphs display (A) time spent immobile in the OF, (B) percent time spent in the open arms of the 
EPM, and (C) number of open arm entries on the EPM, in correlation with tph2 mRNA expression in the 
entire DR; and (D, E) time spent immobile in the OF, (F) immobility behavior during the FST, and (G) the 
number of open arm entries on the EPM, in correlation with DR-subdivision-specific tph2 mRNA 
expression. P < 0.05 indicates a significant correlation according to the Pearson Product Moment (r) and 
the regression coefficient (r2).  
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B) Supplemental material to Chapters IV and V 
 
Table B1. Brain regions chosen for analysis of 5-hydroxytryptophan concentrations in Chapters IV and V. 
Brain region (full name (abbreviation)) Rostrocaudal distance from bregma 
Microdissections    
(n, [diameter (µm)])
Lateral orbital cortex (LO) 4.20 mm 2 [1000] 
Ventral orbital cortex (VO) 4.20 mm 2 [1000] 
Infralimbic cortex (IL) 2.70 mm 2 [1000] 
Prelimbic cortex (PrL) 2.70 mm 2 [1000] 
Dorsomedial caudate putamen (dmCPu, neg. control) 0.60 mm 
0.30 mm 
2 [1000] 
2 [1000] 
Bed nucleus of the stria terminalis (BNST) -0.30 mm 2 [690] 
Paraventricular nucleus (PVN) of the hypothalamus, 
medial parvocellular, lateral magnocellular, ventral, and 
dorsal capsule parts 
-1.80 mm 2 [410] 
Basolateral amygdaloid nucleus (BL), 
anterior and posterior parts 
-2.40 mm 
-2.70 mm 
-3.00 mm 
2 [690] 
2 [690] 
2 [690] 
Central amygdaloid nucleus (Ce) -2.40 mm 2 [690] 
 -2.70 mm 2 [690] 
Lateral hypothalamus, perifornical region of the 
hypothalamus (LH/PeF) 
-3.00 mm 
-3.30 mm 
2 [410] 
2 [410] 
Dorsomedial hypothalamic nucleus (DM), dorsal, 
compact, and ventral parts 
-3.30 mm 2 [690] 
Cornu ammonis 1, dorsal hippocampus (dCA1) -3.90 mm 6 [690] 
Cornu ammonis 1, ventral hippocampus (vCA1) -6.00 mm 6 [690] 
Ventral subiculum (VS) -6.00 mm 4 [690] 
Interpeduncular nucleus (IP) -6.30 mm 
-6.60 mm 
-6.90 mm 
1 [690] 
1 [690] 
1 [690] 
 
(Table continued on the  next page) 
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Brain region (full name (abbreviation)) Rostrocaudal distance from bregma 
Microdissections    
(n, [diameter (µm)])
Entorhinal cortex -6.90 mm 
-7.50 mm 
-8.10 mm 
2 [690]  
2 [690] 
2 [690] 
Median raphe nucleus (MnR) -7.20 mm 1 [410] 
 -7.50 mm 2 [410] 
 -7.80 mm 2 [410] 
 -8.10 mm 2 [410] 
Dorsal raphe nucleus, dorsal part (DRD) -7.20 mm 1 [690] 
 -7.50 mm 1 [310] 
 -7.80 mm 1 [310] 
 -8.10 mm 1 [690] 
Dorsal raphe nucleus, ventral part (DRV) -7.20 mm 1 [310] 
 -7.50 mm 1 [310] 
 -7.80 mm 1 [310] 
 -8.10 mm 1 [310] 
Dorsal raphe nucleus, ventrolateral part/dorsal 
periaqueductal gray (DRVL/VLPAG) 
-7.50 mm 
-7.80 mm 
2 [310] 
2 [310] 
 -8.10 mm 2 [310] 
Dorsomedial periaqueductal gray (DMPAG)   -7.50 mm 
-7.80 mm 
-8.10 mm 
1 [410] 
1 [410 
1 [410] 
Dorsolateral periaqueductal gray, lateral     
periaqueductal gray (DLPAG/LPAG) 
-7.50 mm 
-7.80 mm 
-8.10 mm 
2 [690] 
2 [690] 
2 [690] 
Dorsal raphe nucleus, caudal part (DRC) -8.40 mm 1 [690] 
 -8.70 mm 1 [690] 
Dorsal raphe nucleus, interfascicular part (DRI) -8.10 mm 2 [310] 
 -8.40 mm 2 [310] 
Pontine reticular nucleus, caudal part (PnC) -9.00 mm 
-9.30 mm 
-9.60 mm 
2 [1000] 
2 [1000] 
2 [1000] 
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1. Supplemental materials and methods to Chapter IV 
Plasma hormone and cytokine assays 
Plasma CORT concentrations were measured using a commercially available enzyme 
immunoassay (EIA) kit (Cat. No. ADI-900-097; Enzo Life Sciences, Plymouth Meeting, PA, USA). The 
assay has a detection limit of 27 pg/ml, an intra-assay coefficient of variation of 6.6 – 8.4%, and an inter-
assay coefficient of variation of 7.8 –13.1%. Before the assay, samples were diluted 1:50 in the provided 
Assay Buffer 15, containing 2.5% steroid displacement reagent (also provided). The assay was run in 
triplicate for each standard, and duplicates for each sample. 
 
Plasma noradrenaline (NE) concentrations were determined with an enzyme-linked 
immunosorbent assay (ELISA) kit (Cat. No. BA E-6200; Labor Diagnostika Nord GmbH & Co. KG, 
Nordhorn, Germany) with a detection limit of 50 pg/ml, an intra-assay coefficient of variation of 9.8 – 
16.1%, and an inter-assay coefficient of variation of 8.5 – 15.0%). The assay was run in triplicate for each 
standard, and undiluted duplicates for each sample. 
 
Plasma concentrations of the proinflammatory cytokines interleukin 1-beta (IL-1β) and tumor 
necrosis factor alpha (TNFα) were measured using commercially available ELISA kits from RayBioech, 
Inc. (Norcross, GA, USA). The Cat. No. for the IL-1β kit was ELR-IL1beta-001 (detection limit = 80 pg/ml, 
intra-assay coefficient of variation < 10%, inter-assay coefficient of variation < 12%); the Cat No. for the 
TNFα kit was ELR-TNFalpha-001 (detection limit = 25 pg/ml, intra-assay coefficient of variation < 10%, 
inter-assay coefficient of variation <12 %).  The assays were run in triplicate for each standard, and 
undiluted duplicates for each sample. 
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2. Supplemental results to Chapter IV 
Effect of chronic exogenous CORT on plasma concentrations of CORT, norepinephrine (NE), 
interleukin 1-beta (IL-1β), and tumor necrosis factor alpha (TNFα) 
Chronic treatment with exogenous CORT suppressed both basal (p < 0.001) and stress-induced 
(p < 0.001) plasma CORT concentrations compared to vehicle-treated controls (Table 2), resulting in a 
non-significant GC response to AS stress in the CORT group. Remarkably, the basal plasma 
concentration of NE in CORT-treated rats was also significantly lower compared to vehicle-treated 
controls (Table 2; treatment, F(1, 29) = 12.93, p < 0.01; stress, F(1, 29) = 2.27, p = 0.144; interaction, F(1, 
27) = 0.01, p = 0.968). However, at 30 min after the start of AS, both vehicle- and CORT-treated rats did 
not show a significant stress-induced increase in plasma NE concentrations. In contrast, plasma NE 
concentrations were in tendency suppressed in the rats that had undergone AS stress. No significant 
effects of CORT-treatment or AS stress were detected on the plasma concentrations of IL-1β (Table 2; 
treatment, F(1, 28) = 0.57, p = 0.458; stress, F(1, 28) = 2.69, p = 0.113; interaction, F(1, 26) = 3.01, p = 
0.095), but plasma IL-1β was in tendency elevated in CORT-treated home cage control rats, and post hoc 
pairwise comparisons revealed that IL-1β concentrations were lower after AS stress in CORT-treated 
rats, while plasma concentrations of IL-1β remained unchanged in vehicle controls. The opposite was 
true, again in tendency, for TNFα. Overall, no significant effects of CORT treatment or AS stress were 
detected on the plasma concentrations of TNFα (Table 2; treatment, F(1, 28) = 0.90, p = 0.353; stress, 
F(1, 28) = 3.64, p = 0.068; interaction, F(1, 26) = 1.09, p = 0.306). 
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Table B2. Plasma concentrations of corticosterone (CORT), norepinephrine (NE), interleukin 1-
beta (IL-1β), and tumor necrosis factor alpha (TNFα) (2) 
 Vehicle  CORT 
 Control  Stress  Control  Stress 
CORT (ng/ml) 98.87  ± 19.31  235 ± 34.03 ** 15.08 ± 7.98 ## 34.27 ± 9.69 ## 
NE (ng/ml) 175.98 ± 22.65 147.04 ± 24.38 105.75 ± 12.99 ## 75.20 ± 17.47 # 
IL-1β (pg/ml) 105.32 ± 23.15 108.46 ± 15.86 189.55 ± 64.98  76.32 ± 10.39 (*) 
TNFα (pg/ml) 53.33 ± 5.12   39.99 ± 2.70 (*)  44.34 ± 4.44  40.44 ± 5.67 
(2) Listed are the plasma stress hormone and cytokine concentrations of adult, male rats that were either 
treated with vehicle (0.45% 2-hydroxypropyl-β-cyclodextrin) or corticosterone (CORT, 100 µg/ml) via the 
drinking water for 21 days, before being subjected to home cage control conditions or 30 min of acoustic 
startle (AS) stress. Immediately prior to the start of AS, all rats were intraperitoneally (i.p.) injected with 
the aromatic L-amino acid decarboxylase inhibitor NSD-1015 (in 0.9 % saline). Data are displayed as 
means ± SEM. **p < 0.01, stress effect within the same treatment group; (*)p < 0.05, stress effect within 
the same treatment group (even though F-value of test statistic was not significant); #p < 0.05, ##p < 0.01 
treatment effect versus respective vehicle-treated group, after post hoc analysis with Fisher’s Protected 
LSD test (Vehicle-Control, n = 8; Vehicle-Stress, n = 8; CORT-Control, n = 8; CORT-Stress, n = 8). 
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3. Supplemental discussion to Chapter IV 
Differential effects of chronic CORT on basal and stress-induced plasma norepinephrine and 
cytokine concentrations  
As expected, plasma concentrations of endogenous CORT were significantly decreased, due to 
the adrenal insufficiency induced by exogenous CORT delivery, and the CORT stress response was not 
significant anymore after chronic CORT exposure. While the NE stress response was not measurable 30 
minutes after the initiation of AS stress, CORT-treatment decreased basal concentrations of NE. Because 
adrenal atrophy in CORT-treated rats is mostly restricted to the corticosterone-synthesizing zona 
fasciculata, without affecting the medullary diameter of the adrenal gland (Donner et al., 2012a), 
decreased NE availability in the circulation is likely attributable to an interaction of CORT with 
phenylethanolamine-N-methyltransferase, resulting in intensified conversion of NE into epinephrine 
(Betito et al., 1993; Mannelli et al., 1998). The effects of AS stress and CORT-treatment on the pro-
inflammatory cytokines IL-1β and TNFα in the blood appeared to be mainly immunosuppressive, in that 
chronic CORT-treatment (treatment removed 60 min prior to the start of AS stress) decreased 
concentrations IL-1β after AS stress, while IL-1 beta concentrations of the control group remained 
unaltered after AS stress. In contrast, AS stress slightly decreased TNFα concentrations in the vehicle 
group, but left TNFα in the CORT group unchanged. Synthetic GCs are commonly used as anti-
inflammatory medication, and endogenous GCs are thought to be important immunoregulators in 
preventing an immune response from reaching self-damaging, dangerous levels. However, research has 
also suggested a biphasic and compartment-dependent effect of GCs on cytokines depending on the 
sampling time during a stress response. Acute stress, such as inescapable tail shock ((O'Connor et al., 
2003); unpublished observations, (Donner et al., 2012b)), tends to initially promote proinflammatory 
plasma cytokine concentrations, as well as leukocyte activation (Wiegers et al., 2001) and entrance from 
the spleen into the blood circulation, while prolonged stress responses or GC elevation may cause 
leukocytes and cytokines to move into tissues of anticipated damage control, such as the skin, lungs, 
gastrointestinal and urinary tracts (Dhabhar, 2003; Speaker and Fleshner, 2012). The observation that IL-
1β plasma concentrations were in tendency higher in the CORT group, is consistent with increased basal 
plasma cytokine concentrations after chronic stress exposure (Mekaouche et al., 1994; Reber et al., 
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2007; Dhabhar, 2009) or in patients suffering from depression (Dowlati et al., 2009), probably due to GC 
resistance. Since extreme individual variance prevented the detection of a clear stress- or treatment 
effect on cytokines in our study, time-course experiments and a closer analysis of individual differences of 
the inherent cytokine milieu and its association with behavioral and neuronal correlates are needed to 
address some of these discrepancies. Recent studies in a mouse model of repeated social defeat 
suggest that inherent or initial plasma cytokine concentrations are predictive of whether an individual 
responds in an adaptive or maladaptive way to subsequent stressors (Hodes et al., 2012). 
 
Especially the plasma hormone concentration of NE needs to be interpreted carefully because all 
rats were injected with the AADC-inhibitor NSD-1015, and because AADC also catalyzes the conversion 
of L-dihydroxyphenylalanin (L-DOPA) to the NE precursor dopamine.  
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Figure B1. Percent change in 5-hydroxyindoleacetic acid (5-HIAA) in microdissected brain regions of 
interest plotted versus the p-value, indicating the difference from the control group. Adult, male Wistar 
rats received one acute intracerebroventricular 2 µl-infusion of vehicle or 6.3 μg ovine CRF, and were 
sacrificed 2 h later to analyze 5-HIAA content in brain regions of interest, using high pressure liquid 
chromatography, following by electrochemical detection (HPLC-ED). Abbreviations: AcbC, Nucleus 
accumbens, core, caudal portion; Acb Sh, Nucleus accumbens shell, caudal portion; AHiAL, 
Amygdalohippocampal area, anterolateral part; BMP, Basomedial amygdaloid nucleus, posterior division; 
CeA, Central nucleus of the amygdala (medial and lateral components) ; Ent, Entorhinal cortex (medial 
protion); HDB, Horizontal limb of the diagonal band of Broca; IP, Interpeduncular nucleus; LC, locus 
coeruleus; LSdc, Dorsal part of the lateral septal nucleus, caudal part; PnC, Caudal (reticular) pontine 
nucleus; SHi, Septohippocampal nucleus; RadCA3, Stratum radiatum hippocampus CA3; RadCA2, 
Stratum radiatum, hippocampus CA2. The study was conducted by Lowry et al. at the University of Bristol 
in 2001, and the figure generously provided by Dr. Christopher Lowry.  
